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ePidemioLogy of coLorectaL cancer
The incidence of colorectal cancer (CRC) shows considerable geographical differences around 
the world. The highest incidence rates are mainly seen in the Western world including North 
America, Australia/New Zealand, Western Europe, and Japan. Development countries report 
the lowest incidence rates. In Europe, CRC is the second most common diagnosed cancer in 
women and third in men (13% of all cancer cases in both women and men). Incidence rates 
are somewhat higher in men (1.2:1.0). The lifetime incidence of CRC in patients at average risk 
is approximately five percent.1 Incidence rates show demographic disparities over the last 
decades, with a gradual increase in South/Eastern Europe, stabilising numbers in North and 
West Europe, and a declining trend in the United States.2-4 Age is a major risk factor for the 
development of CRC. CRC rarely develops before the age of 40 (IKC), except in patients with a 
genetic predisposition.5, 6 Incidence rates rapidly increase beyond the age of 50.2, 3
In Europe, CRC ranked second (12% of all cancer related mortality) in terms of cancer related 
mortality 1, despite the significant increase in five-year survival in the last two decades.7 This 
improvement was in particular due to resection of rectal cancer with sharp dissection of the 
mesorectum en bloc with the rectum (total mesorectal excision) combined with pre-operative 
radiotherapy 8, and usage of new chemotherapeutic agents in various combinations.9 Addi-
tionally, improvement in outcome can be attributed to detection of the disease at an earlier 
stage due to screening and surveillance programmes.
risk and Preventive factors of coLorectaL cancer
Several environmental factors are associated with the development of CRC. Alcohol consump-
tion of more than 45g/day (relative risk (RR) 1.4; CI 1.2 to 1.7), cigarette smoking (RR 1.2; CI 
1.1-1.3), and consumption of more than 120g/day of red or processed meat (RR 1.3; CI 1.2-1.4) 
are significantly associated with an increase in CRC incidence.10-12 Furthermore, obesity has 
been identified as risk factor for CRC incidence and mortality.13-16 Individuals with a body mass 
index (BMI) of over 40 are significantly more likely to die from CRC (RR 1.5-1.6). A meta-analysis 
estimated a 30% increase in risk on CRC among diabetics compared to non-diabetics (RR 1.3 
CI 1.2-1.4).17
Recently, aspirin use has been identified as primary prevention of CRC most likely by inhibit-
ing the malignant transformation of adenomas.18, 19 At least 300 mg aspirin a day for about five 
years reduced the incidence of CRC with 10-year latency (Hazard ratio 0.74). No association 
between calcium + vitamin D supplementation or folic acid usage and CRC incidence has been 
established so far.20-22 Regular physical activity, either occupational or leisure time, does have a 
preventive effect on the development of CRC (RR 0.76, CI 0.72-0.81).23
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risk stratification 
Nation-wide screening programme are designed for average risk individuals.24 Individuals with 
a history of adenomas 25, previous CRC, inflammatory bowel disease; a first degree relative with 
CRC diagnosed ≤ 60 years 26, 27; or a hereditary cancer syndrome 5, 6 are at increased risk for CRC 
and should enter specialised screening or surveillance programmes.28
screening for coLorectaL cancer
CRC fulfils the screening and surveillance criteria of Wilson and Jungner 29, i.e. the disease 
poses an important health problem with significant morbidity and mortality, the disease has 
a clearly detectable and treatable precursor (adenomas), and early detection of CRC improves 
the prognosis. The five-year survival is 90% if the disease is diagnosed while still localized, only 
68% for regional disease, and less than 10% for disseminated disease (Table 1).30 In addition, 
Winawer et al. have clearly shown that endoscopic removal of adenomas results in a lower-
than-expected incidence of CRC compared with reference populations.31 Extensive, but mainly 
indirect evidence suggests that the majority of CRC arise from adenomas. However, only a 
minority of adenomas ultimately progress to CRC. Histopathology and size determine the risk 
on malignant transformation. The National polyp study workgroup introduced the concept of 
advanced adenoma defined as adenomas ≥10mm, or with a villous component of >25%, or 
containing high grade dysplasia 32 as all these factors appeared independent risk factors for 
the progression to CRC.33 Furthermore, individuals with an advanced adenoma or more than 
two adenomas removed at screening turned out to be at increased risk for metachronous 
lesions when undergoing follow-up (surveillance) colonoscopy.34-36 Several CRC screening 
studies therefore used the detection rate of invasive CRC, as well as advanced adenomas as 
surrogate end-point for the effectiveness of a screening tool, as randomised-controlled trials 
(RCT) evaluating mortality reduction of screening require a long term follow-up. Furthermore, 
stage distribution of detected CRC has been suggested as a surrogate end-point as well, given 
the significant difference in prognosis between early stage and dissimilated cancer (Table 1).
table 1: Stage TNM classification 5-year survival.
Stage T N M Five year survival
I T1–2 N0 M0 90%
IIA T3 N0 M0 80%–85%
IIB T4 N0 M0 70%–80%
IIIA T1–2 N1 M0 65%–80%
IIIB T3–4 N1 M0 50%–65%
IIIC T1–4 N2 M0 25%–50%
IV T1–4 N0–2 M1 5%–8%
Derived from Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer.(1)
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Extensive evidence has shown that screening can reduce CRC related mortality. In 2003 the 
European Health Council recommended screening for CRC within the age group 50-75 years.37 
Unfortunately, only 43% of the target population in the European Union has nowadays access 
to population-based screening as part of a regional or national programme. In fact, in 2007 
only 18% of the target population underwent adequate screening for CRC.38 The International 
Colorectal Cancer Screening Network (ICRCSN) presented data on screening programmes 
worldwide. A few countries, including Finland, England, Scotland, Australia and several prov-
inces in Canada have introduced a nation-wide call-recall screening programme. In France, 
Spain, Italy and Sweden, screening is offered at a regional level. Japan, Taiwan, USA, Germany, 
Poland, Czech Republic and Austria offer screening at an individual basis, also known as oppor-
tunistic programmes.38 The Netherlands is currently considering introduction of a nation-wide 
screening programme.39
There are several methods for CRC screening, which vary in the level of supporting evidence, 
effectiveness, test-related burden and uptake. Screening tests can be divided in tests which 
primarily detect cancer, including guaiac-based faecal occult blood test (gFOBT), faecal immu-
nochemical test (FIT) and faecal DNA test, and tests that can detect both polyps (adenomas) 
and CRC, like flexible sigmoidoscopy (FS), total colonoscopy (TC) and computed tomography 
colonography (CTC). The most commonly used tests; FOBT, FIT, FS, and TC are discussed in detail 
below. Less frequently used screening tests like faecal DNA testing and CTC will be discussed 
briefly.
screening strategies
Guaiac-based faecal occult blood test (gFOBT) 
Guaiac-based FOBT can detect occult blood based on the detection of haem in faeces, as it 
reacts to the peroxidase activity of haem. The standard protocol is a home-based test consist-
ing of two samples each of three consecutive bowel movements. A positive test is followed 
by a TC. Most studies encouraged participants to restrict their diet and medication prior to 
performing the test as this might affect the number of false-positive and false-negative test 
results. The restrictions differ between studies, but generally involve avoiding red meat, fish, 
poultry, some fruits and vegetables, vitamin C, non-steroidal anti-inflammatory drugs (NSAID) 
and aspirin.40-44 However, a meta-analysis did not find clear evidence for improved accuracy 
of the test when these dietary and medicine restrictions were applied 45, and a double-blind 
RCT did not find a relation between regular use of NSAIDs or aspirin and the number of false-
positive test results.46 Additionally, strict dietary and medication restrictions have been shown 
to lower uptake and should therefore not be advised in screening programmes.47, 48 
The sensitivity and specificity of gFOBT screening varies widely due to the variation in type of 
test (brand), method of stool collection, number of stool samples per test, the use of rehydrated 
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stool samples, the threshold used for a positive test, and screening interval.49, 50 Differences 
between test brands were shown in a systematic review, reporting that the sensitivity and 
specificity of a single test for detecting CRC was respectively 37.1% and 97.7% with unhydrated 
Hemoccult II testing and 79.4% and 87.7% with analysis by Hemoccult II Sensa.49 Hydration of 
a faecal sample of a Hemoccult II improved the test sensitivity for CRC (50%), but reduced the 
specificity of the test (94%).51 Rehydration of gFOBT slides is not recommended because it can 
negatively influence the interpretation of the test results and substantially increase the number 
of false-positive test results due a reduced specificity.24 A single unhydrated gFOBT test thus has 
a low sensitivity and the majority of prevalent CRCs will be missed. Repeated screening is needed 
in order to obtain adequate programme sensitivity. Until recently a single sample in-office gFOBT 
performed by the general practitioner has been used for CRC screening especially in the United 
States. Collins et al. clearly demonstrated that this method has a considerable lower sensitivity 
and specificity than the home-based three sample gFOBT and is therefore not recommended.52
Guaiac-based FOBT can reduce mortality due to the detection of CRC at an early stage. Five 
randomised controlled longitudinal studies have consistently shown that gFOBT screening can 
reduce relative risk for CRC with 13%-33%.53-57 A meta-analysis combined the results of the five 
RCT including 157 164 screenees and 156908 controls invited for biennial screening with 11-18 
years follow-up and reported a 16% relative risk reduction of CRC-related mortality (RR 0.84 CI: 
0.78-0.90).58 In an individual study, the maximum risk reduction with annual gFOBT screening 
was 33%.56 Today, both annual and biennial screening intervals are recommended.24, 56, 59
Attendance to screening is an important determinant of the effectiveness of a screening tool 
at a population level. The percentage of people attending the first round of gFOBT screening 
was between 49-68%.58, 60 Attendance rates tend to be lower in successive screening rounds.54 
However, in the nation-wide call-recall British screening programme uptake levels remained 
stable over the first three screening rounds. Overall only 38% of the invitees persisted in their 
choice to attend screening over time and attend all screening rounds.61 This implies, given 
the low sensitivity of a single gFOBT that only a small proportion of invitees receive adequate 
screening. Furthermore, uptake of gFOBT screening varies among subgroups within the target 
population. Women are more likely to participate than men. An age between 55-64 years is also 
associated with increased gFOBT uptake levels compared to younger (50-54) and older age 
groups (65-75).61, 62 
Feacal immunochemical test (FIT)
Faecal immunochemical testing specifically detects human (haemo) globin by using mono- or 
polyclonal antibodies. Globin is the protein component of haemoglobin. The antibodies are 
attached to latex, dye or enzymes, which form complexes in presence of globin that can be 
detected. The degree of agglutination, turbidity or colour change of the solution is read as 
an optical change and translated to a concentration of haemoglobin per amount of faeces or 
sample solution. Dietary restrictions are not required as FIT specifically detects human (haemo) 
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globin, without any cross-reaction with dietary haem. The use of NSAID’s, aspirin, or anticoagu-
lants slightly improves the sensitivity of FIT without a reduction in specificity for the detection 
of advanced adenomas and CRC.63 The limited effect of medication and dietary restrictions on 
test accuracy and a potential negative effect on participation rate make medication and dietary 
restrictions unwarranted.48, 64
Faecal immunochemical tests are more sensitive than gFOBT for detection of haemoglobin 
(Hb) in faeces.49 FIT can be analysed quantitative and non-quantitative. For the latter method, 
faeces can be collected on a card containing anti-human Hb which forms a complex with faecal 
Hb which binds in a positive test reaction zone producing a coloured line, which can be anal-
ysed by a reader. This non-quantitative method is not suitable for population-based screening 
as the analysis is laborious and subject to inter-observer variability. Therefore quantitative 
faecal immunochemical tests have been developed with various types available including OC-
sensor (Eiken Chemical Co., Tokyo, Japan), Hem-SP (Fujirebio, Japan) and FOB Gold (Medinostics 
Products Supplier; Sentinel Diagnostics SpA, Milan, Italy). With these techniques, FIT samples 
can be analysed automatically which has important advantages for reproducibility, quality 
control, capacity, and thus personnel need and costs.50, 65 Another advantage is the quantita-
tive test result, which allow determining an optimal cut-off value for a nation-wide screening 
program.65-70 For the OC-sensor a cut-off value between 75-100ng/ml seems most favourable 
as they provide an optimal balance between detection rate and predictive values,65, 69, 71, 72 
whereas cut-off levels of respectively 20ng/ml 73 and 100ng/ml 74 for the Hem-Sp and the 
FOB-gold have been suggested. Countries implementing nation-wide screening can decide 
on the cut-off value based on a positivity rate that meets the available colonoscopy resources 
in a country. At the same time, the number of colonoscopies is an important determinant of 
the neoplasia detection rate, and thus of the potential preventive effect of a CRC screening 
programme.  
The number of consecutive bowel movements collected for a single screening round var-
ies between one and three samples. The two- or three sample FIT has a higher sensitivity for 
detecting CRC than a single FIT.65, 75-77 A single test has a sensitivity and specificity for detecting 
advanced neoplasia of respectively 27% and 95% 73, and a two or three samples test of 67% 
and 87-94%.65, 70 Li et al. postulated that two consecutive stool samples is a more cost-effective 
approach than three-sample, as both strategies demonstrated similar sensitivity and specific-
ity. However, randomised population-based trials on the optimal number of consecutive stool 
samples are awaited. In general a two or three sample FIT is considered positive when one of 
the samples is above a certain threshold level. Recently, Guittet et al. showed that the best gain 
in sensitivity and specificity is obtained when the mean Hb levels of both tests are used.75 
Definitive evidence on the effectiveness of FIT screening is lacking. A small Japanese 
case-control study suggested that repeated screening by FIT would reduce mortality from 
colorectal cancer by 52-60%. Two randomised trials consistently showed a higher detection 
rate and similar number of false-negatives for FIT compared to gFOBT.69, 72 FIT therefore seems 
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a more effective screening tool and may reduce CRC-related mortality considerable more than 
reported for gFOBT screening. 
Participation rates tend to be higher for FIT compared to the gFOBT (60-62% vs. 47-50%).62, 
78 This may be influenced by the differences in perceived discomfort, the number of faecal 
samples required and the difference in faecal sampling method. 
Flexible sigmoidoscopy (FS)
Flexible sigmoidoscopy is an endoscopic technique that examines the distal part (rectum, 
sigmoid and descending colon) of the colon. The procedure is usually performed with a 
forward-looking video endoscope (usually 60–70 cm). The goal of FS is to examine the colon as 
far as can be achieved to the limits of FS endoscope length and without causing undue pain or 
distress.79 A single, self-administered, enema is used as bowel preparation in most population-
based screening studies.62, 80-82 Self-administration of the enema at home has been shown to 
be acceptable, as a minority of participants refuses self-administration and receives the enema 
at the screening unit.62, 80 This is important for FS screening, because most screening units lack 
facilities to apply all enemas. A single self-administrated enema resulted in adequate bowel 
cleansing (when lesions ≥5 mm polyps are not obscured)79 in 93-95%.80, 83 In the remaining 
subjects oral laxatives combined with an enema can be considered, as this combination has 
demonstrated improved preparation quality 84, 85. 
FS is in general performed without sedation and can therefore be performed in an office 
setting. In such a setting, only a small proportion of participants report severe embarrassment, 
discomfort or pain during the procedure.80, 83, 86, 87 The majority of subjects are willing to return 
for successive screening rounds.86-89 This is essential for an effective screening programme, 
since screening tests must be repeated at regular intervals. Furthermore, experience with CRC 
screening will be communicated to other potential screenees, which may influence participa-
tion. Perceived burden of FS screening varies by gender. Women report significantly more 
burden than men and are therefore less willing to return for successive screening rounds.89 
Endoscopists should therefore be even more aware of potential pain in women, and consider 
protective action (e.g. using sedation or a more flexible, smaller calibre endoscope). Male 
endoscopists are reported to be a barrier to screening for women.89 A nation-wide screening 
programme might be more effective when female endoscopists take part in FS screening. 
FS is considered a rather safe procedure. Serious complications like bleeding following 
polypectomy or perforation occur in 1-2 per 1000 screenees.80, 82 
The criteria to refer a participant for a TC are still under debate. Subjects with three or more 
adenomas or advanced neoplasia are at increased risk of synchronous proximal advanced neo-
plasia. 90-93 Most studies therefore considered a FS positive in case of an advanced adenoma, ≥ 
3 adenomas; or invasive CRC.62, 82, 83 Subjects with polyps sized ≥10 mm are usually also referred 
for TC.62, 94 A lower referral threshold size for distal adenomas (5mm) does not appear to consid-
erably increase the yield of proximal advanced adenomas and is therefore not recommended.82
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FS screening has the potential to reduce CRC related mortality based on both endoscopic 
removal of adenomas and the early detection of CRC. Case-control studies reported a CRC mor-
tality reduction of 59-79% within the reach of the endoscope following a single FS. Recently, 
a Norwegian population-based RCT reported the effect of a single FS on CRC incidence and 
mortality after seven years. 95 The intention-to-screen analysis demonstrated no difference in 
the seven year cumulative incidence of CRC or CRC-related mortality between the screening 
and control group. However, prevalent CRCs detected at the first screening round diluted any 
incidence reducing effect of polypectomy. It may take longer than seven years to determine 
the effectiveness of FS screening on CRC incidence. For those actually attending screening a 
significant reduction in CRC related mortality was apparent (hazard ratio 0.41, CI 0.21-0.82, 
P=0.01). The longitudinal results of three larger RCTs performed in the United Kingdom, United 
States and Italy are expected in the near future.82, 94, 96   
Further evidence on the effectiveness of FS comes from TC studies. Examination of the 
distal colon, followed by a TC if an adenoma of any size had been found, would have identified 
66-80% of all subjects with an advanced neoplasia.91, 97 FS seems a less effective screening 
tool in women than in men as the detection rate of advanced adenoma is approximately 35% 
compared to 66% in men.98 Furthermore, increasing age is also associated with a higher miss 
rate of advanced neoplasia in the proximal colon.98
Limited evidence on the optimal screening interval after a negative examination is available. 
Case-control studies found that the negative association between FS and CRC-related mortality 
persisted for up to 6-10 years.99-101 More recent data provided direct evidence to support the 
safety of the five-year interval after a normal FS, as the detection rate of advanced neoplasia 
five-year after a negative FS is only 1%.102, 103 Current guidelines therefore recommend at least 
a five-year interval in presence of high quality FS. 
The quality of the examination determines the effectiveness of FS screening. Although 
longitudinal data on the association between adenoma detection rate and mortality reduction 
are lacking, the detection rate of adenomas has been suggested to be a surrogate marker for 
the quality of examination.104 The detection rate varies widely between endoscopists irrespec-
tive of the level of experience. Individual performances of an endoscopist thus also contribute 
to difference in detection rate. Atkin et al. suggested that a high quality FS program should 
achieve an adenoma detection rate of at least 10% for screening FS in an average risk popula-
tion over 55 years of age.104 
The participation rate to FS screening differs between countries (24-67%).62, 81, 105, 106 
These uptake rates cannot be directly compared to studies where only eligible and interested 
respondents to a questionnaire were included.82, 94 Differences in attendance rate can partly 
be explained by the method of scheduling the FS appointment. In some studies subjects were 
asked to schedule their own appointment, which may negatively influence the participation 
rate.62 In other studies the appointment for FS was prefixed to be confirmed or modified.81, 82, 
94 Women are less likely to attend FS screening than men, which may be influenced by attitude 
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and believes about FS screening that might thereby form a barrier to FS screening. 62, 82, 94, 105, 
106 A special approach for inviting women in a future nation-wide FS screening programme 
should therefore be considered. 
Total colonoscopy (TC)
Total colonoscopy is considered the golden standard for the detection of colorectal neoplasia. A 
colonoscopy is performed with a forward-looking colonoscope. The scope should be advanced 
until the caecum has been reached. Bowel preparation is in general performed with polyethyl-
ene glycol (PEG) or sodium phosphate.97, 98, 106, 107 A meta-analysis demonstrated no significant 
differences in efficacy between both preparations.108 Sodium phosphate is better tolerated than 
PEG, but associated with an increased risk of clinically significant electrolyte disturbances.108 
Colonoscopy is well accepted under conscious sedation.86, 89 The bowel preparation is often 
considered the worst part of the procedure.89 Clinically significant complications requiring 
hospitalisation occur in 1 per 1000 screenees including perforation and bleeding.109 In a large 
population-based colonoscopy screening trial no mortality within 30 days of the colonoscopy 
was reported.107 
Randomised controlled data on the preventive effect of a colonoscopy on CRC incidence 
and/or mortality are lacking. The National Polyp Study estimated a 76-90% reduction of CRC 
incidence by regular colonoscopic surveillance examinations.110 However, these results should 
be interpreted with caution. The two reference groups in this study were derived from different 
populations, which could introduce a selection bias. Furthermore, all subjects included in this 
trial had a polyp removed at the index colonoscopy and were therefore at increased risk of 
CRC. The results of this trial can therefore not be extrapolated to an average risk screening 
population. Recently a large case-control study executed in Canada including average risk men 
and women showed that colonoscopy was associated with lower CRC mortality rates (OR 0.69; 
CI 0.63-0.74). This study suggested that colonoscopy screening predominantly affects left-sided 
CRCs as no preventive effect on right-sided CRC was observed.111 The lack of protection for the 
right colon is most likely due to the use of billing codes without actual evaluation of endoscopy 
reports and pictures. Furthermore, poor bowel preparation or inadequate withdrawal time in 
the right colon might also increase the miss rate of right-sided polyps and therefore lowering 
the effect on CRC-related mortality. Furthermore, adenomas in the right-sided colon are more 
likely to have a flat morphology, and therefore more likely to be missed at colonoscopy.112 
These flat adenomas more frequently contain highly malignant characteristics (high-grade 
dysplasia)113 suggesting a more aggressive pathway in the development of flat adenomas to 
CRC.114 However, RCT to determine effectiveness of colonoscopy on CRC-related mortality are 
required to confirm the data of Baxter et al.
Colonoscopy allows for full examination of the colon. Polyps can nevertheless be missed.115, 
116 A meta-analysis on tandem colonoscopy studies reported an association between polyp 
size and miss rate as adenoma miss rate increased significantly with smaller size from 2%  for 
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large adenomas (≥10 mm) to 13% for small adenomas (6–9mm), and to 26% for diminutive 
adenomas (1–5 mm).116 
Attempts should be made to reduce the polyp miss rate and therefore the effectiveness of 
TC screening. Rex et al. have summarized evidence on quality indicators for TC. A high quality 
screening colonoscopy depends on: (i) an appropriately trained and experienced endoscopist; 
(ii) obtaining informed consent, including a specific discussion of risks associated with colo-
noscopy; (iii) adequate bowel preparation and visualisation of the colon; (iv) caecal intubation 
in ≥95% of cases; (v) mean withdrawal time of more than six minutes in TC with normal results 
performed in patients with intact anatomy 117; (vi). adenoma detection rate of ≥25% in average 
risk men and ≥15% in average risk women aged 50 years or older in a first colonoscopy (vii) 
documentation of perforation and post-polypectomy bleeding, which should be observed in 
less than respectively 0.1% and 1.0%; (vii) recommendations for surveillance or repeat screen-
ing based on published guidelines.25 
Indirect evidence from a case-control study suggested a very low risk of CRC for 20 years 
after a negative colonoscopy.118 Prospective studies provided evidence for a protective effect 
of at least five years after a negative colonoscopy.34, 119 Recently, Brenner et al. reported a low 
risk on advanced adenoma for at least fifteen years after a negative colonoscopy.120. The cur-
rent guideline recommends a ten year screening interval although lengthening of the interval 
might be considered.24  
Uptake rate of colonoscopy screening is approximately 25% when a call-recall approach is 
applied.106, 121
Faecal DNA test
During the adenoma carcinoma sequence DNA alterations accumulate. Adenomas and CRCs 
continuously shed mucosal surface cells into the faeces. The DNA material from these cells can 
be isolated and analysed by means of a multi-target DNA stool assay. By this means, tests usu-
ally aim to detect mutations in TP53, K-ras, APC, BAT-26 and BRAF. In contrast to FOBTs, sDNA 
tests require an entire stool specimen (30g minimum) to ensure adequate sample of stool for 
evaluation.
An American study with 5486 asymptomatic subjects showed increased sensitivity and 
specificity for advanced neoplasia using faecal DNA compared to gFOBT. DNA testing neverthe-
less missed more than 50% of the advanced neoplasia.122 Recently a cost-effectiveness analysis 
using a Markov model demonstrated that immunochemical and guaiac-based tests are to be 
preferred over DNA testing.123
The U.S. Preventive Services Task Force (USPSTF) concludes that there is insufficient evi-
dence to assess the sensitivity and specificity of faecal DNA testing for colorectal neoplasia, 
and that therefore the balance of benefits and harms cannot be determined for this test.124 
Further research is required before implementing a nation-wide screening programme with 
faecal DNA testing.
Ch
ap
te
r 1
20
Computed Tomography Colonography (CTC)
Computed Tomography Colonography is able to visualise the entire colorectum. Currently a 
≥16 slice scanner is most commonly used in studies on CRC screening. This technique allows a 
2- and 3-dimentional visualisation of the colon. Cathartic preparation along with a liquid diet 
the day prior to the CTC, similar to the preparation of TC, is required to obtain adequate visu-
alisation of the colon. Subjects report bowel preparation to be the most important drawback 
to participating CRC screening.125 Therefore, a less burdensome limited bowel preparation 
using faecal tagging has been introduced.126 This rapidly evolving technique has an adequate 
sensitivity, which is only slightly lower than seen with cathartic cleansing.126 
International experts agree on the referral of subjects with polyps ≥10mm for a TC. The 
debate regarding the referral of subjects for TC relates to subjects with small polyps (6-9mm) 
as most advanced lesion. Pickhardt et al. concluded in an extensive review that, based on a low 
miss rate of advanced neoplsia and an substantial increase of the cost-effectiveness, subjects 
with small polyps should have a surveillance CTC after three years.127 Subjects with diminutive 
polyps or a normal CTC are recommended to be screened with a five year interval.24  
The complication rate of CTC is considerably low, with a serious perforation in 1 per 3000 
subjects.128 The dose of radiation as used for CTC screening in a 50 year old individual is esti-
mated to increase the risk on CRC with 0.044% and all cancers with 0.14%.129 Furthermore, the 
CT can detect extra-colonic findings in a considerable number of screenees. In approximately 
10% of subjects the extra-colonic findings are clinically relevant and require evaluation or 
intervention, which will increase the costs of a screening programme.130  
The sensitivity achieved with CTC for the detection of advanced adenomas is highly depen-
dent on the skills of the reader.131 A pooled per patient analysis reported an average sensitivity 
and specificity for subjects with large polyps (≥10mm) of respectively 93% (CI 73-98%) and 
97% (CI 95-99%). The sensitivity and specificity decreased to respectively 86% (CI 75-93%) and 
86% (CI 76-93%) when small polyps (6-9mm) were included. However, this per patient analysis 
clearly did not provide insight in the performance of the CTC per individual polyp. The sensitiv-
ity was significantly lower when a per polyp analysis was performed, with a sensitivity of 77% 
(CI 70-83) for large polyps and 70% (CI 63-76%) for polyps ≥6mm.132
A limitation of all studies on CTC screening is the use of TC as golden standard, since the 
sensitivity of the TC for the detection of advanced neoplasia is not 100%. No randomised con-
trolled trials on the efficacy of CTC for prevention of CRC have been performed. Studies on CTC 
mainly use the detection of advanced neoplasia as surrogate end-point for efficacy. Recently 
USPSTF concluded that evidence to assess the harms related to extra-colonic findings of CTC is 
insufficient, and the balance of benefits and harms cannot be determined.124 More extensive 
research is needed until CTC can be used as a screening strategy in an average risk population.
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starting and stoPPing ages for screening
Screening for CRC with gFOBT, FIT, FS or TC should be initiated at the age of 50 in an average risk 
population.24, 37, 133 The higher incidence of CRC before the age of 50 in African Americans war-
rant initiation of CRC screening in this group at the age 45 rather than 50 year.134 Furthermore, 
clinicians might consider offering screening at a younger age to heavy smokers, as they are at 
increased risk for CRC. The USPSTF recently recommended to continuing screening until age 
75 years.124 
concLusions
The various test methods available for CRC screening have been shown to be feasible for CRC 
screening. However, the tests differ in the level of supporting evidence, reducing effect on CRC 
related mortality, potential risks and test burden. In the Netherlands gFOBT, FIT and FS are 
considered as potential screening tests for a nation-wide screening programme. 
aims of tHe tHesis
The general aim of this thesis is to explore all aspects (i.e. participation, diagnostic yield, test 
burden, preference for a test, cost-effectiveness) of the three most relevant screening tests in 
a European setting, i.e. gFOBT, FIT and FS with regard to implementation of a nation-wide call-
recall screening programme in the Netherlands.
outLine of tHe tHesis
Introduction of a CRC screening program in the Netherlands is being explored. The benefits of 
screening depend on the efficacy and costs of the screening method as well as on population 
attendance. The currently most relevant screening methods for the Netherlands are gFOBT, 
FIT and FS, with the latter being more expensive but also with potentially higher preventive 
impact. In this thesis, we firstly determined attendance for and detection rates of advanced 
neoplasia with gFOBT, FIT and FS screening in a randomised population-based trial (Chapter 2). 
FIT samples can be analysed automatically which has important advantages for reproducibil-
ity, quality control, capacity, and thus personnel need and costs. Another advantage of FIT is the 
quantitative test result, which allows determining of an optimal cut-off value for a nation-wide 
screening program. The cut-off value for a positive test can be based on a positivity rate that 
meets the available colonoscopic resources. At the same time, the number of colonoscopies is 
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an important determinant of the neoplasia detection rate, and thus of the potential preventive 
effect of a CRC screening programme. We therefore determined the optimal cut-off value of the 
FIT (OC-Sensor micro) in an average risk screening naïve Dutch population (chapter 3). 
Uptake of FS screening is low in various European populations. A significant proportion of 
the population would therefore not receive any screening if a single test population-based 
screening programme based on FS would be introduced. Several surveys have identified 
worries about pain, discomfort, or injury associated with FS screening as the main reasons for 
refusing FS screening. Those barriers may be overcome by offering non-participants an alterna-
tive screening test, for example FIT. We determined uptake and diagnostic yield of FIT screening 
among non-participants of FS screening in an average risk screening naïve population (chapter 
4). This approach allowed insight in reasons for non-compliance to FS screening.
Experience with a screening test may affect the willingness to attend successive screening 
round, and may be communicated to other potential screenees, which may affect uptake of 
CRC screening programmes in successive cohorts. A few studies have reported on the test 
burden of gFOBT and FIT screening. The perceived test burden of FS screening has been more 
widely studied, but trials comparing the burden of gFOBT, FIT and FS screening are lacking. In 
this thesis, we assessed differences in perceived burden and willingness to return for a second 
screening round among participants of a randomised population-based trial comparing gFOBT, 
FIT and FS screening (chapter 5). 
The willingness to undergo screening is influenced by perceived advantages and drawbacks 
of CRC screening tests and furthermore, by knowledge and awareness of CRC, CRC risk and 
CRC screening. To optimise a CRC screening programme it is of paramount importance to gain 
insight in factors that influence population preferences for CRC screening programmes, and the 
trade-offs individuals are willing to make between benefits and drawbacks of a CRC screening 
programme. Research has shown that patient preferences can have a major impact on their 
willingness to use services and furthermore, there is an increasing emphasis on involvement 
of patients in health care decisions. We therefore investigated preferences for CRC screening 
using a labelled (chapter 6) and an unlabelled (chapter 7) discrete choice experiment (DCE). 
DCE is a survey methodology with its origin in market research. DCEs are widely used for the 
assessment of preferences in transport and environmental economics and marketing research. 
They are increasingly used for investigating health care preferences.  
Advanced adenomas are considered the surrogate biological marker for CRC risk and are the 
primary target of screening. Accurate pathologic assessment of colorectal lesions is therefore of 
paramount importance. However, concern has been expressed about the reproducibility of the 
histological interpretation, even between expert pathologists. As a limited reproducibility has 
a major influence on intensity, burden, cost-efficacy, and potentially outcome of CRC screen-
ing, we reported the inter-observer variation in the histological diagnosis of colorectal polyps 
detected in a CRC screening programme. Furthermore, the inter-observer variation between 
general and expert pathologists was assessed (chapter 8).
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All the longitudinal randomised controlled FOBT trials on mortality reduction have been 
performed with the Hemoccult II test. These trials took many years before showing their final 
results. It is not be feasible to subject the FIT to such a trial within the time frame of this thesis. 
As a proxy, we therefore used a model-based analysis (MISCAN-Colon model) to estimate 
expected effects and costs given the differences in characteristics based on data of our ran-
domised trial comparing gFOBT and FIT (chapter 9). The MISCAN-Colon model is structured in 
such a way that an assumed change in specificity and/or sensitivity is translated into a change 
in stage distribution, in types of treatments, in overall prognosis and thus in mortality.
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abstract
Screening for colorectal cancer (CRC) is widely accepted, but there is no consensus on the pre-
ferred strategy. We conducted a randomised trial comparing participation and detection rates 
(DR) per screenee of guaiac-based faecal occult blood test (gFOBT), immunochemical FOBT 
(FIT), and flexible sigmoidoscopy (FS) for CRC screening. A representative sample of the Dutch 
population (n=15011), aged 50-74 years, was 1:1:1 randomised prior to invitation to one of the 
three screening strategies. Colonoscopy was indicated for screenees with a positive gFOBT or 
FIT, and for those in whom FS revealed a polyp with a diameter ≥10 mm; adenoma with ≥25% 
villous component or high grade dysplasia; serrated adenoma; ≥3 adenomas; ≥20 hyperplastic 
polyps; or CRC. The participation rate was 49.5% (95% confidence interval (CI) 48.1-50.9%) for 
gFOBT, 61.5% (CI:60.1-62.9%) for FIT and 32.4% (CI 31.1-33.7%) for FS screening. gFOBT was 
positive in 2.8%, FIT in 4.8% and FS in 10.2%. The DR of advanced neoplasia was significantly 
higher in the FIT (2.4%; OR 2.0; CI 1.3-3.1) and the FS arm (8.0%; OR 7.0; CI 4.6-10.7) than in 
the gFOBT arm (1.1%). FS demonstrated a higher diagnostic yield of advanced neoplasia 
per 100 invitees (2.4; CI 2.0-2.8) than gFOBT (0.6; CI 0.4-0.8) or FIT (1.5; CI 1.2-1.9) screening. 
This randomised population-based CRC-screening trial demonstrated superior participation 
and detection rates for FIT compared to gFOBT screening. FIT screening should therefore be 
strongly preferred over gFOBT screening. FS screening demonstrated a higher diagnostic yield 
per 100 invitees than both FOBTs. 
Uptake and detection rate of screening for colorectal cancer 35
background 
Screening can reduce the colorectal cancer (CRC) mortality rate based both on early detection 
of CRC and endoscopic removal of adenomas.1, 2 CRC screening is therefore widely accepted, 
but there is no consensus on the preferred strategy. The European Council recommends faecal 
occult blood (FOBT) screening CRC in average risk men and women aged 50–74 years.3 More 
than 50% of the target population in the European Union is however offered no screening at all. 
In those regions where screening is being offered, this usually occurs with guaiac-based FOBT 
(gFOBT) or more rarely with flexible sigmoidoscopy (FS). 
Four large randomised controlled trials (RCT) have consistently shown that biennial gFOBT 
screening reduces CRC mortality.4-7 This reduction mainly occurs due to early detection 
of CRC. However, gFOBT is hampered by a low sensitivity for advanced neoplasia (11-37%), 
which explains the limited impact of repeated gFOBT screening on CRC mortality.8, 9 Recently, 
immunochemical FOBT (FIT) screening has become available. FIT has a better sensitivity and 
similar specificity for detecting advanced neoplasia compared to the gFOBT, since it specifically 
detects human haemoglobin.8, 10-15  
Sigmoidoscopy screening is possibly more effective than FOBT screening due to the consid-
erable higher sensitivity for detection of early neoplastic lesions and the possibility of removing 
adenomas during the screening procedure.16, 17 Case-control studies reported a CRC mortality 
reduction of 59-79% within the reach of the endoscope following single FS.18, 19 The results of 
RCTs on mortality reduction of FS screening are expected in the near future.20-23 
In addition to mortality reduction, uptake of screening is the second major determinant of 
effectiveness of a CRC screening programme. Until now, randomised trials directly comparing 
the three most relevant screening methods in an unselected asymptomatic population are 
lacking. We therefore conducted a randomised population-based trial to compare gFOBT, FIT 
and FS screening in an average risk screening naïve population. The primary endpoint of this 
study was the participation rate to each of the three screening strategies. Detection rate (DR) of 
advanced neoplasia with each screening strategy was the secondary aim.
metHods
Study population 
Names, dates of birth, and postal addresses of all individuals aged 50-74 years in the region Rijn-
mond in the Southwest of the Netherlands were obtained from the eight regional municipality 
offices. From this dataset of 338000 individuals, a random sample of 15011 individuals was 
taken by computer generated algorithm and 1:1:1 randomised using this computer generated 
algorithm (Tenalea, Amsterdam, the Netherlands). Randomisation was done per postal address 
after stratifying by age, sex and social economic status (SES) into group A (gFOBT), B (FIT) or 
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C (FS) (Fig 1). The SES was based on the data of Statistics Netherlands (www.cbs.nl) providing 
average SES per postal code area, each representing small neighborhoods). Randomisation 
occurred prior to invitation. Informed consent was asked after randomisation. Individuals with 
a history of inflammatory bowel disease or CRC, a colonoscopy, sigmoidoscopy or barium con-
trast enema in the last three years, major health problems, or those who moved away or died 
were excluded from analyses. Recruitment took place between November 2006 and November 
2007. 
Interventions
All individuals were sent a pre-invitation letter containing information on CRC screening. Two 
weeks later an invitation letter was sent with information on possible advantages and risks of 
screening and on the specific screening test that was offered. This was accompanied by an 
informed consent form, which had to be signed and returned. A test set was sent along with 
the invitation in case of gFOBT or FIT screening. The FS group received an invitation letter with 
a telephone number of the screening unit to schedule an appointment. A reminder was sent 
six weeks afterwards to all non-respondents. Information about the study was further given to 
all general practitioners (GP) in the region by direct visits of research physicians  prior to start 
of the study, providing them with background, a contact address, and an information folder. All 
information was made available via a dedicated website (www.dikkedarmkankerpreventie.nl), 
mailings and information sites of the municipality offices, regional newspapers and national 
and regional broadcasting. 
Group A: Guaiac-based FOBT 
All randomised individuals received three guaiac imprinted test cards at invitation (Hemoccult 
II, Beckman Coulter Inc., Fullerton USA) to be used on three consecutive bowel movements 
without dietary restrictions or medication limitations. Participants returned the test kit by 
mail to the Gastroenterology and Hepatology laboratory of the Erasmus Medical Centre. Tests 
were analysed without re-hydration. A test was considered positive if one or more panels were 
positive. A digital picture of the test cards was taken and stored in a database. A subset of 241 
photographs was re-evaluated by a second technician blinded for the initial test results. A third 
technician reviewed the tests in case of inter-observer variation. 
Group B: Immunochemical FOBT
Subjects received one immunochemical FOBT kit (OC-Sensor micro, Eiken Chemical Co., Tokyo, 
Japan) to collect a single faecal sample of one bowel movement. Participants returned the 
test kit by mail to the same laboratory as mentioned above for quantitative analysis using the 
automatic OC-sensor μ instrument (Eiken Chemical Co., Tokyo, Japan). The test was considered 
positive above a cut-off value of 100 nanogram haemoglobin/ml according to the instructions 
of the manufacturer and in agreement with previous studies using the same test.24, 25
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Group C: Flexible sigmoidoscopy
Individuals randomised to FS, once scheduled for an appointment, received a 120ml phosphate 
enema (Clyssie, B. Braun Medical B.V., Oss, The Netherlands) by mail with instructions for self-
administration. Administration of the enema by a nurse in the screening unit was offered as an 
alternative. Flexible sigmoidoscopy was performed with a regular forward-looking video-colo-
noscope (Olympus Europe, Hamburg, Germany). All sigmoidoscopies were performed by expe-
rienced endoscopists (>200 colonoscopies) in a dedicated screening centre. The endoscope 
was advanced as far as could be achieved without causing undue pain or distress aiming to 
reach the splenic flexure. The FS was considered complete when the endoscope was advanced 
beyond the colon descending–sigmoid junction into the proximal descending colon and more 
than 50 cm of the anal verge with endoscope in straightened position. Participants did not 
receive sedatives. The reach of the endoscope in straightened position was recorded in cm and 
location, as was the adequacy of bowel preparation. If bowel preparation was inadequate, the 
participant was offered an additional enema in the screenings unit followed by repeated FS 
during the same appointment, or to schedule a new appointment with oral bowel preparation 
(Prunacolon 75 ml) in combination with an enema. During FS, characteristics including size, 
and location of all polyps were noted and recorded. The size of each polyp was measured using 
an open biopsy forceps with 7mm span. All polyps up to a diameter of 9 mm were removed 
at FS and sent for histological evaluation. Polyps with a diameter of ≥10 mm were left in situ 
for removal during colonoscopy. Participants were referred for colonoscopy when one of the 
following criteria was met: presence of a polyp with a diameter ≥10 mm; an adenoma with ser-
rated, villous histology (≥25% villous) or high-grade dysplasia; ≥3 adenomas; ≥20 hyperplastic 
polyps; or invasive CRC.22 In accordance with the international classification, CRC was defined 
as the invasion of malignant cells beyond the muscularis mucosa. One experienced gastroin-
testinal pathologist evaluated all samples. A second gastrointestinal pathologist evaluated a 
subset of 50 adenomas and all advanced neoplasia. 
Test results
In case of a positive gFOBT, FIT or FS the GP was informed by telephone and mail within two 
weeks. The GP informed the participant about the test result and referred the participant for 
colonoscopy. A colonoscopy was scheduled within four weeks after the screening test results 
had become available. Participants with a negative gFOBT or FIT and participants with no or 
low-risk polyps at FS were informed by mail within two weeks.
Ethical approval
The study was approved by the Dutch Ministry of Health (2006/02WBO). The approval included 
the pre-randomisation design. The study letters and information brochures were approved by 
the Institutional Review Board of the Erasmus Medical Centre (MEC-2005-264). 
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Power calculation
The primary outcome measurement was the participation rate. The sample size was chosen 
based on a presumed overall 50% participation rate to yield an 80% power to discern a 2.0% 
difference in participation between the three screening strategies and a 2.5% difference in 
participation between a maximum of three equal-sized subgroups per arm.
Statistical analysis
Differences in proportions between screening strategies were calculated using the χ2 test. Dif-
ferences in means between screening strategies were calculated using a Student t-test. The 
participation rate was calculated by dividing participants by all eligible subjects (defined as all 
randomised subjects minus the excluded subjects). An univariate logistic regression model was 
fitted to the data to determine differences in participation rate between the three screening 
strategies. Separate uni- and multivariate models were fitted to the three screening arms with 
participation as function of age, sex, SES and rural vs. urban domicile. Interaction of age and sex 
was determined using a multivariate model for each screening arm. A significant interaction was 
found in the gFOBT arm between age and sex on participation (p=0.009). Age and sex-specific 
participation rates to gFOBT screening were therefore presented in the result section. The DR 
was defined as the proportion of screenees with advanced neoplasia. This definition included 
subjects with CRC, and those with advanced adenomas. Advanced adenoma was defined as 
adenoma ≥10 mm, with a villous histology (≥25% villous) or with high-grade dysplasia. The DR 
was calculated using the most advanced lesion detected per screenee. A multivariate logistic 
regression model with advanced neoplasia or CRC as a function of age, sex and screening test 
was used to determine the differences in DR between screening tests. The diagnostic yield 
per 100 invitees was calculated as subjects with an advanced neoplasia or CRC divided by all 
eligible subjects. All p-values were two-sided and considered significant if <0.05. 
resuLts
Participation
Of the 15011 subjects who were randomised prior to invitation to one of the three tests, 670 
were excluded from analysis  (4.5%; 608 subjects met one of the exclusion criteria, 43 had 
moved away and 19 had died). The overall participation rate was 48.0% (CI 47.1-48.7%). In total 
49.5% (CI 48.1-50.9%) attended gFOBT, 61.5% (CI 60.1-62.9%) FIT and 32.4% (CI 31.1-33.7%) FS 
screening (Fig 1). 
In univariate analysis sex, age, SES and rural versus urban domicile were associated with par-
ticipation rate in all screening arms (all p<0.05) (Fig. 2). Multivariate analysis showed indication 
between sex and age on participation in the gFOBT arm (p=0.009). The age-specific participation 
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rate to gFOBT screening was significantly higher in women than in men aged 50-59 years (OR 
1.6; CI 1.4-2.0), while no difference between both sexes was seen in the age groups 60-64 (OR 
1.1; CI 0.9-1.4) and 65-74 (OR 1.0; CI 0.8-1.2). The participation rate of men aged 50-59 was 
significantly lower than men aged 60-64 years (OR 0.8; CI 0.7-1.0; p<0.05). Participation rates 
were similar for the different age groups in female invitees to gFOBT screening. Independent 
predictors for higher participation to FIT screening were female sex, and age 60-64 years. Male 
sex and age 60-64 years were independent predictors for a higher participation to FS screening. 
Living in a rural area and a high SES were associated with a higher participation rate in all three 
screening arms (Table 1). 
Fig 2: 
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fig 2: Age specific participation rates to guaiac-based faecal occult blood test (gFOBT), immunochemical 
faecal occult blood test (FIT) and flexible sigmoidoscopy (FS) screening of men and women
Uptake and detection rate of screening for colorectal cancer 41
Screening strategies
GFOBT was analysable in 2,351 cases (99%), and was positive in 65 cases (2.8%). Sixty-two (95%) 
subjects underwent a colonoscopy, which was complete in all cases. Advanced adenomas were 
found in 22 (0.9%), and a CRC in six screenees (0.3%) (Table 2). Of the six CRCs, three (50%) were 
classified as early stage (stage I 1, stage II 2) and three (50%) as advanced CRCs (stage III 2, stage 
IV:1). The positive predictive value (PPV) of gFOBT was 45.2% for an advanced neoplasia and 
9.7% for a CRC. 
FIT was complete in 2975 subjects (99.9%). A cut-off value of 100ng/ml resulted in 143 (4.8%) 
positive tests. In total 137 (96%) of the positive screenees underwent colonoscopy. This proce-
dure was complete in 134 (98%) subjects. A double contrast barium enema was performed in 
one subject with an incomplete colonoscopy. Advanced adenoma were detected in 59 (2.0%) 
table 1: Participation rate by age, gender, social economic status and rural versus urban in all screening 
arms; multivariate analysis.
gFOBT
OR (CI)
FIT
OR (CI)
FS
OR (CI)
Men
Women
1
1.1(0.9-1.4)‡
1
1.3 (1.1-1.4)*
1
0.9 (0.8-1.0)*
50-59yr
60-64yr
65-74yr
0.8 (0.7-1.0)‡*
1
1.0 (0.8-1.2)‡
0.8 (0.7-0.9)*
1
1.0 (0.8-1.2)
0.9 (0.7-1.0)*
1
0.8 (0.6-0.9)*
SES low
SES middle
SES high
1
1.2 (1.1-1.4)*
1.1 (1.0-1.3)
1
0.9 (0.8-1.1)
1.3 (1.1-1.5)*
1
1.0 (0.8-1.2)
1.2 (1.0-1.4)*
Strong urban
Urban
Rural 
1
1.7 (1.4-2.1)*
2.6 (1.9-3.6)*
1
1.2 (1.0-1.5)
2.3 (1.6-3.3)*
1
1.2 (1.0-1.5)
1.8 (1.3-2.6)*
ORs adjusted for all the other variables in the table; 
‡ Interaction of age and sex in gFOBT arm. Therefore age-specific OR (60-64yrs olds) are presented for 
men and women and sex specific ORs (male) for the different age groups. 
* P<0.05; 
table 2: Most advanced lesion identified by screening. 
  N (%) gFOBT FIT FS*
Completed screening test
Positive screening tests 
Colonoscopy performed
2351
65 (2.8)
62 (95)
2975
143 (4.8)
137 (96)
1386
142 (10.2)
141 (99)
Detection rate 
Non-neoplastic polyp 
Non-advanced adenoma
Advanced adenoma 
Colorectal cancer
4 (0.2)
12 (0.5)
22 (0.9)
6 (0.3)
7 (0.2)
23 (0.8)
59 (2.0)
14 (0.5)
272 (19.6)
183 (13.2)
103 (7.4)
8 (0.6)
Positive predictive value
Advanced adenoma 
Colorectal cancer
35.5
9.7
43.1
10.2
n.a.
n.a.
* Findings during sigmoidoscopy and colonoscopy; 
Advanced adenoma: adenoma ≥10 mm, villous component (≥25% villous) or high-grade dysplasia; 
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and CRC in 14 (0.5%) screenees (Table 2). Of all detected CRCs (n=14) due to FIT screening, 12 
(86%) were early stage (Stage I 5; Stage II 7) and two were advanced (Stage III). The PPV of a 
FIT for finding an advanced neoplasia (53.3%) or a CRC (10.2%) were similar to the PPV of the 
gFOBT (respectively p=0.42; p=0.93). 
FS evaluation was complete in 1386 screenees (91%). Incomplete examination was due to 
insufficient bowel preparation in 88 (5.8%) subjects and failure to obtain full introduction (>50cm 
with straightened scope) in 51 (3.4%) subjects. In total 142 (10.2%) screenees were referred 
for colonoscopy. In total 1243 screenees without polyps (n=817; 59%) or with non-advanced 
polyps (424; 31%) were discharged. All but one of the positive screenees underwent a complete 
colonoscopy (99%). In total 103 screenees (7.4%) had an advanced adenoma and 8 (0.6%) a CRC 
(Table 2), including six early stage CRCs (75%; stage I 6) and two advanced CRCs (stage III 2). 
One complication occurred within 30 days after FS. A 67-year old screenee presented one week 
after FS with symptoms of a colovaginal fistula due to a previous diverticulitis. It was considered 
that air insufflation might have led to symptoms, since no signs of diverticulitis were seen or 
biopsies had been taken during FS. An uncomplicated sigmoid resection was performed. In 
total four patients (1.1%) experienced minimal rectal bleeding following polypectomy during 
colonoscopy without hospitalisation.
Comparison of advanced neoplasia detection rate and yield
Older age (65-75 years: OR 2.3; CI 1.7-3.2) and male sex (OR 2.7; CI 2.0-3.6) were independent 
predictors for detecting advanced neoplasia. After adjusting for age and sex (Table 3), FIT 
detected significantly more advanced neoplasia than gFOBT (OR 2.0; CI 1.3-3.2). The DR of 
advanced neoplasia was considerable higher in the FS arm than in the gFOBT (OR 7.0 CI 4.6-
10.7) and FIT (OR 3.4; CI 2.5-4.7) arms. The DR of CRCs did not differ significantly among the 
three screening arms (Table 3). 
The diagnostic yield of advanced neoplasia per 100 invited subjects was significantly higher 
with FIT (1.5; CI 1.2-1.9) than with gFOBT (0.6; CI 0.4-0.8; p<0.001). FS demonstrated the highest 
diagnostic yield of advanced neoplasia of 2.4 (CI 2.0-2.8) per 1000 invited subjects compared to 
gFOBT (p<0.001) and FIT (p<0.001). 
table 3: Odds ratios for the probability of detection of colorectal neoplasia in screened individuals which 
FIT and FS in comparison with gFOBT.
Advanced Neoplasia 
OR (CI)
Colorectal cancer 
OR (CI)
gFOBT
FIT 
FS
1
2.0 (1.3-3.2)
7.0  (4.6-10.7)
1
1.8 (0.7-4.7)
2.2 (0.8-6.3)
Advanced neoplasia: adenoma ≥10 mm, villous component (≥25% villous) or high-grade dysplasia; 
colorectal cancer.
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discussion
Our data demonstrated a 12% higher participation rate to FIT than gFOBT screening, which is 
in agreement with the study of van Rossum et al, who used a similar study design.24 It has been 
postulated that dietary restrictions required for gFOBT screening are responsible for a lower 
uptake.26 However, our study shows that gFOBT screening performed without dietary restric-
tions remains associated with a lower uptake than FIT screening. A more demanding sampling 
procedure and the number of consecutive bowel movements that had to be collected (gFOBT 
three vs. FIT one) seem likely explanations for this difference in participation rate.27 
Participation to FS screening was significantly lower than to both FOBTs. The participation 
rate to FS screening in our population is in agreement with most previous population-based FS 
screening studies 16, 17, 21, but significantly lower than seen in the Norwegian FS screening trial 
(67%).21 Our data on participation cannot be directly compared to studies where only eligible 
and interested respondents to a questionnaire were included in the study.20, 22 However, mul-
tiplying inclusion with participation rates among those included results in overall participation 
rates in the range of 10-39%.20, 22 Furthermore, invitees in our study were asked to schedule 
their own FS appointment, which may have negatively influenced the participation rate. In 
other studies the appointment for FS was prefixed to be confirmed or modified.20, 22
Sex and age were independent predictors for participation in all screening arms. In both 
FOBT arms, men were less likely to attend. A low participation rate was especially found among 
men aged 50-55 years (gFOBT 37%; FIT 51%). In contrast, uptake of FS screening was lower 
among women. This is in accordance with previous studies.16, 17, 20, 22 Attitude and believes 
about FS screening might form a barrier to FS screening. Women more often experience fear 
and embarrassment to undergo FS.28 A special approach to women in a future nation-wide FS 
screening programme should therefore be considered. 
FS screening detected a substantial higher proportion of advanced neoplasia than both 
FOBTs, mainly due to a high DR of advanced adenoma (7.4%). This higher proportion of 
advanced neoplasia detected at FS suggests a more significant CRC incidence and mortality 
reduction with FS than with FOBT screening. However, the comparison of the DR between both 
FOBTs and FS screening in this study is limited, since only one screening round was taken into 
account. Data of successive FOBT screening rounds should be considered to obtain a more 
accurate comparison of the DR of both FOBTs and FS screening. Our results did demonstrate 
a respectively three and seven times higher DR of advanced neoplasia of FS compared to FIT 
and gFOBT screening suggesting a more favourable cumulative DR of advanced neoplasia for a 
five-yearly FS compared to a biennial gFOBT or FIT screening programme. A 10-yearly interval 
for FS screening might be justified if an experienced endoscopist performed an examination 
of at least the distal 50 cm of the colon on well-prepared subjects. These criteria are not rou-
tinely achieved in many screening settings. Current guidelines therefore recommend a 5-year 
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screening interval.29 Further information on the optimal screening interval is awaited from the 
ongoing prospective FS studies.20-23
The DR of advanced neoplasia (8.0%) in the FS arm was high compared to other studies 
(3.6-5.2%).16, 17, 20-22 A possible explanation for the higher DR may lie in inclusion of subjects 
between 65 and 74 years of age whereas others included subjects between 55 and 64 years 
of age, since more advanced neoplasia were detected in screenees aged 65-74 than screenees 
aged 50-64.20, 22 This is in agreement with studies reporting an increased prevalence of 
advanced neoplasia at older age.23, 30, 31 The high DR can also be explained by a more extended 
endoscopic examination during FS. In this study, FS was performed until the splenic flexure 
(81% of completed FS) or at least proximal descending colon, while other studies reached for 
the transition from sigmoid to descending colon as anatomic extent of FS.20, 22, 23 
A high compliance of positive screenees to a follow-up colonoscopy positively influences 
the DR. In this study, nearly all positive screenees underwent a colonoscopy (97%). This is 
significantly higher than observed in other screening studies in which participation rates for 
colonoscopy after FOBT or FS screening generally ranged between 80-93%.11, 16, 17, 20 This dif-
ference in compliance rate may be population dependent. However, our compliance rates to 
colonoscopy after a positive gFOBT or FIT were considerably higher than observed in the study 
of van Rossum et al (83%), which had a similar design and was conducted in the same country.24 
We think that this difference was primarily due to the fact that we, other than van Rossum et al., 
put the GP in charge of informing the screenee on the positive test result and further handling 
the referral of the screenee to one of the affiliated hospitals. The GP thus acted as a central 
stakeholder in the follow-up process. 
This study has some limitations. Firstly, the trial has been performed in a screening-naïve 
population. A previous European study reported a low awareness of CRC and CRC screening 
in Europe and especially in The Netherlands.32 Awareness of CRC and the effectiveness of 
screening does increase participation.33 Therefore various media were used to promote this 
study. However, maximizing awareness requires time and effort. We hypothesize that this may 
further increase the uptake of screening. Secondly, in this study a pre-randomisation design 
was used to reflect a nation-wide screening programme as closely as possible. Subjects meet-
ing the exclusion criteria were therefore excluded after randomisation. Exclusion numbers were 
higher in the FS arm than in the other arms partly due to the extra opportunity of recognising 
exclusion criteria for FS subjects during the telephone call they had to make. Not excluding 
those subjects would not have changed the participation rates considerably (gFOBT 47.5%, 
FIT 59.5%, FS 30.4%) and did therefore not influence the results of this study. Thirdly, this study 
describes the first screening rounds in our population. Data on participation and detection 
rates of successive screening rounds are needed to provide insight in long-term effectiveness 
of a population-based screening programme. Fourthly, colonoscopy was not incorporated as a 
primary screening tool in this study. We acknowledge that colonoscopy is considered the gold 
standard for CRC screening. However, colonoscopy as primary screening tool is hampered by a 
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low participation rate and prospective data on the efficacy are lacking. Finally, we only referred 
screenees for colonoscopy if one of the predefined high risk criteria was met at FS.  Screenees 
with two or fewer tubular adenomas < 10mm were therefore not referred for colonoscopy. Our 
approach was in agreement with two large ongoing trials studying the impact of first round 
FS screening on CRC mortality 22, 34, but in contrast with another European RCT on FS.21 In the 
latter study, all subjects with a distal adenoma of any size were referred for colonoscopy. Our 
approach has the disadvantage of missing cases with proximal advanced neoplasia in the pres-
ence of no more than two small distal tubular adenomas. However, a previous study reported 
that 1.9% of these screenees with one or two small distal adenomas (5-9mm) have proximal 
advanced lesions compared to 9.9% of screenees with distal adenomas >10 mm.34 Our refer-
ral criteria therefore limit the required colonoscopy capacity while referring screenees with a 
higher risk on a proximal advanced neoplasia.
In conclusion, this randomised population-based CRC-screening trial demonstrates that FIT 
outperforms gFOBT screening in participation and detection rate. FIT screening should there-
fore be strongly preferred over gFOBT screening. Apart from this, it is important to recognise 
that FS screening in a first screening round provides a considerably higher diagnostic yield of 
advanced adenomas and CRC per 100 invitees than both FOBTs, despite a lower participation 
rate. This supports the consideration of a dual-mode screening programme, offering FS as first 
screening method and FIT as alternative. Long-term prospective RCTs have to be awaited to 
determine the CRC incidence and mortality reduction due to HT and FS screening.
acknowLedgements
This trial was funded by the Dutch Cancer Society (EMCR 2006-3673), the Dutch Ministry of 
Health, Health Care Prevention Program–Implementation (ZonMw 2006-5877), Olympus 
Medical Systems Europe GmbH, Hamburg, Germany and Eiken Chemical Co., Tokyo, Japan. 
The authors thank the members of the advisory board, E van der Donk (Tenalea) for retrieval 
of the population sample and randomisation, CWN Looman for statistical advise, J Haringsma 
for the organisation of the endoscopy programme, pathologists J. van Krieken and H. van der 
Valk for the re-evaluation of pathology samples, all general practitioners in the region, gastro-
enterologists and surgeons of Erasmus MC, IJsselland Hospital, St Fransicus Gasthuis Hospital, 
Vlietland Hospital, Haven Hospital, Ikazia Hospital, Medical Centre Rijnmond-South and Albert 
Schweitser Hospital, residents, secretaries, nurses and all participants of the trial. 
Ch
ap
te
r 2
46
reference List
 1.  Ries L.A.G., Melbert D., Krapcho M., Mariotto A., Miller BA., Feuer E.J., Clegg L., Horner M.J., Howlader 
N., Eisner M.P., Reichman M., Edwards B.K., (eds). SEER Cancer Statistics Review, 1975-2004. Bethesda, 
MD: National Cancer Institute 2007.
 2.  Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, 
Panish JF, . Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study 
Workgroup. N Engl J Med 1993;329:1977-1981.
 3.  Council Recommendation on Cancer Screening.  2003/0093. Commission of the European Communi-
ties Brussels 2003.
 4.  Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for 
colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471.
 5.  Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality 
from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N 
Engl J Med 1993;328:1365-1371.
 6.  Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham 
CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 
1996;348:1472-1477.
 7.  Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-
up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. 
Results for 68,308 subjects. Scand J Gastroenterol 1994;29:468-473.
 8.  Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-
cancer screening. N Engl J Med 1996;334:155-159.
 9.  Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Fecal DNA versus fecal occult blood for 
colorectal-cancer screening in an average-risk population. N Engl J Med 2004;351:2704-2714.
 10.  Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical 
fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 
2005;129:422-428.
 11.  Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, Tichet J, Launoy G. Comparison of a 
guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a 
general average risk population. Gut 2007;56:210-214.
 12.  Li S, Wang H, Hu J, Li N, Liu Y, Wu Z, Zheng Y, Wang H, Wu K, Ye H, Rao J. New immunochemical 
fecal occult blood test with two-consecutive stool sample testing is a cost-effective approach for 
colon cancer screening: results of a prospective multicenter study in Chinese patients. Int J Cancer 
2006;118:3078-3083.
 13.  Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical 
test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal 
neoplasia. Cancer 2006;107:2152-2159.
 14.  Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y. A quantitative immunochemical faecal occult blood 
test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Ali-
ment Pharmacol Ther 2006;23:1359-1364.
 15.  Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, 
Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood 
tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-1470.
 16.  Segnan N, Senore C, Andreoni B, Arrigoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, DiPlacido 
R, Ferrari A, Ferraris R, Ferrero F, Fracchia M, Gasperoni S, Malfitana G, Recchia S, Risio M, Rizzetto M, 
Saracco G, Spandre M, Turco D, Turco P, Zappa M. Randomized trial of different screening strategies 
for colorectal cancer: patient response and detection rates. J Natl Cancer Inst 2005;97:347-357.
 17.  Segnan N, Senore C, Andreoni B, Azzoni A, Bisanti L, Cardelli A, Castiglione G, Crosta C, Ederle A, Fantin 
A, Ferrari A, Fracchia M, Ferrero F, Gasperoni S, Recchia S, Risio M, Rubeca T, Saracco G, Zappa M. 
Uptake and detection rate of screening for colorectal cancer 47
Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal 
cancer screening. Gastroenterology 2007;132:2304-2312.
 18.  Selby JV, Friedman GD, Quesenberry CP, Jr., Weiss NS. A case-control study of screening sigmoidos-
copy and mortality from colorectal cancer. N Engl J Med 1992;326:653-657.
 19.  Newcomb PA, Norfleet RG, Storer BE, Surawicz TS, Marcus PM. Screening sigmoidoscopy and colorec-
tal cancer mortality. J Natl Cancer Inst 1992;84:1572-1575.
 20.  Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, Ferraris R, Gasperoni S, Penna A, Risio M, 
Rossini FP, Sciallero S, Zappa M, Atkin WS. Baseline findings of the Italian multicenter randomized 
controlled trial of “once-only sigmoidoscopy”--SCORE. J Natl Cancer Inst 2002;94:1763-1772.
 21.  Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian Colorectal Cancer 
Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up 
in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-642.
 22.   Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK 
multicentre randomised trial. Lancet 2002;359:1291-1300.
 23.  Weissfeld JL, Schoen RE, Pinsky PF, Bresalier RS, Church T, Yurgalevitch S, Austin JH, Prorok PC, Goha-
gan JK. Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening 
examination of a randomized trial. J Natl Cancer Inst 2005;97:989-997.
 24.  van Rossum LG, Van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Van Krieken HH, Verbeek AL, Jansen 
JB, Dekker E. Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for 
Colorectal Cancer in a Screening Population. Gastroenterology 2008.
 25.  Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S, Mantellini P, Lopane P, Perco 
M, Rubeca T, Salvadori P, Visioli CB, Zappa M. Colorectal cancer screening programme by faecal occult 
blood test in Tuscany: first round results. Eur J Cancer Prev 2004;13:19-26.
 26.  Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening 
for colorectal cancer. Med J Aust 2001;175:195-198.
 27.  Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal 
haemoglobin test technologies on population participation in screening for colorectal cancer. J Med 
Screen 2003;10:117-122.
 28.  Farraye FA, Horton K, Hersey H, Trnka Y, Heeren T, Provenzale D. Screening flexible sigmoidoscopy 
using an upper endoscope is better tolerated by women. Am J Gastroenterol 2004;99:1074-1080.
 29.  Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, 
Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ. Screening 
and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint 
guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, 
and the American College of Radiology. Gastroenterology 2008;134:1570-1595.
 30.  Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen 
asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J 
Med 2000;343:162-168.
 31.  Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, Kikendall JW, Kim HM, Weiss DG, Emory 
T, Schatzkin A, Lieberman D. Colonoscopic screening of average-risk women for colorectal neoplasia. 
N Engl J Med 2005;352:2061-2068.
 32.  Keighley MR, O’Morain C, Giacosa A, Ashorn M, Burroughs A, Crespi M, Delvaux M, Faivre J, Hagenmuller 
F, Lamy V, Manger F, Mills HT, Neumann C, Nowak A, Pehrsson A, Smits S, Spencer K. Public awareness 
of risk factors and screening for colorectal cancer in Europe. Eur J Cancer Prev 2004;13:257-262.
 33.  Wee CC, McCarthy EP, Phillips RS. Factors associated with colon cancer screening: the role of patient 
factors and physician counseling. Prev Med 2005;41:23-29.
 34.  Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, Ferraris R, Gasperoni S, Penna A, Risio M, 
Rossini FP, Sciallero S, Zappa M, Atkin WS. Baseline findings of the Italian multicenter randomized 
controlled trial of “once-only sigmoidoscopy”--SCORE. J Natl Cancer Inst 2002;94:1763-1772.

chapter 3
screening for colorectal 
cancer; random 
comparison of guaiac and 
immunochemical faecal 
occult blood testing at 
different cut-off levels
L. Hol1, J.A. Wilschut3, M. van 
Ballegooijen3, A.J. van Vuuren1, 
H. van der Valk4, J.C.I.Y. Reijerink5, 
A.C.M. van der Togt6, E.J. 
Kuipers1,2, J.D.F. Habbema3, M.E. 
van Leerdam1
1Departments of Gastroenterology 
and Hepatology, 2Internal Medicine 
and 3Public Health, Erasmus Medical 
Centre, Rotterdam, the Netherlands
4 Association of Laboratory Pathology 
and Cytology (Pathan), Rotterdam, 
the Netherlands 
5Cancer screening organisation 
for southwestern Netherlands, 
Vlaardingen, the Netherlands, 
6Comprehensive Cancer Centre, 
Rotterdam, the Netherlands 
Ch
ap
te
r 3
50
abstract
Immunochemical faecal occult blood testing (FIT) provides quantitative test results, which 
allows optimisation of the cut-off value for follow-up colonoscopy. We conducted a randomised 
population-based trial to determine test characteristics of FIT (OC-Sensor micro, Eiken, Japan) 
screening at different cut-off levels and compare these to guaiac-based faecal occult blood 
test (gFOBT) screening in an average risk population. A representative sample of the Dutch 
population (n=10011), aged 50-74 years, was 1:1 randomised before invitation to gFOBT and 
FIT screening. Colonoscopy was offered to screenees with a positive gFOBT or FIT (cut-off 50ng 
haemoglobin/ml). When varying the cut-off-level between 50 and 200ng/ml, the positivity 
rate of FIT ranged between 8.1% (95% CI 7.2-9.1%) and 3.5% (CI 2.9-4.2%), the detection rate 
of advanced neoplasia ranged between 3.2% (CI 2.6-3.9%) and 2.1% (CI:1.6-2.6%), and the 
specificity ranged between 95.5% (CI 94.5-96.3%) and 98.8% (CI 98.4-99.0%). At a cut-off value 
of 75ng/ml the detection rate was two-times higher than with gFOBT screening (gFOBT:1.2%; 
FIT:2.5%; p<0.001), while the number needed to scope (NNscope) to find one screenee with 
advanced neoplasia was similar (2.2 vs. 1.9; p=0.69). FIT is considerably more effective than 
gFOBT screening within the range of tested cut-off values. From our experience, a cut-off value 
of 75ng/ml provided an adequate positivity rate and an acceptable trade-off between detec-
tion rate and NNscope. 
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introduction
Colorectal cancer (CRC) is a major health problem in the Western World. Screening can reduce 
CRC-related mortality due to detection of early carcinomas and removal of pre-malignant 
lesions.1, 2 The American Gastroenterology Association (AGA)3, the US Multi-Society Task Force 
4, Asia Pacific Working Group on Colorectal Cancer screening5 and the European council rec-
ommend CRC screening for average risk individuals over 50 years of age.6  Several countries 
have a nation-wide screening programme based on gFOBT, since this is the only available test 
with a proven mortality reduction 7-9, but consider changing to an immunochemical FOBT (FIT) 
programme based on accumulating evidence that FIT is superior to gFOBT screening, including 
a higher attendance 10-12 and detection rate 10, 13, 14, as well as a higher sensitivity without a 
significant drop in specificity.13, 15-19 Furthermore, FIT specifically binds human haemoglobin, 
which makes drugs and diet restrictions superfluous. 
Immunochemical faecal occult blood testing samples can be analysed automatically, which 
has important advantages for reproducibility, quality control, capacity, and thus personnel 
need and costs.17, 20 Another advantage of FIT is the quantitative test results, which allows 
determining an optimal cut-off value for a nation-wide screening programme.13, 16, 17, 21, 22 
The cut-off value for a positive test can be based on a positivity rate that meets the available 
colonoscopy resources. At the same time, the number of colonoscopies is an important deter-
minant of the neoplasia detection rate, and thus of the potential preventive effect of a CRC 
screening programme. 
Data on positivity rate and test performance at different cut-off levels of FIT screening in 
an average risk population are highly needed to determine the optimal cut-off value for FIT 
screening. We therefore conducted a randomised trial to compare the positivity rate, detec-
tion rate and specificity of FIT (OC-Sensor micro, Eiken Chemical Co., Tokyo, Japan) screening 
at different cut-off levels with gFOBT (Hemoccult II; Beckman Coulter Inc., Fullerton, CA, USA) 
screening in an average risk screening naïve population. 
metHods
Study population 
The study was performed in the Rijnmond region in the Southwest of the Netherlands. This 
region includes Rotterdam and surrounding villages and harbours 338000 inhabitants in the 
target population. The region thus combines both rural and urban settings. Ten thousand 
eleven individuals aged 50-74 years old were randomly selected from the Municipal registries. 
The selected individuals were 1:1 randomised per household after stratifying for age, sex and 
social economic status into group A (gFOBT) or B (FIT) using a computer generated allocation 
algorithm (Tenalea, Amsterdam, The Netherlands) (Figure 1). Randomisation occurred before 
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invitation. Informed consent was asked after randomisation. Individuals with a history of inflam-
matory bowel disease or CRC, a colonoscopy, sigmoidoscopy or barium contrast enema in the 
last three years, major health problems or inability to sign informed consent were excluded. 
Recruitment took place between November 2006 and November 2007. 
Interventions
The randomly selected 10011 individuals were sent a pre-invitation letter containing informa-
tion on CRC screening. Two weeks later an invitation letter was sent with information on pos-
sible advantages and risks of screening. This was accompanied by an informed consent form, 
which had to be signed and returned. A test set was sent along with the invitation. A reminder 
was sent six weeks afterwards to all non-respondents. Information about the study was further 
given by direct visits of research physicians to all general practitioners (GP) in the region, as 
well as via a dedicated website (www.dikkedarmkankerpreventie.nl), mailings and information 
sites of the municipality offices, regional newspapers, and national and regional broadcasting. 
Group A: Guaiac-based FOBT 
All individuals randomised to gFOBT received three guaiac imprinted test cards (Hemoccult II) 
to be used on three consecutive bowel movements without dietary restrictions or medication 
limitations. Participants returned the test kit by mail to the Gastroenterology and Hepatology 
laboratory of the Erasmus Medical Centre. Tests were analysed without re-hydration. A test was 
considered positive if at least one of six panels was positive. A digital picture of test cards was 
taken and stored in a database. As a quality control, 241 (10%) photographs were re-evaluated 
by a second technician blinded for the initial test results. A third technician reviewed the pho-
tographs in case of inter-observer variation. 
Group B: Immunochemical FOBT
Subjects randomised to FIT screening received one FIT kit (OC-Sensor micro) to collect a single 
faecal sample of one bowel movement without dietary restrictions or medication limitations. 
Participants returned the test kit by mail to the same laboratory that analysed the gFOBT for 
quantitative analysis using the automatic OC-Sensor micro instrument (Eiken Chemical Co., 
Tokyo, Japan). Participants were referred to colonoscopy at haemoglobin levels above 50ng/ml. 
Follow-up
In case of a negative gFOBT or FIT, both the general practitioner (GP) and the participant were 
informed by mail within two weeks. No further follow-up was necessary. In case of a positive 
gFOBT or FIT (faecal Hb level ≥ 50ng/ml), the GP was informed both by telephone and mail 
within two weeks. The GP informed the participant about the test result and referred the par-
ticipant for colonoscopy. A colonoscopy was scheduled within two weeks after the screening 
test results had become available. 
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Colonoscopy
All colonoscopies were performed in eight hospitals and performed by experienced endosco-
pists (individual experience >200 colonoscopies). The reach of the endoscope in cm and the 
location, as well as the adequacy of bowel preparation was recorded. During colonoscopy, 
characteristics including size, pedunculated or sessile aspect and location of all polyps were 
noted and recorded. Location was defined as rectum, sigmoid, descending, transverse, ascend-
ing colon or cecum and measured in cm from the anal verge with the endoscope in straight-
ened position. Size of each polyp was estimated using an open biopsy forceps with 7mm span. 
An experienced gastrointestinal pathologist evaluated all removed polyps. In accordance with 
the international classification, CRC was defined as the invasion of malignant cells beyond the 
muscularis mucosa. Patients with intramucosal carcinoma or carcinoma in situ were classified 
as having high-grade dysplasia.
Ethical approval
The study was approved by the Dutch Ministry of Health (2006/02WBO). The approval included 
the pre-randomisation design. The study letters and information brochures were approved by 
the Institutional Review Board of the Erasmus Medical Centre (MEC-2005-264).  
Statistical analysis
Differences in proportions between screening strategies were calculated using a χ2 test. Dif-
ferences in means between screening strategies were calculated using a Student t-test. All 
p-values were two-sided and considered significant if <0.05. Uni- and multivariate logistic 
regression analyses were used to determine the influence of sex and age on positivity rate, 
number needed to scope, detection rate and number needed to screen. The positivity rate 
was defined as the proportion of participants having a positive gFOBT or FIT test. For FIT, the 
positivity rate was separately calculated for cut-off levels of respectively 50, 75, 100, 125, 150, 
175 and 200ng/ml. The detection rate was defined as the proportion of participants having 
advanced neoplasia. This was calculated as the number of screenees with an advanced neopla-
sia divided by all screenees with a complete screening test. Advanced neoplasia included CRC, 
and advanced adenoma. Advanced adenoma was defined as adenoma ≥10 mm, or with histol-
ogy showing either a >25% villous component or high-grade dysplasia. We compared faecal 
haemoglobin measurements between screenees with a normal colonoscopy and screenees 
with non-neoplastic polyps, non-advanced adenomas, advanced adenomas and CRC as most 
advanced lesion by the Kruskal–Wallis nonparametric analysis of variance (ANOVA) and the 
Mann–Whitney test, since the data were not normally distributed. Participation, positivity and 
detection rate, positive predictive value (PPV) and specificity were calculated and described 
as percentages with 95% confidence intervals (CI). The specificity for advanced neoplasia and 
CRC was calculated under the rare disease assumption as the ratio of number of all negative 
screenees and total number of screenees subtracted by the number of true positives.23 Number 
Ch
ap
te
r 3
54
needed to scope describes the number of colonoscopies to find one screenee with an advanced 
neoplasia or CRC. Number needed to screen was calculated as the number of complete screen-
ing tests needed to find one advanced neoplasia or CRC. Differences in PPV between sexes or 
age groups in the FIT arm were described for a cut-off of 100ng/ml, since this cut-off value is 
most commonly used.10, 16, 21, 24
resuLts
In total 10011 subjects were randomised prior to invitation to one of two FOBTs. Three-hundred-
seventy (3.7%) were excluded from analyses (332 subjects met one of the exclusion criteria, 26 
had moved away and 12 had died). A total of 2375 out of 4796 (50%; CI 48-51%) participants 
attended gFOBT screening. The gFOBT was analysable in 2351 cases (99%). 2979 out of 4843 
(62%; CI 60-63%) subjects attended FIT screening and the test was complete in 2975 subjects 
(99.9%) (Figure 1). The distribution of age (mean ± SD gFOBT 61±7 yrs; FIT 61±7 yrs old) and sex 
(male gFOBT 46%; FIT 48%) of the analysable subjects did not differ between the two screening 
arms. 
Proportion of positive tests 
In total 65 screenees had a positive gFOBT (2.8%; CI 2.2-3.6%). Immunochemical faecal occult 
blood testing was positive in 241 screenees (8.1%; CI 7.2-9.1%) at a 50ng/ml cut-off and in 
103 screenees (3.5%; CI 2.9-4.2%) at a 200ng/ml cut-off (Table 1). A significant decrease in the 
proportion of positive tests was seen between a cut-off value of 50 and 75ng/ml (8.1 vs. 5.7%), 
followed by a more gradual decrease between 75 and 200 ng/ml (Table 1). Male screenees 
were more likely to have a positive gFOBT (3.7 vs. 1.9% OR 1.4 CI 1.1-1.8) or FIT (FIT100: 6.8 vs. 
3.0%; OR 2.3; CI 1.6-3.3) than female screenees. The proportion of positive gFOBTs was slightly 
higher in screenees aged 60-74 than in screenees aged 50-59 yrs old, but this difference was not 
significant (3.1 vs. 2.3%; OR 1.3; CI 0.8-2.2). In the FIT arm, the proportion of positive tests was 
significantly higher in screenees aged 60-74 years than in screenees aged 50-59 years (FIT100: 
6.1 vs. 3.3%; OR 1.8; CI 1.3-2.6) (Fig 2).
Colonoscopy findings per test and cut-off value
Sixty-two (95.4%) of the 65 gFOBT-positive screenees and 226 (93.8%) of the 241 screenees with 
a FIT result ≥50ng/ml underwent a colonoscopy. A double contrast barium enema was per-
formed in three subjects with an incomplete colonoscopy. Two colonoscopies were incomplete 
due to an obstructing tumour. The colonoscopy findings are shown in Table 2 and are related 
to the amount of haemoglobin in the faeces. A significantly higher proportion of screenees 
with faecal haemoglobin levels of 150-200 (48%) and ≥200 (61%) had advanced neoplasia 
than screenees with faecal haemoglobin levels of 50-150ng (25%) (respectively p=0.009 and 
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p<0.001), whereas the proportions were similar amongst screenees with values of 50-100ng/
ml and 100-150ng/ml (25 vs.18%; p=0.60)
Haemoglobin levels per finding
The median faecal haemoglobin (Hb) level of positive screenees with a normal colonoscopy 
was 93 ng/ml. Median Hb measurement in screenees with as most advanced finding a non-
neoplastic polyp was 109 ng/ml, a non-advanced adenoma was 112 ng/ml, an advanced 
adenoma was 373 ng/ml, a CRC was 404 ng/ml. Faecal Hb levels of screenees with a normal 
colonoscopy did not significantly differ from those of screenees with non-neoplastic (p=0.88) 
or non-advanced adenoma (p=0.89), while the faecal Hb level of screenees with an advanced 
adenoma or CRC were significantly higher than those of screenees with a normal colonoscopy 
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Fig 1 gFOBT FIT
10011 were randomised
5004 were invited
2375(50%) attended
65 (2.8%) had a 
positive screen
62 underwent TC
206 were excluded
2351 returned a 
complete gFOBT
24 (1.0%) returned 
incomplete gFOBT
2286 had a negative 
screen
3 refused TC
28 (1.2) had an 
advanced neoplasia
4796 were eligible
5007 were invited
2979 (62%) attended
241 (8.1%) had a 
positive screen
226 underwent TC
2975 returned a 
complete FIT
4 (0.1%) returned 
incomplete FIT
2734 had a negative 
screen
15 refused TC
95 (3.2) had an 
advanced neoplasia
4843 were eligible
2421 did not 
participate 
164 were excluded
1864 did not 
participate 
fig 1: Trial profile.
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fig 2: Positivity rate of gFOBT and FIT at different cut-offs in men and women aged 50-59 and 60-74 years 
old.
table 2: Colonoscopic findings per screenee according to the haemoglobin levels of the positive FIT.
Haemoglobin level in ng/ml
50-100
n (%)
100-150
n (%)
150-200
n (%)
≥200
n (%)
Total screenees 89 (100) 22 (100) 17 (100) 98 (100)
No findings 37 (42) 11 (50) 4 (23) 19 (19)
Non-neoplastic polyp 8 (9) 1 (5) 3 (18) 3 (3)
Non-advanced adenomas 22 (25) 6 (27) 2 (12) 15 (15)
Advanced adenomas 20 (22) 3 (14) 7 (41) 49 (49)
CRC 2 (2) 1 (5) 1 (6) 12 (12)
Advanced neoplasia 22 (25) 4 (18) 8 (47) 61 (61)
Advanced adenoma: adenoma ≥ 10 mm, villous component (≥ 25% villous) or high-grade dysplasia; CRC: 
colorectal cancer.
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(both p<0.001). The difference between those with advanced adenoma and those with CRC 
was not significant (p=0.53). 
Test characteristics
The positive predictive value (PPV) of gFOBT for advanced neoplasia and for CRC was 45% (CI: 
33-58%) and 10% (CI: 4-20%) respectively. Immunochemical faecal occult blood testing demon-
strated a more favourable PPV for detecting advanced neoplasia at higher cut-off values (Table 
1), but this difference was only significant at cut-off values >175ng/ml (gFOBT 45% vs. FIT175 
63%; p=0.029 and FIT200 62%; p=0.035). The PPV for CRC was similar for gFOBT and FIT at all 
cut-off levels, although the PPV of FIT steadily increased with increasing cut-off value (Table 1). 
The NNscope to detect one screenee with an advanced neoplasia or CRC was respectively 
2.2 and 10.3 for gFOBT. The corresponding numbers with FIT screening were 2.4 and 14.1 at 
50ng/ml and 1.6 and 8.2 at 200ng/ml cut-off values (Table 1) for advanced neoplasia and CRC 
respectively. Men demonstrated a lower NNscope for advanced neoplasia than women (gFOBT: 
men 1.8; women 3.8; p=0.04; FIT100: men 1.7; women: 2.5; p=0.03) (Fig 3). No differences in 
NNscope for advanced neoplasia or CRC were seen between different age groups (gFOBT 
p=0.33; FIT100 p=0.81). 
The estimated specificity for not having advanced neoplasia and CRC was significantly lower 
for FIT at cut-off values ≤100ng/ml than gFOBT (Table 1). Above a cut-off value of 100ng/ml the 
estimated specificity was similar to the gFOBT. 
Detection rate
In the range of tested cut-off levels, FIT detected more advanced neoplasia than gFOBT (gFOBT: 
1.2%; 95% CI 0.8-1.7%; FIT50: 3.2%: CI 2.6-3.9%; FIT200: 2.1%; CI 1.6-2.6%), while similar detection 
rates for CRC were found for gFOBT and FIT screening. 
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fig 3: Numbers needed to scope to find one screenee with an advanced neoplasia in men and women at 
different cut-off values.
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Male sex was associated with a higher detection rate of advanced neoplasia in both screen-
ing arms (gFOBT: OR 4.2; CI 1.7-10.4; FIT100: OR 3.5 CI 2.0-6.1). Screenees aged 60-74 years old 
demonstrated a higher detection rate of advanced neoplasia than screenees aged 50-59 years 
old in the FIT arm (FIT100 OR 1.9; CI 1.2-3.2), while no significant difference between both age 
groups was found in the gFOBT arm (OR 1.5; CI 0.7-3.3).
The number needed to screen (NNscreen) to find at least one advanced neoplasia was 
favourable at all cut-off levels for FIT compared to the gFOBT arm (Table 1). Male screenees 
demonstrated significantly lower numbers needed to screen to detect one advanced neopla-
sia than women (gFOBT: men 57 vs. women 181; p=0.002; FIT 100100: men 26 vs. women 91; 
p<0.001). 
discussion
We compared FIT screening at different cut-off levels with conventional guaiac-based FOBT 
screening in an average risk screening-naïve population. Our results demonstrate that FIT 
within the complete range of tested cut-off values (50-200ng/ml) outperforms gFOBT screen-
ing as it is associated with both higher attendance as well as higher detection rates of advanced 
neoplasia, even though the positive predictive value for detecting advanced neoplasia did not 
differ significantly between both tests. The outperformance of FIT over gFOBT on both atten-
dance and yield is very relevant for the potential impact of faecal occult blood-based screening 
on the mortality due to colorectal cancer. 
Furthermore, FIT provides quantitative results, which allows determination of an optimal 
cut-off value for a nation-wide screening programme based on colonoscopy capacity and the 
intended detection rate in the screened population. A low cut-off value (50ng/ml) provided a 
high detection rate of advanced neoplasia, but also more false positive test results and thus a 
higher number of unnecessary colonoscopies. False-positive results are associated with anxiety 
25 and increased costs.26 Increasing the cut-off value resulted in a decrease in detection rate 
but a more favourable positive predictive value. The key question is at which cut-off value the 
magnitude of benefits (possible early detection of CRC or removal of adenomas) is sufficient 
to outweigh the harms (burden, complications, demand on colonoscopy capacity, and costs 
of screening). The cut-off at which this trade-off becomes acceptable must be determined in a 
full cost-effectiveness analysis. However, the ratio between detection rate and number needed 
to scope to find one screenee with an advanced neoplasia is a good indicator for this trade-off, 
since it reflects both benefit (detecting an advanced neoplasia) and harm (the need to undergo 
colonoscopy). We found that the NNscope was higher with FIT than with gFOBT screening 
when using a FIT cut-off of 50 ng/ml, but this changed in favour of FIT when increasing the 
cut-off to 75 ng/ml (Table 1). At a 75ng/ml cut-off value, the detection rate with FIT was two-
fold higher than with gFOBT. At the same time, increasing the FIT cut-off from 50 to 75 ng/ml 
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had a considerably stronger limiting effect on the proportion of FIT positives (falling from 8.1 
to 5.7%) than any other similar further increase of the FIT cut-off (Table 1). Further increasing 
the cut-off level from 75 to 100ng/ml would result in a larger decline in detection rate (8.8%) 
than in number needed to scope (7.3%) and therefore a less favourable trade-off (Table 1). For 
these reasons, we conclude that FIT provided the most optimal trade-of when using a 75ng/
ml cut-off value. This conclusion is in agreement with observations from a colonoscopy study 
determining the one time sensitivity and specificity of the same OC-Sensor micro FIT test in 
a population of individuals at higher risk for CRC.17 The latter study and our results come to a 
lower cut-off  than the recommended cut-off value of 100ng/ml by the manufacturer (Eiken 
Chemical Co., Tokyo, Japan) and by a previous study examining the performance of the OC-
Sensor  micro at different cut-off levels.27 
Our findings on positivity rate, positive predictive value (PPV) and the detection rate of CRC 
at a cut-off of 100 ng/ml are in agreement with other studies using the OC-Sensor micro with 
this specific cut-off.10, 21, 27-29 Both our study and the similarly designed study by Van Rossum 
et al. however found a significantly higher PPV and detection rate for advanced neoplasia (PPV 
52-53%, DR 2.4-2.5%) than other studies (PPV 20-39%; DR 0.8-1.2%), even though these stud-
ies all focused on the same age group, and applied the same test and definition of advanced 
neoplasia.21, 27-29 A possible explanation is that both Dutch studies were carried out in a 
screening-naïve population, while other studies from Italy and France were performed paral-
lel to a nation-wide programme and therefore were more likely to have included previously 
screened subjects with a lower risk on advanced neoplasia.21, 27-29
The positivity rate is the main driver for the number of colonoscopies among attendants. In 
countries with a gFOBT screening programme, changing to FIT screening with a 50 ng/ml cut-
off value would require a considerable (gFOBT 2.8% vs. FIT50ng/ml 8.1% positivity rate) increase 
in colonoscopy capacity for screening. This effect is augmented by a higher attendance rate 
to FIT than to gFOBT screening.10, 30 Thus, FIT screening enables more efficient screening with 
increased participation 10, 11, 30 and improved test performances 10, 13, 14, 18, 19, 31, 32, potentially 
allowing a decrease in screening intensity by lengthening screening interval. 
The detection rate of advanced neoplasia was significantly higher in men than in women in 
both screening arms. Likewise, the number needed to screen to detect an advanced neoplasia 
was lower in men than in women. Similar differences in detection rates for advanced neoplasia 
between both sexes were found in two colonoscopy screening studies.33-35 Furthermore, the 
CRC incidence rates are on average 1.5 times higher in men than in women aged 50-75 year.2, 
36 Thus, higher pre-test probabilities for advanced neoplasia in men explains this difference. 
Several studies have therefore suggested to develop sex-specific recommendations for CRC 
screening.37, 38 However, these recommendations have so far not been incorporated in CRC 
screening guidelines, among others because more complex guidelines can negatively influ-
ence attendance rate. However, a differentiated approach taking sex and potentially age into 
account would be relatively easy with FIT screening. One could argue to use different cut-off 
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values for men and women to achieve a similar number needed to scope, which would result in 
a considerable higher cut-off value for women than for men (Figure 3). 
This study was not designed to estimate the sensitivity and specificity of the faecal occult 
blood test, since negative screenees did not undergo a colonoscopy (golden standard). The 
aim of this study was to compare test characteristics of the gFOBT and FIT at different cut-
off values. The detection rate and false-positive test results could be used as an indication 
for respectively test sensitivity and specificity, since both tests were performed in a similar 
population. Specificity for advanced neoplasia of gFOBT and FIT were estimated under the rare 
disease assumption based on the number of false positive screenees. The specificity can be 
overestimated if the number of false negatives increases, which is seen in diseases with a high 
prevalence and more sensitive tests.23 Therefore, the specificity of advanced adenoma could be 
slightly overestimated in both screening arms due to a higher prevalence. Another limitation of 
the design of this study is that the mean haemoglobin levels per lesion (non-neoplastic polyp, 
non-advanced adenoma, advanced adenoma or CRC) only pertain to screenees who had a 
positive test (faecal Hb level ≥ 50ng/ml) and subsequently underwent a follow-up colonoscopy. 
These results can therefore not be generalised to all screenees. However, this observation could 
be used for prioritizing of colonoscopies in subjects with a positive test, a topic which can be 
very relevant in areas and at time periods of shortage of endoscopic capacity, even when all 
subjects with a test result above a chosen cut-off should undergo endoscopy within a limited 
time span. Furthermore, this study describes the first screening round in our population. Data 
on PPV and detection rate of successive screening rounds are needed to provide insight in 
long-term effectiveness of a population-based screening programme.  
In conclusion, this randomised population-based trial provides important data on the test 
characteristics of FIT screening at different cut-off values. Immunochemical faecal occult blood 
testing is considerably more effective than gFOBT within the complete range of tested cut-off 
values. From our experience, a cut-off value of 75ng/ml provided an adequate positivity rate 
and an acceptable trade-off between detection rate and number needed to scope to find a 
screenee with an advanced neoplasia. Increasing the cut-off value can be considered in case of 
insufficient colonoscopy capacity, at the cost of a gradual decrease in detection rate. The opti-
mal cut-off value within a specific population can be based on a local screening programme 
taking major determinants into account including the incidence of neoplasia, the intended 
screenings-interval, colonoscopy capacity, and cost-efficacy. With this in mind, the use of vari-
able cut-offs for different sub-groups is a further option for individualised CRC screening. 
acknowLedgements
This trial was funded by the Dutch Cancer Society (EMCR 2006-3673), the Dutch Ministry of 
Health, Health Care Prevention Programme–Implementation (ZonMw 2006-5877), Olympus 
Ch
ap
te
r 3
62
Medical Systems Europe GmbH, Hamburg, Germany and Eiken Chemical Co., Tokyo, Japan. The 
authors thank the members of the advisory board, E van der Donk (Tenalea) for retrieval of the 
population sample and randomisation, CWN Looman for statistical advise, J Haringsma for the 
organisation of the endoscopy programme, pathologists J. van Krieken and H. van Dekken for 
the (re-) evaluation of pathology samples, all general practitioners in the region, gastroenter-
ologists, pathologist and surgeons of Erasmus MC, IJsselland Hospital, St Fransicus Gasthuis 
Hospital, Vlietland Hospital, Haven Hospital, Ikazia Hospital, Medical Centre Rijnmond-South 
and Albert Schweitzer Hospital, residents, secretaries, nurses and all participants of the trial. 
Immunochemical faecal occult blood testing at different cut-off levels 63
reference List
 1.  Winawer SJ, Zauber AG, Ho MN, O’Brien MJ, Gottlieb LS, Sternberg SS, Waye JD, Schapiro M, Bond JH, 
Panish JF, . Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study 
Workgroup. N Engl J Med 1993;329:1977-1981.
 2.  Ries L.A.G., Melbert D., Krapcho M., Mariotto A., Miller BA., Feuer E.J., Clegg L., Horner M.J., Howlader 
N., Eisner M.P., Reichman M., Edwards B.K., (eds). SEER Cancer Statistics Review, 1975-2004. Bethesda, 
MD: National Cancer Institute 2007.
 3.  Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, Ganiats T, Levin T, Woolf S, Johnson D, Kirk L, 
Litin S, Simmang C. Colorectal cancer screening and surveillance: clinical guidelines and rationale-
Update based on new evidence. Gastroenterology 2003;124:544-560.
 4.  Levin B, Lieberman DA, McFarland B, Andrews KS, Brooks D, Bond J, Dash C, Giardiello FM, Glick S, 
Johnson D, Johnson CD, Levin TR, Pickhardt PJ, Rex DK, Smith RA, Thorson A, Winawer SJ. Screening 
and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint 
guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, 
and the American College of Radiology. Gastroenterology 2008;134:1570-1595.
 5.  Sung JJ, Lau JY, Young GP, Sano Y, Chiu HM, Byeon JS, Yeoh KG, Goh KL, Sollano J, Rerknimitr R, Mat-
suda T, Wu KC, Ng S, Leung SY, Makharia G, Chong VH, Ho KY, Brooks D, Lieberman DA, Chan FK. Asia 
Pacific consensus recommendations for colorectal cancer screening. Gut 2008;57:1166-1176.
 6.  Council Recommendation on Cancer Screening.  2003/0093. Commission of the European Communi-
ties Brussels 2003.
 7.  Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham 
CM. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 
1996;348:1472-1477.
 8.  Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality 
from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N 
Engl J Med 1993;328:1365-1371.
 9.  Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for 
colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471.
 10.  van Rossum LG, Van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, Van Krieken HH, Verbeek AL, Jansen 
JB, Dekker E. Random Comparison of Guaiac and Immunochemical Fecal Occult Blood Tests for 
Colorectal Cancer in a Screening Population. Gastroenterology 2008.
 11.  Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal 
haemoglobin test technologies on population participation in screening for colorectal cancer. J Med 
Screen 2003;10:117-122.
 12.  hol l, van Leerdam ME, van Ballegooijen M, van Vuuren AJ, Reijerink J.C.I.Y., Van der Togt A.C.M., 
Habbema JDF, Kuipers EJ. Attendance to Screening for Colorectal Cancer in the Netherlands; Random-
ized Controlled Trial Comparing Two Different Forms of Faecal Occult Blood Tests and Sigmoidoscopy. 
Gastroenterology 2008;134:A87.
 13.  Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsene D, Boutreux S, Tichet J, Launoy G. Comparison of a 
guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a 
general average risk population. Gut 2007;56:210-214.
 14.  Smith A, Young GP, Cole SR, Bampton P. Comparison of a brush-sampling fecal immunochemical 
test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal 
neoplasia. Cancer 2006;107:2152-2159.
 15.  Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical 
fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 
2005;129:422-428.
 16.  Wong WM, Lam SK, Cheung KL, Tong TS, Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, Choi HK, 
Lee YM, Lai KC, Hu WH, Chan CK, Yuen MF, Wong BC. Evaluation of an automated immunochemical fecal 
Ch
ap
te
r 3
64
occult blood test for colorectal neoplasia detection in a Chinese population. Cancer 2003;97:2420-
2424.
 17.  Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E, Birkenfeld S, Leshno M, Niv Y. A quantitative 
immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007;146:244-255.
 18.  Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-
cancer screening. N Engl J Med 1996;334:155-159.
 19.  Allison JE, Sakoda LC, Levin TR, Tucker JP, Tekawa IS, Cuff T, Pauly MP, Shlager L, Palitz AM, Zhao WK, 
Schwartz JS, Ransohoff DF, Selby JV. Screening for colorectal neoplasms with new fecal occult blood 
tests: update on performance characteristics. J Natl Cancer Inst 2007;99:1462-1470.
 20.  Young GP, St John DJ, Winawer SJ, Rozen P. Choice of fecal occult blood tests for colorectal cancer 
screening: recommendations based on performance characteristics in population studies: a WHO 
(World Health Organization) and OMED (World Organization for Digestive Endoscopy) report. Am J 
Gastroenterol 2002;97:2499-2507.
 21.  Castiglione G, Grazzini G, Miccinesi G, Rubeca T, Sani C, Turco P, Zappa M. Basic variables at different 
positivity thresholds of a quantitative immunochemical test for faecal occult blood. J Med Screen 
2002;9:99-103.
 22.  Fraser CG, Mathew CM, McKay K, Carey FA, Steele RJ. Automated immunochemical quantitation of 
haemoglobin in faeces collected on cards for screening for colorectal cancer. Gut 2008;57:1256-1260.
 23.  Brecht JG, Robra BP. A graphic method of estimating the specificity of screening programmes from 
incomplete follow-up data. Methods Inf Med 1987;26:53-58.
 24.  Vilkin A, Rozen P, Levi Z, Waked A, Maoz E, Birkenfeld S, Niv Y. Performance characteristics and evalu-
ation of an automated-developed and quantitative, immunochemical, fecal occult blood screening 
test. Am J Gastroenterol 2005;100:2519-2525.
 25.  Taylor KL, Shelby R, Gelmann E, McGuire C. Quality of life and trial adherence among participants 
in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst 2004;96:1083-
1094.
 26.  Castiglione G, Zappa M, Grazzini G, Sani C, Mazzotta A, Mantellini P, Ciatto S. Cost analysis in a popula-
tion based screening programme for colorectal cancer: comparison of immunochemical and guaiac 
faecal occult blood testing. J Med Screen 1997;4:142-146.
 27.  Castiglione G, Zappa M, Grazzini G, Rubeca T, Turco P, Sani C, Ciatto S. Screening for colorectal cancer 
by faecal occult blood test: comparison of immunochemical tests. J Med Screen 2000;7:35-37.
 28.  Grazzini G, Castiglione G, Ciabattoni C, Franceschini F, Giorgi D, Gozzi S, Mantellini P, Lopane P, Perco 
M, Rubeca T, Salvadori P, Visioli CB, Zappa M. Colorectal cancer screening programme by faecal occult 
blood test in Tuscany: first round results. Eur J Cancer Prev 2004;13:19-26.
 29.  Dancourt V, Lejeune C, Lepage C, Gailliard MC, Meny B, Faivre J. Immunochemical faecal occult 
blood tests are superior to guaiac-based tests for the detection of colorectal neoplasms. Eur J Cancer 
2008;44:2254-2258.
 30.  Hol L, van Leerdam ME, van BM, van Vuuren AJ, van DH, Reijerink JC, van der Togt AC, Habbema JD, 
Kuipers EJ. Screening for colorectal cancer: randomised trial comparing guaiac-based and immuno-
chemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-68.
 31.  Greenberg PD, Bertario L, Gnauck R, Kronborg O, Hardcastle JD, Epstein MS, Sadowski D, Sudduth R, 
Zuckerman GR, Rockey DC. A prospective multicenter evaluation of new fecal occult blood tests in 
patients undergoing colonoscopy. Am J Gastroenterol 2000;95:1331-1338.
 32.  Zappa M, Castiglione G, Paci E, Grazzini G, Rubeca T, Turco P, Crocetti E, Ciatto S. Measuring interval 
cancers in population-based screening using different assays of fecal occult blood testing: the District 
of Florence experience. Int J Cancer 2001;92:151-154.
 33.  Regula J, Rupinski M, Kraszewska E, Polkowski M, Pachlewski J, Orlowska J, Nowacki MP, Butruk E. 
Colonoscopy in colorectal-cancer screening for detection of advanced neoplasia. N Engl J Med 
2006;355:1863-1872.
Immunochemical faecal occult blood testing at different cut-off levels 65
 34.  Schoenfeld P, Cash B, Flood A, Dobhan R, Eastone J, Coyle W, Kikendall JW, Kim HM, Weiss DG, Emory 
T, Schatzkin A, Lieberman D. Colonoscopic screening of average-risk women for colorectal neoplasia. 
N Engl J Med 2005;352:2061-2068.
 35.  Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G. Use of colonoscopy to screen 
asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J 
Med 2000;343:162-168.
 36.  Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008 1. CA Cancer J Clin 
2008;58:71-96.
 37.  Lieberman D. Race, gender, and colorectal cancer screening 1. Am J Gastroenterol 2005;100:2756-
2758.
 38.  Brenner H, Hoffmeister M, Arndt V, Haug U. Gender differences in colorectal cancer: implications for 
age at initiation of screening 5. Br J Cancer 2007;96:828-831.

chapter 4
uptake of faecal 
immunochemical test 
screening among non-
participants in a flexible 
sigmoidoscopy screening 
programme.
 
 
L. Hol1, E.J. Kuipers1,2, M. van 
Ballegooijen3, A.J. van Vuuren1, 
J.C.I.Y. Reijerink4, J.D.F. Habbema3, 
M.E. van Leerdam1
Departments of 1Gastroenterology 
and Hepatology, 2Internal Medicine, 
3Public Health
Erasmus Medical Centre, Rotterdam, 
the Netherlands.
4Cancer Screening Organisation 
for Southwestern Netherlands, 
Vlaardingen, the Netherlands.
Ch
ap
te
r 4
68
abstract
A screening programme based on single modality testing may prevent individuals with a 
preference for a different test from participating. We conducted a population-based trial in a 
screening naïve population to determine whether non-participants to flexible sigmoidoscopy 
(FS) screening were willing to attend faecal immunochemical test (FIT) screening. In total 
8407 subjects were invited in a primary FS screening programme. Invitees did not know at the 
time of the primary FS invitation that non-participants would be offered FIT screening. 4407 
non-participants of FS screening were invited for a one-sample FIT screening (cut-off 50ng 
haemoglobin/ml). The participation rate to the primary FS screening program was 31% (CI 
30-32%). Among the FS non-participants 25% (CI 24-26%) did attend FIT screening. The overall 
participation rate of the two-stage recruitment for FS and FIT screening was 45% (CI 44-46%). 
FIT screenees were older (p=0.02), more often women (p<0.001) and had a lower social eco-
nomic status (p=0.01) than FS screenees. The detection rate for advanced adenoma was 3.5% 
(CI 2.5-4.8%), and for CRC 0.3% (CI 0.1-0.8%) among participants to secondary FIT screening. 
The detection rate of the two-stage recruitment was 202 (6.1%) for an advanced adenoma, and 
16 (0.5%) for a CRC. Offering FIT screening to non-participants in a FS screening programme 
increases the overall participation rate considerably, as a quarter of non-participants of FS 
screening were willing to attend FIT screening. The attendance remains however lower than 
for primary FIT screening (62%). Women in the target population were more likely to refuse FS 
than FIT screening. Countries introducing FS screening should be aware of these preferences.
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introduction
Compelling evidence supports the effectiveness of screening for colorectal cancer (CRC).1-5 
International guidelines therefore recommend screening for average risk individuals over age 
50 years to detect and prevent CRC.6-8 There are various test methods available for CRC screen-
ing. Each test has been shown to be cost-effective and some even cost-saving, but tests differ 
in the level of supporting evidence, reducing effect on CRC related mortality, potential risk and 
test burden.9, 10 The faecal occult blood test (FOBT) derives its reducing effect on CRC mortal-
ity from early detection of CRC.1 Endoscopic screening strategies like flexible sigmoidoscopy 
(FS) and total colonoscopy (TC) have been proven to be effective at both early detection of 
CRC and removal of pre-malignant lesions (adenoma).2-5, 11 Endoscopic screening therefore 
provides a potential larger effect on CRC related mortality than FOBT screening. Irrespective 
of the method chosen, screening programmes have to be widely accepted to be effective on a 
population level. A possible drawback for the implementation of an endoscopic based nation-
wide screening programme is the reported low participation rate.12-18 In the Netherlands were 
FOBT and FS have been considered as mass screening tool in a randomised trial, uptake of FS 
was significantly lower than of FOBT screening (32 vs. 62%).13 A significant proportion of the 
population would therefore not receive any screening if a single test population-based screen-
ing programme based on FS would be introduced. 
Offering a non-invasive test to non-participants of a FS screening strategy may increase the 
overall uptake of CRC screening in a population, as some non-participants may have a clear 
preference for another screening test. Several studies demonstrated that a preference for FOBT 
was based on the simple and non-invasive character of the test, whereas FS was preferred based 
on test accuracy.19-22 A screening programme based on a single test may prevent individuals 
with a specific preference for a different test from participating. It is however unknown to what 
proportion of the population this concerns to.
To maximise acceptance of FS screening, it is important to determine reasons for non-
participation. Worries about pain, discomfort, or injury associated with FS screening as 
the main reasons for refusing FS screening.23 Those barriers may be overcome by offering 
non-participants an alternative screening test, for example FOBT. However, studies on non-
participation almost invariably rely on questionnaires or interviews, are limited by low response 
rates, and for this reason does not provide adequate insight in the actual decision subjects 
would make. Therefore data on uptake of FOBT screening among non-participants of a FS based 
programme are required, as available studies generally considered a single test in one setting.
We conducted a population-based trial to determine uptake and diagnostic yield of faecal 
immunochemical test (FIT) screening among non-participants of FS screening in an average 
risk screening naïve population. We compared the overall participation rate with the figures of 
primary FIT screening. Furthermore, the detection rate of advanced neoplasia of FIT screening 
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was assessed. This approach allowed insight in reasons for non-compliance to FS screening and 
to which extend the uptake of a nation-wide screening programme could be increased.
metHods
As part of a Dutch population based randomised screening trial comparing participation and 
detection rate of guaiac based faecal occult blood testing (gFOBT), FIT, and FS screening 13, we 
evaluated the additional uptake and diagnostic yield of FIT screening among non-participants 
of a FS screening programme. The trial protocol and data on participation rate and diagnostic 
yield of gFOBT, FIT and FS screening have been described elsewhere.13 Briefly, a random sample 
of 15011 individuals was taken by a computer generated algorithm and 1:1:1 randomised using 
this computer generated algorithm (Tenalea, Amsterdam, the Netherlands). Randomisation was 
done per postal address after stratifying by age, sex and social economic status (SES) into group 
A (gFOBT), B (FIT) or C (FS). Randomisation occurred prior to invitation. In total 5000 subjects 
were invited for FS as part of the randomised trial. The results on uptake and diagnostic yield 
have been published recently.13 As a continuation of the study, an additional 3407 subjects 
were invited for FS using the exact same protocol. Data of all invitees to FS screening will be 
described in the results section. The data of the invitees directly allocated to FIT are described 
previously, but will also be included in Table 2 to allow direct comparison of the randomised 
data.
The SES was based on the data of Statistics Netherlands (www.cbs.nl) providing average 
SES per postal code area (very high, high, intermediate, low, very low) each representing 
small neighbourhoods. Individuals with a history of inflammatory bowel disease or CRC, a 
colonoscopy, sigmoidoscopy or barium contrast enema in the last three years, major health 
problems, or those who moved away or died were excluded from analyses. Recruitment took 
place between November 2006 and May 2008. The Dutch Ministry of Health approved the 
study protocol (2006/02WBO). The study letters and information brochures were approved by 
the Institutional Review Board of the Erasmus Medical Centre (MEC-2005-264).
Interventions
Details of the recruitment process are described elsewhere.13 Briefly, all individuals were sent a 
pre-invitation letter, followed by an invitation letter two weeks later. A test set was sent along 
with the invitation in case of FIT screening. The FS group received an invitation letter with a 
telephone number of the screening unit to schedule an appointment. A reminder was sent 
six weeks afterwards to all non-respondents. At the time of the primary FS invitation subjects 
were not informed that non-participants would have another test offered. Non-participants to 
FS screening were invited for FIT screening. The invitation letter, information and test set were 
similar as used for subjects directly invited for FIT. Information about the study was further 
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given to all general practitioners (GP) in the region by direct visits of research physicians prior 
to start of the study, providing them with background information, a contact address, and an 
information folder. All information was also made available via a dedicated website (www.dik-
kedarmkankerpreventie.nl), mailings and information sites of the municipality offices, regional 
newspapers and national and regional broadcasting. 
Faecal immunochemical test
Subjects received one FIT kit (OC-Sensor micro, Eiken Chemical Co., Tokyo, Japan) to collect 
a single faecal sample of one bowel movement. Participants returned the test kit by mail to 
the laboratory of the Gastroenterology and Hepatology department of the Erasmus University 
Medical Centre for quantitative analysis using the automatic OC-sensor micro instrument 
(Eiken Chemical Co., Tokyo, Japan). The test was considered positive above a cut-off value of 50 
nanogram haemoglobin/ml.
Flexible sigmoidoscopy
Individuals randomised to FS, once scheduled for an appointment, received a 120ml phosphate 
enema (Clyssie, B. Braun Medical B.V., Oss, The Netherlands) by mail with instructions for self-
administration. Administration of the enema by a nurse in the screening unit was offered as 
an alternative. Flexible sigmoidoscopy was performed with a regular forward-looking video-
colonoscope (Olympus Europe, Hamburg, Germany). All sigmoidoscopies were performed 
by experienced endoscopists (>200 colonoscopies) in a dedicated screening centre. The 
endoscope was advanced as far as could be achieved without causing undue pain or distress 
aiming to reach the splenic flexure. The FS was considered complete when the endoscope was 
advanced beyond the colon descending–sigmoid junction into the proximal descending colon 
and more than 50 cm of the anal verge with endoscope in straightened position. Participants 
did not receive sedatives. All polyps up to a diameter of 9 mm were removed at FS and sent for 
histological evaluation. Polyps with a diameter of ≥10 mm were left in situ for removal during 
colonoscopy. Participants were referred for a total colonoscopy (TC) when one of the following 
criteria was met: presence of a polyp with a diameter ≥10 mm; an adenoma with serrated, vil-
lous histology (≥25% villous) or high-grade dysplasia; ≥3 adenomas; ≥20 hyperplastic polyps; 
or invasive CRC. In accordance with the international classification, CRC was defined as the 
invasion of malignant cells beyond the muscularis mucosa. 
Test results
In case of a positive FS or FIT the GP was informed by telephone and mail within two weeks. The 
GP informed the participant about the test result and referred the participant for colonoscopy. 
A colonoscopy was scheduled within four weeks after the screening test results had become 
available. Participants with a negative FS or FIT were informed by mail within two weeks.
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Statistical analysis
Differences in proportions were calculated using the χ2 test. Differences in means were calcu-
lated using a Student t-test. The participation rate per screening test was calculated by dividing 
participants by all eligible subjects (defined as invited subjects minus the excluded subjects). 
The overall participation rate was calculated by eligible subjects divided by the total number 
of participants of FS and FIT screening. Separate uni- and multivariate models were used with 
participation as function of age, sex, and SES. Interaction of age and sex was determined using 
a multivariate model. No significant interaction between age and sex was determined (p=0.13). 
The detection rate was defined as the proportion of screenees with advanced adenoma or CRC. 
Advanced adenoma was defined as adenoma ≥10 mm, with a villous histology (≥25% villous) 
or with high-grade dysplasia. The detection rate was calculated using the most advanced 
lesion detected per screenee. Number needed to screen was defined as number of advanced 
adenoma or CRC divided by number of participants with a complete screening test. Number 
needed to invite was defined as number of advanced adenoma or CRC divided by number of 
eligible screenees. All p-values were two-sided and considered significant if <0.05.
resuLts
Uptake
First invitation: FS: A total of 8407 subjects were pre-randomised to FS screening and received 
an invitation. In total 524 subjects met one of the exclusion criteria, leaving 7883 potential 
participants. Participation rate to the FS program after the first invitation was 26% (CI 25-27%), 
and increased to 31% (2433/7883; CI 30-32%) after a reminder was sent six weeks later. The 
mean age of FS screenees was 60.5±SD 6.4, 53% (1279/2433) were men, 23% had a very high, 
23% high, 18% intermediate, 18% low, 18% very low SES.
Second invitation: FIT: In total 5450/7883 did not participate of whom 977 reported not wanting 
to have further invitations for CRC screening for various reasons (e.g. had cancer with or with-
out treatment, were hospitalised for other disease, or mentally disabled) and were therefore 
not included in this study. The remaining 4473 non-participants of FS screening were invited 
for FIT screening (Fig 1), of which 66 were excluded from analysis (1.5%; 39 subjects met one 
of the exclusion criteria, 17 had moved away and 10 had died). The participation rate to FIT 
screening was 25% (1092/4407; CI 24-26%) (Fig 1). The mean age of screenees was 61.3±SD 6.0, 
43% (473/1092) were men, 22% had a very high, 19% high, 19% intermediate, 18% low, 22% 
very low SES. 
Women (28% CI 26-30%) were more likely to attend FIT screening than men (21% CI 19-23%). 
Uptake was associated with age, as screenees aged 60-64 (28% CI 25-30%; p=0.002) and 65-69 
(26% CI 23-30 p=0.035) were more likely to attend FIT screening than screenees aged 50-54 
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(22% CI 19-24%). Uptake among screenees aged 55-59 (24% CI 22-26%; p=0.45) and 70-74 (23% 
CI 20-27%;p=0.20) was similar to screenees aged 50-54. SES did not affect uptake. Multivariate 
analysis confirmed the univariate results (Table 1). 
Two-stage recruitment: The overall participation rate of the two-stage recruitment for FS and 
FIT screening was 45% ((2433+1092)/(7883-66)) (CI 44-46). The group non-participants to FS 
screening that did attend FIT screening, were older (61.3 vs. 60.5 yr; p=0.02), more often women 
(57% vs. 47%; p<0.001) and had a lower SES (p=0.01) compared to the group of subjects that 
primarily attended FS screening. 
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Fig1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4473 of non-participants were invited for FIT 
1092 (24.8%) attended
110 (10.1%) had a 
positive FIT 
96 underwent TC 
1090 returned a 
complete FIT 
2 (0.0%) returned an 
incomplete FIT 
910 had a negative FIT
14 (12.7%) refused TC
41/1090 (3.8%) had an 
advanced neoplasia 
4407 were eligible 
66 (1.5%) were 
excluded 
3315 did not participate 
8407 were invited for FS  
5450 did not participate 
977 (17.9%) refused 
any invitation 
7883 were eligible 
524 (6.2%) were 
excluded 
2433 (30.8%) attended
FS screening 
fig 1: trial profile. The current trial is shown in the grey box.
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Test characteristics
First invitation: FS: FS evaluation was complete in 2231/2433 screenees (92%). Incomplete 
examination was due to insufficient bowel preparation in 130 (5.3%) subjects and failure to 
obtain full introduction (>50cm with straightened scope) in 72 (3.0%) subjects. In total 232 
(10.4%) screenees were referred for colonoscopy. All but two of the positive screenees under-
went a colonoscopy (99%). The most advanced lesion was a non-advanced adenoma in 287 
(12.9%; 11.5-14.3%) screenees, these subjects were therefore not referred for a TC. An advanced 
adenoma was found in 164 (7.4%; CI 6.3-8.5%) screenees and a CRC in 13 (0.6%; 0.3-1.0%) 
screenees (Table 2). The number needed to screen to detect an advanced adenoma was 14 (CI 
12-16) and for a CRC was 172 (CI 100-295). Forty-eight (CI 41-56) screenees had to be invited to 
detect one advanced adenoma and 606 (CI 352-1044) to detect a CRC.
Second invitation: FIT: The FIT was incomplete in 2/1092 (0.2%) of the participants. In total 
110/1090 (10.1%) screenees had a positive test and were referred to undergo a colonoscopy. 
Fourteen (12.7%) screenees refused to undergo a colonoscopy. Four of the 96 colonoscopies 
were incomplete and therefore a double contrast barium enema was performed in one screenee 
and a CT-colonography in two screenees. One screenee had an incomplete examination due 
to extensive diverticulosis an no further investigation was performed. The most advanced 
lesion was a non-advanced adenoma in 28 screenees (2.6%; 3.7-1.8%), advanced adenoma in 
38 (3.5%; CI 2.5-4.8%) screenees and a CRC in 3 (0.3%; CI 0.1-0.8%) screenees. Stage II CRC was 
found in two cases. Advanced CRC was found in one screenee (stage IV) (Table 2). The positive 
predictive value to find an advanced adenoma or CRC was respectively 39.6% and 3.1%. The 
number needed to screen to detect an advanced adenoma was 29 (CI 21-39) and for a CRC 
363 (CI 118-1126). One hundred and six (CI 85-159) screenees had to be invited to detect one 
advanced adenoma and 1469 (CI 474-4554) to detect a CRC. 
Two-stage recruitment: The detection rate with either FS or FIT screening for a non-advanced 
adenoma was 315 (9.5%; 8.5-10.5%), 202 (6.1%; CI 5.3-6.9%) for an advanced adenoma, and 16 
(0.5%; CI 0.3-0.8%) for a CRC. The number needed to screen to detect an advanced adenoma 
table 1: Uptake of FIT among non-participants to FS screening by age and gender
N (%) OR (CI)ǂ
Men 472/2221 (21) 1
Women 620/2186 (28) 1.5 (1.3-1.7)*
Age groups
(years)
50-54 226/1031 (22) 1
55-59 296/1223 (24) 1.2 (1.0-1.4)
60-64 275/983 (28) 1.4 (1.2-1.7)*
65-69 178/675 (26) 1.3 (1.0-1.6)*
70-74 117/495 (24) 1.1 (0.9-1.4)
* p-value <0.05; ǂ multivariate analysis
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was 16 (CI 14-19) and a CRC was 208 (CI 127-339), and the number needed to invite to detect an 
advanced adenoma was 39 (CI 34-44) and for a CRC was 489 (CI 300-797). 
discussion
This study determined uptake of FIT screening among non-participants in a population-based 
FS screening programme. Previous studies have shown major differences in uptake of different 
screening tests, a difference which has a major impact on the eventual efficacy of population-
based screening. This difference is in part related to the expected burden of a test. A recent 
Italian study found that 23% of non-participants of a FS screening programme reported 
anticipated pain, discomfort, or injury as main reasons for refusing FS screening.23 Our results 
validate this finding in a true experimental setting, since 25% of non-participants to FS screen-
ing were willing to undergo a non-invasive and less burdensome FIT test. 
Individuals in the target population demonstrate distinct preferences for a screening test, 
and may persist in their choice over time.19-22 Screening based on individual preferences for a 
screening strategy may thus significantly increase uptake. Although this study was not designed 
to determine uptake when subjects were offered a direct choice, given the two stage method 
of recruitment, we did find a significant increase in overall participation rate when FIT screening 
was added to a FS screening programme. Our data demonstrated that participation rate of the 
group directly allocated to FS screening was 31%.13 The overall participation rate increased 
to 45%, which significantly improved the diagnostic yield of the screening programme, as 
demonstrated by the lower number of invitees to detect an advanced adenoma or CRC. On the 
other hand, the overall participation rate was considerably lower than we reported in the group 
directly assigned to FIT screening (62%) (Table 2).13 The two-stage recruitment used in this trial 
table 2: Most advanced lesion and number of adenomas identified by FS screening and FIT screening 
among non-participants to FS screening.
Directly allocated 
to FIT
First-stage:
FS screening
Second-stage:
FIT screening
Two-stage 
recruitment
N (%) N (%) N (%)
Participation rate  2979 (62) 2433 (32%) 1092 (25) 3525 (45)
Positivity rate 241 (8.1) 232 (10.4) 110 (10.1)
Hyperplastic polyp 15 (0.5) 455 (20.4) 4 (0.4) 459 (13.8)
Tubular adenoma   <10mm 45 (1.5) 287 (12.9) 28 (2.6) 315 (9.5)
≥10mm 31 (1.0) 78 (3.5) 16 (1.5) 94 (2.8)
Villous histology / HGD 48 (1.6) 86 (3.9) 22 (2.0) 108 (3.3)
Advanced adenoma 79 (2.7) 164 (7.4) 38 (3.5) 202 (6.1)
Carcinoma 16 (0.5) 13 (0.6) 3 (0.3) 16 (0.5)
Number of adenomas
1 67 (2.3) 303 (13.6) 29 (2.7) 332 (10.0)
2 28 (0.9) 75 (3.4) 17 (1.6) 92 (2.8)
≥3 33 (1.1) 76 (3.4) 22 (2.0) 98 (3.0)
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can however not be used for a nation-wide programme, as invitees to FS screening were not 
informed that not participants would be invited for FIT screening. Participants to FS screening, 
who would have preferred FIT screening if offered a direct choice will feel misinformed. In a 
nation-wide screening programme invitees should be offered a direct choice.
Two population-based studies in which subjects were offered a direct choice between FOBT 
and FS screening reported similar uptake rates as obtained with an invitation to participate in a 
single test programme with either FOBT or FS.16, 24 Offering a choice between screening tests may 
lead to additional uptake, but simultaneously also a loss of participants. The complex decision 
process, i.e. individuals have to decide on participation to screening and on the preferred test, 
may lead to uncertainty and non-compliance to the screening programme as a whole. Addition-
ally, the large amount of information subjects will receive on invitation (different tests and their 
benefits and risks), might withhold subjects without a distinct test preference from attending.
In accordance with other studies we previously found that women were significantly less 
likely to attend FS screening than men.12, 13, 15 This study now clearly demonstrated that women 
refusing FS screening are more likely to attend FIT than men, who refuse FS screening. Countries 
that implement FS screening should therefore be aware of this potential barrier to participation 
among women.
A smaller proportion of screenees with a positive screening test attended a colonoscopy 
(87%) as compared to our population-based data of screenees directly allocated to FIT screen-
ing (98%). In this study a similar protocol for referring positive screenees was used.13 This again 
suggests that non-participants to FS screening have a negative attitude towards endoscopy 
and are therefore more likely to refuse a follow-up colonoscopy. 
The detection rate of advanced adenoma and CRC in this study mirrors the detection rate 
in the population-based study in which subjects were directly invited for FIT screening (Table 
2; p=0.39).25 This suggests a similar a priori risk on CRC. Blom et al recently demonstrated 
that non-respondents to a FS programme have higher risk on CRC than participants, due to 
unhealthy habits (e.g. smoking).26 This would be consistent with a higher risk on CRC screening 
applying for the non-participants of both tests in our trial. However, we could not confirm the 
data of Blom in our two-recruitment strategy.
A potential limitation of the study is that any reminder has a positive effect on uptake.27 The 
additional uptake after a reminder for FS screening was 4%. A small proportion of the additional 
uptake of FIT screening among non-participants may not be related to test preferences but 
solely depends on the effect of the reminder. This would expectedly be lower than 4%.
In conclusion, offering FIT screening to non-participants in a FS screening programme 
increases the overall participation rate considerably, as a quarter of non-participants of FS 
screening were willing to attend FIT screening. This figure was lower than the participation 
rate (62%) of a randomised FIT screening arm in the same programme. Women in the target 
population were more likely to refuse FS screening based on test-related factors. Countries 
introducing FS screening should be aware of these preferences.
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abstract
Perceived burden of colorectal cancer (CRC) screening is an important determinant of participa-
tion in subsequent screening rounds and therefore crucial for the effectiveness of a screening 
programme. This study determined differences in perceived burden and willingness to return 
for a second screening round among participants of a randomised population-based trial com-
paring a guaiac-based faecal occult blood test (gFOBT), a faecal immunochemical test (FIT), and 
flexible sigmoidoscopy (FS) screening. A representative sample of the Dutch population (aged 
50-74 years) was randomised to be invited for gFOBT, FIT and FS screening. A random sample 
of participants of each group was asked to complete a questionnaire about test burden and 
willingness to return for CRC screening. In total 402/481 (84%) gFOBT, 530/659 (80%) FIT, and 
852/1124 (76%) FS screenees returned the questionnaire. The test was reported as burdensome 
by 2.5% of gFOBT, 1.4% of FIT, and 12.9% of FS screenees (comparing gFOBT vs. FIT p=0.05; vs. 
FS p<0.001). In total 94.1% of gFOBT, 94.0% of FIT, and 83.8% of FS screenees were willing to 
attend successive screening rounds (comparing gFOBT vs. FIT p=0.84; vs. FS p<0.001). Women 
reported more burden during FS screening than men (18.2% vs. 7.7%; p<0.001). FIT slightly 
outperforms gFOBT with a lower level of reported discomfort and overall burden. Both FOBTs 
were better accepted than FS screening. All three tests have a high level of acceptance, which 
may affect uptake of subsequent screening rounds and should be taken into consideration 
before implementing a CRC screening programme.
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introduction
Colorectal cancer (CRC) is the second most common cause of cancer-related death in Europe.1 
Randomised controlled trials (RCT) provided compelling evidence to support screening of 
average-risk individuals with faecal occult blood testing (FOBT). 2 One RCT on flexible sigmoid-
oscopy (FS) screening with seven years of follow-up showed a 59% reduction in CRC-related 
mortality.3 Nation-wide screening programmes are currently being implemented in several 
countries in Europe. In the Netherlands, guaiac-based FOBT (gFOBT), faecal immunochemical 
test (FIT) and FS are considered as potential screening tests for a nation-wide call-recall screen-
ing programme to start in the near future. 
Uptake of screening is of considerable importance for the effectiveness of CRC screening 
programmes. The attendance rate of initial and successive screening rounds has remained 
low in many countries.4 Important reasons for non-participation in CRC screening are related 
to the anticipated burden of a screening test, such as anticipated embarrassment, pain, and 
discomfort.4, 5
Experience with a screening test may affect the willingness to attend successive screening 
rounds. Given the need for repeated testing at regular intervals (e.g. FS at 5 or 10-yearly periods) 
to achieve effective screening and the relatively short screening interval of FOBT (annual or bien-
nial) screening, it is of particular importance to determine screening experiences among par-
ticipants. Additionally, experience with CRC screening may be communicated to other potential 
screenees, which may also affect uptake of CRC screening programmes in successive cohorts.
A few studies have reported on the test burden of gFOBT and FIT screening.6-8 Although the 
perceived test burden of FS screening has been more widely studied 9-12, trials comparing the 
burden of gFOBT, FIT and FS screening are lacking. 
Therefore, this study assessed differences in perceived burden and willingness to return for 
a second screening round among participants of a randomised population-based trial compar-
ing gFOBT, FIT and FS screening. 
metHods
As part of a Dutch population-based randomised screening trial 13, we evaluated the perceived 
burden and willingness to return for a successive screening test of various CRC screening tests 
among participants of gFOBT, FIT and FS screening by means of a questionnaire survey. The 
trial protocol and data on attendance and diagnostic yield of the different screening methods 
have been described elsewhere.13 Recruitment took place between November 2006 and May 
2008. The Dutch Ministry of Health approved the study protocol (2006/02WBO). The study 
questionnaire was approved by the Institutional Review Board of the Erasmus Medical Centre 
(MEC-2005-264). 
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Subjects
A random sample of the Dutch population aged 50-74 years was asked to participate in a 
randomised screening trial.14 A total of 2375 (uptake: 50%) persons attended gFOBT screening, 
2979 (uptake: 62%) persons FIT screening, and 2432 (uptake: 31%) FS screening. A random 
sample of screenees (481 gFOBT participants, 659 FIT participants and 1124 FS participants) 
was asked to participate in the questionnaire study on acceptance and burden of the screen-
ing test they underwent (Figure 1). For both FOBTs 20-22% of all screenees were selected to 
participate in this study. For FS a larger proportion of screenees was selected, because power 
analysis indicated that at least 800 respondents were needed to allow comparative analysis of 
the prevalence of physical symptoms before and after the FS. 
Questionnaires and measurements
gFOBT and FIT screenees were asked to complete a single questionnaire one week after the test 
was received at the laboratory, but before the screenee received the test result. FS participants 
were asked to complete a questionnaire in the waiting area of the endoscopy unit prior to their 
procedure and a second questionnaire one week after the procedure at home. The different 
components of the questionnaire are discussed below.
Embarrassment, discomfort and pain
Embarrassment and discomfort resulting from FOBT were measured by three separate items 
that were adapted from earlier studies and related to three stages of the procedure (collect-
ing faeces, performance of the test, and returning the test to the laboratory), each with three 
response options (not, quite, or very embarrassing/unpleasant).15, 16 
Pain, embarrassment and discomfort before, during and after the FS were measured one 
week after the screening test. The four stages of the procedure, i.e. preparation, digital rectal 
examination (DRE), FS itself, and the period directly after the FS, with three response options 
(not, quite, or very painful, embarrassing or unpleasant) were assessed separately.
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2375 screenees 2979 screenees 
481 (20%) invited 659 (22%) invited 
402 (84%) responded 530 (80%) responded 
2432 screenees 
Pre-FS 
1022 (91%) 
responded 
1124 (46%) invited  
852 (76%) returned both  
79 did not respond 129 did not respond
FIT FS gFOBT 
Post-FS 
915 (81%) 
responded 
272 did not respond
fig 1: Trial profile
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We estimated the overall embarrassment, pain and discomfort for both FOBTS and FS after 
combining the items into summary scores, by adding the item responses (not = 0, quite = 1, 
very = 2) per stage of the procedure divided by the number of stages measured.
Overall acceptance
Overall acceptability of the screening method was examined by three items. For each of the 
three screening tests 5-point Likert scales were used to elicit subjects’ perceptions of overall 
burden of the entire screening procedure (“very burdensome” - “not burdensome at all”), will-
ingness to return for a successive screening round, and whether the participant would recom-
mend friends/family members to undergo the same screening test (“certainly” - “certainly not”). 
For overall burden, Likert scores of 1-2 were used to indicate burdensome. Likert scores of 1-2 
were used to indicate willingness to return for a successive screening round, as well as a posi-
tive recommendation to friends/family members to undergo the same screening test, whereas 
scores of 4-5 were used to indicate not willing to return and a negative recommendation.
Symptoms before and after FS
To detect whether the FS caused physical symptoms, we compared the occurrence of eight 
symptoms in the week before the test and one week afterwards: rectal blood loss, diarrhoea, 
constipation, nausea or vomiting, flatulence or feeling bloated, faecal incontinence, anal pain, 
and abdominal pain. Questions were composed analogous to those of previous studies.15, 16
Perceived risk of developing colorectal cancer
We also assessed patients’ subjective evaluation of their risk of developing CRC as a potential 
determinant of the perceived burden, using seven response options (very small, small, quite 
small, intermediate, quite substantial, substantial, very substantial).17 
Subject characteristics
Demographic data were collected, including patients’ classification of  own health using the 
EQ−5D classification.18
Statistical analyses
Statistical analysis was performed using the SPSS statistical package, version 15.0.1. Analysis 
was performed using the χ2 test or Student’s t-test when appropriate, for nominal and ordinal 
data. Symptoms before and after FS were compared using McNemar’s test. A two-sided p-value 
of <0.05 was considered significant. Differences between the summary scores of embarrass-
ment, discomfort or pain were calculated using the independent-samples t-test (Cronbach’s 
alphas gFOBT/FIT: a=0.79; FS: a=0.81). The data from the EQ-5D classification of own health 
were transformed into an EQ-5D index score using the algorithm described by Dolan.19 Univari-
ate ordinal regression analyses were performed to compare overall burden, recommendation 
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to friends/family to attend screening, and willingness to return for screening between the 
three screening tests. To study associations between determinants (screenees age, gender, 
EQ5D-index score, perceived risk and for FS arm only; previous endoscopy experience, gender 
of endoscopist) and overall burden, recommendation to friends/family to attend screening and 
willingness to return we used univariate and multivariate ordinal regression analyses (stepwise 
inclusion p <0.1). For the subgroup analyses to determine the effect of same-sex endoscopist 
among women on embarrassment, discomfort and pain during the FS itself a Bonferroni cor-
rection was used to compensate for multi-comparison. Spearman’s rank correlation was per-
formed to determine the correlation between overall burden and recommendation to friends/
family to attend screening and the willingness to return for screening.
resuLts
Response and respondent characteristics
In total 402/481(84%) gFOBT and 530/659 (80%) FIT screenees returned their questionnaire 
(Figure 1). Of the FS screenees 1022/1124 (91%) completed the questionnaire prior to the FS 
and 915/1124 (81%) returned the second questionnaire after the procedure. In total 852/1124 
(76%) of FS screenees returned both questionnaires. The respondents’ characteristics are shown 
in Table 1. Characteristics of responding screenees to both FOBT programmes were similar. FS 
table 1: Subject characteristics.
gFOBT FIT FS
Total included screenees (n)
Mean age in years (SD) 
Gender (% male)
Ethnicity (% Caucasian)
Marital status (%):
Married/living with partner 
Employment status (%):
Pensioner/early retirement 
In paid work
Unemployed 
Education (%):
Elementary
Secondary 
Tertiary and postgraduate
General health, EQ-5D index score:  
mean (SD)
402
60.8 (6.3)
45.3
95.2
88.7
35.0
40.6
4.3
10.7
71.8
17.6
0.90 (0.13)
530
61.6 (6.3)
50.6
95.1
87.3
38.9
38.3
4.6
12.8
63.3
23.9
0.91 (0.13)
852
60.7 (6.4)
50.7
94.5
88.6
35.0
46.9
4.3
9.3
64.1
26.7
0.93 (0.11)
Endoscopy experience (%)
Colonoscopy
Sigmoidoscopy
14.0
0.5
15.5
0.6
17.1
1.3
Perceived risk (%)
Very small - small 
Quite substantial - substantial
43.9
1.7
54.1
3.8
45.8
4.0
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screenees reported a marginally better general health status as measured by the EQ-5D index 
score than both FIT and gFOBT screenees (p <0.001), and were slightly older than FIT screenees 
(p=0.008). All other characteristics including gender, ethnicity, marital, and employment status, 
level of education, endoscopy experience and perceived risk on CRC were equally distributed 
between the three screening arms.
Embarrassment, discomfort, and pain
Screenees rated overall embarrassment during gFOBT and FIT equally (0.07 vs. 0.06; p=0.30) 
(Table 2). A larger proportion of gFOBT than FIT screenees described the test as uncomfortable 
(0.15 vs. 0.11; p=0.02), mainly due to more discomfort while collecting faeces and performing 
the test (Table 2).
Overall score for embarrassment, discomfort, and pain during FS were 0.18, 0.42, and 
0.27, respectively. FS screenees reported embarrassment most frequently during the DRE 
(quite/very: 24.0%). In total 13.4, 19.3 and 11.0% of screenees reported to have been quite/
very embarrassed during the preparation, the endoscopy itself, and the period after the FS, 
respectively. Pain and discomfort were mainly reported during the endoscopy (quite/very: 55.0 
and 53.9%). In total, 17.4 and 15.4% of the screenees experienced the procedure as very painful 
or uncomfortable (Table 3). The mean overall embarrassment and discomfort were significantly 
higher for FS than for gFOBT and FIT screening (p <0.001).
Symptoms before and after FS
Undergoing FS screening was not significantly associated with the occurrence of diarrhoea 
(reported prevalence one week before and one week after FS screening being: 7.4 vs. 6.4%), 
constipation (4.7 vs. 6.1%), anal pain (5.8 vs. 4.5%), faecal incontinence (1.0 vs. 1.1%), nausea 
and vomiting (2.6 vs. 2.4%), or rectal blood loss (1.4 vs. 2.8%). Screenees significantly more often 
reported abdominal pain (9.2 vs. 15.8%; p<0.001), and flatulence or feeling bloated (23.6 vs. 
33.4%; p<0.001) one week after than before the FS.
table 2: Embarrassment and discomfort per stage of gFOBT and FIT screening.
gFOBT
Not % Quite % Very % Mean 
summary
Score 
(SEM)
FIT
Not % Quite % Very % Mean 
summary
Score 
(SEM)
p-value
Embarrassment 0.07 (0.01) 0.06 (0.01) 0.30
Collecting faeces
Performing the test
Returning the test
90.7
94.0
95.7
8.1
5.8
4.0
1.3
0.3
0.3
93.7
95.2
94.6
6.1
4.8
5.2
0.2
0.0
0.2
0.06
0.45
0.14
Discomfort 0.15 (0.01) 0.11 (0.01) 0.02
Collecting faeces
Performing the test
Returning the test
77.1
83.6
96.7
20.6
15.4
3.3
2.3
1.0
0.0
85.1
90.4
96.2
13.6
8.4
2.9
1.3
1.1
1.0
0.00
0.00
0.63
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Overall acceptance
Significantly less FIT than gFOBT described the test as burdensome (p=0.05), whereas FS was 
more often reported to be burdensome than gFOBT (p<0.001) and FIT (p<0.001) (Fig 2a). 
Significantly more women than men reported burden during FS screening (18.2% vs. 7.7%; 
p<0.001). Younger screenees (<60 years) were more likely to experience test burden during 
FIT and FS screening than older screenees (≥60 years) (FIT 2.2% vs. 0.7%; p=0.002; FS 15.5% vs. 
10.5%; p=0.002), whereas age was not associated with reported burden of gFOBT screening 
(3.2% vs. 2.0%; p=0.22). Reported burden was higher among screenees with a low compared 
with a high level of education in all screening arms (gFOBT 8.7% vs. 0.0%; FIT 4.9% vs. 0.0%; FS 
11.6% vs. 6.8%; p-values <0.001).
Female screenees reported less burden when the FS was performed by a same-sex endos-
copist (22.8 vs.15.5%; p=0.02), while in male screenees no such association was found (8.0 vs. 
7.5%; p=0.20). Women less often described the FS itself as embarrassing if the FS was performed 
by a female instead of a male endoscopist (quite/very: 18.4% vs. 34.4% p<0.001), whereas no 
differences in pain or discomfort was found. In men no such association was found.
The vast majority of FOBT screenees would encourage friends and/or relatives to attend FOBT 
screening (gFOBT 96.0%, FIT 95.8%; p=0.76) and was willing to attend a successive screening 
round (gFOBT 94.1%; FIT 94.0%; p=0.84). A significantly smaller proportion of FS screenees was 
willing to attend another round of FS screening (83.8%, p-values <0.001) or would encourage 
friend and/or relatives (FS 87.1%, p-values <0.001) to undergo FS screening compared to both 
FOBTs (Fig 2b,c). There was a significant correlation between perceived burden and willing-
ness to attend another round (gFOBT ρ –0.38; FIT ρ-0.52; FS ρ –0.50; all p-values<0.001) and a 
positive recommendation to friends and/or relatives (gFOBT ρ –0.41; FIT ρ-0.40; FS ρ –0.53; all 
p-values<0.001). 
table 3: Embarrassment, discomfort and pain per stage sigmoidoscopy screening.
Sigmoidoscopy
 Not % Quite % Very % Mean summary
Score (SEM)
Embarrassment
Preparation
Digital rectal examination
Sigmoidoscopy
Directly afterwards
86.7
76.0
80.7
89.0
12.4
22.1
16.9
9.8
1.0
1.9
2.4
1.2
0.18 (0.01)
Discomfort
Preparation
Digital rectal examination
Sigmoidoscopy
Directly afterwards
68.6
75.9
46.1
69.1
28.3
22.5
38.4
25.0
3.1
1.7
15.4
5.9
0.42 (0.01)
Pain
Preparation
Digital rectal examination
Sigmoidoscopy
Directly afterwards
95.5
90.3
45.0
81.5
4.3
8.8
37.6
15.4
0.2
0.8
17.4
3.1
0.27 (0.01)
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Men who underwent a FS were more willing to attend a successive screening round than 
women (86.4% vs. 78.8%; p=0.014). EQ5D-index score, perceived risk on CRC, and previous 
endoscopy experience were not significantly associated with experienced burden, recommen-
dation to friends and/or relatives, or with willingness to return for a successive screening round. 
discussion
Population-based screening needs to be well accepted in order to achieve an adequate uptake 
in first and successive screening rounds. This is the first population-based study comparing 
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fig 2: Using a five-point Likert scale: scores on overall burden, the recommendation subjects would give to 
others to participate in screening, and willingness of screenees to return for successive screening rounds.
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perceived test burden and willingness to return for a successive screening round between 
gFOBT, FIT and FS in an average-risk population. All three screening tests were well accepted 
among participants, given the large proportion of screenees willing to return for successive 
screening rounds and the positive recommendation for screening that most subjects intended 
to give their family and/or friends. FIT was perceived as slightly less burdensome than gFOBT 
screening due to less reported discomfort during faecal collection and test performance. The 
number of faecal samples required may explain the difference in discomfort during faecal col-
lection, as the gFOBT had to be performed on three consecutive bowel movements and FIT was 
a one-sample test. This is further underlined by an Australian study that showed similar accept-
ability of FIT and gFOBT when a two-sample FIT was used.20 The difference in faecal sampling 
method between gFOBT (card) and FIT (swab) might also clarify the difference in discomfort, as 
reported by a British study showing that potential screenees preferred a sterile transport swab 
to a smear card.21 The higher acceptability of FIT is in line with results of two RCTs, both demon-
strating a higher uptake of FIT compared to gFOBT.22, 23 The higher acceptability is an important 
argument for choosing FIT in preference to gFOBT as the screening method for a nation-wide 
screening programme, apart from additional arguments regarding test performance charac-
teristics.23-26 Therefore, the Dutch Health Council recently recommended introducing a nation-
wide FIT-based CRC screening programme.
FS is clearly more burdensome than both FOBTs, as 55% of screenees reported some kind 
of discomfort or pain. However, in agreement with previous studies only a small proportion 
of screenees reported severe embarrassment, discomfort or pain during the procedure.9, 10, 
27-29 In this and other studies all FS were performed without conscious sedation, which seems 
acceptable for FS screenees.9, 28
Perceived burden of FS screening varied by gender. Our observations reflect those of other 
studies reporting that women were more likely to experience burden during FS 30, 31, and were 
therefore less willing to return for successive screening rounds. This contributes to the reported 
lower uptake among women for a first FS screening round.9, 28, 32 A lower uptake in first and 
successive screening rounds will limit the effectiveness of FS as a screening modality in women. 
Therefore, endoscopists should be even more aware of potential burden in women, and should 
consider steps to minimise burden and thereby improve uptake for successive screening 
rounds (e.g. using sedation or a more flexible, smaller-calibre endoscope).
Several studies have shown a preference for a female endoscopist among women.33, 34 
Nickelson and colleagues revealed embarrassment as the most important reason for prefer-
ring a same-sex endoscopist. The present study shows that the expectation reflects the actual 
experience, as women reported more embarrassment during the FS itself when performed by a 
female compared to a male endoscopist. A nation-wide screening programme might therefore 
be more effective when women are offered a choice between a male or female endoscopist.
Our study has shown that preparation with a single enema self-administered at home was 
well accepted by screenees.13 A few screenees reported significant embarrassment (1.0%), 
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discomfort (3.1%) or pain (0.2%) during preparation. Furthermore, as described previously, a 
high proportion of screenees was willing to perform the bowel preparation at home (85%).35,36
The present study showed that the willingness to undergo successive screening rounds was 
significantly lower for FS screenees than for both FOBTs. Nevertheless, only a small minority of 
screenees was not willing to attend successive screening rounds of gFOBT (1.2%), FIT (1.3%) or 
FS (8.3%) screening, which is in line with previous studies.6, 10, 12, 37 This finding is essential for 
an effective screening programme, since screening tests must be repeated at regular intervals 
to be effective. Furthermore, experience with CRC screening will be communicated to other 
potential screenees. This may largely affect uptake of successive cohorts, given the low level of 
awareness of CRC and CRC screening in Europe and especially in the Netherlands.38 In the pres-
ent study, the majority of respondents would recommend family/friends to undergo screening 
with the same test they underwent themselves. This will positively affect uptake of screening 
resulting in increasing uptake levels in successive screening rounds. 
A drawback of this study is that, because the majority of respondents were of Caucasian 
ethnicity (95%), our results can not be extrapolated to a non-Caucasian population. Further 
studies on test burden in a non-Caucasian population are therefore needed. Furthermore, 
FS screenees were slightly older than FIT screenees and healthier than both gFOBT and FIT 
screenees, since those subgroups were more likely to participate in screening. However, these 
differences in subject characteristics did not affect the interpretation of the results, since these 
marginal differences are clinically irrelevant. Furthermore, perceived test burden can only be 
measured in screenees and not in non-participants.
In conclusion, gFOBT, FIT and FS are well accepted screening tests among participants. FIT 
slightly outperforms gFOBT with a lower level of reported discomfort and overall burden. Both 
FOBTs were better accepted than FS screening. The high level of acceptance may affect uptake 
of subsequent screening rounds and should be taken into consideration before implementing 
a CRC screening programme. Furthermore, attempts should be made to improve acceptance of 
FS screening among women if FS is considered to be the test of choice, since women reported 
significantly more discomfort during FS screening.
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abstract
Guidelines underline the role of individual preferences in the selection of a screening test, 
since insufficient evidence is available to recommend one screening test to another. We con-
ducted a study to determine individuals’ preferences and to predict uptake for CRC screening 
programmes with various screening tests. A discrete choice experiment (DCE) questionnaire 
was conducted among screening naïve and previously screening subjects aged 50-75. Subjects 
were asked to choose between scenarios based on faecal occult blood test (FOBT), flexible 
sigmoidoscopy (FS), total colonoscopy (TC) with various test specific screening intervals and 
mortality reductions, and no screening (opt-out). In total 489/1498 (33%) screening-naïve 
(52% male; mean age±SD 61±7yrs) and 545/769 (71%) previously screened subjects (52% 
male; mean age±SD 61±6yrs) returned the questionnaire. Type of screening test, screen-
ing interval, and risk reduction of CRC related mortality influenced subjects’ preferences (all 
p<0.05). Screening-naïve and previously screened subjects equally preferred five-yearly FS 
and ten-yearly TC (p=0.24; p=0.11), but favoured both strategies to annual FOBT screening (all 
p-values <0.001) if, based on the literature, realistic risk reduction of CRC related mortality were 
applied. Screening-naïve and previously screened subjects were willing to undergo a ten-yearly 
TC instead of a five-yearly FS to obtain an additional risk reduction of CRC related mortality of 
45% (p<0.001). These data provide insight to which extend interval and risk reduction of CRC 
related mortality affect preferences for CRC screening tests. Assuming realistic test characteris-
tics, subjects in the target population preferred endoscopic screening to FOBT screening partly 
due to the more favourable risk reduction of CRC related mortality by endoscopy screening. 
Increasing potential screenees’ knowledge on risk reduction by different screening strategies 
is therefore warranted to prevent unrealistic expectations and to optimise informed choice. 
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introduction
Colorectal cancer (CRC) is the second cause of cancer-related death in the Western world. 
Screening can reduce CRC related mortality by removal of adenomas and early detection of 
CRC.1-5 There is compelling evidence to support screening of average-risk individuals over 50 
years of age.2, 4-7 Guidelines underline the role of individual preferences in the selection of a 
screening test 8-10, since insufficient evidence is available to recommend one screening test 
to another. Individual preferences for a certain screening test have been found to influence 
uptake in a CRC screening programme.11 Uptake is a key factor determining the effectiveness of 
such a screening programme. However, uptake levels are fairly low in many countries (<60%).4, 
5, 12-15 Several countries, including The Netherlands, are currently considering introduction of a 
nation-wide CRC screening programme. It is therefore essential to obtain insight into individual 
preferences for available screening strategies prior to the implementation of a nation-wide 
screening programme. 
Previous surveys demonstrated a broad variation in preferences for CRC screening tests, 
since tests differ in benefit (CRC mortality reduction) on the one hand and potential harms 
on the other hand (perceived burden, complications). Subjects who valued effectiveness most 
highly chose for colonoscopy screening, whereas others preferred faecal occult blood testing 
(FOBT) because of the less invasive character.11, 16-18 These studies however did not provide 
data on the relative importance of test characteristics on preferences, for example, how much 
potential health gain does a subject require to undergo invasive endoscopic screening?
Discrete choice experiments (DCEs) are becoming more widely used in health care 
research.19-23 A DCE is capable of establishing preferences and to predict uptake in controlled 
experimental conditions, through responses to realistic and hypothetical scenarios. DCEs may 
be valuable for patient centred evaluations of health technologies.24 
This study was conducted to determine individuals’ preferences and to predict uptake for 
CRC screening programmes with various screening tests, and the relative importance of dif-
ferent test characteristics for these preferences in an average risk population. Furthermore, we 
aimed to identify differences in preference structures between subgroups in the population. 
metHods 
Study population
A total of 1498 screening-naïve individuals aged 50-74 years old were randomly selected from 
municipal registries of the Rotterdam region in the Southwest of the Netherlands. We also 
invited a random sample of 769 screened subjects of a CRC screening trial comparing guaiac-
based FOBT (gFOBT), faecal immunochemical test (FIT) and flexible sigmoidoscopy (FS) (Fig 
1). This screening trial was carried out in the same target population as mentioned above.12 
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Age, sex and social economic status were equally distributed among the screening naïve and 
screening experienced invitees.
Discrete choice experiments 
DCEs can measure individuals’ preferences for health care interventions. DCEs are based on 
the assumptions that a healthcare intervention can be described by its characteristics (attri-
butes) (e.g. frequency of undergoing the intervention) and that the individual valuation of the 
intervention is determined by pre-defined levels (e.g. monthly, yearly) of those attributes. The 
health care intervention (e.g., screening test) as well as its test characteristics have to be speci-
fied before generating an experimental design. In a DCE individuals choose between several 
realistic and hypothetical scenarios. Preference estimates can be obtained from the choice data 
and describe the relative preference for characteristics of the health care intervention.
Attributes and levels
FOBT, FS and total colonoscopy (TC) are most widely used as CRC screening test and therefore 
incorporated in this study design. The characteristics and their levels were derived from the 
literature, expert opinions (n=3) and interviews with potential screenees (n=40). Experts were 
asked to comment on a list of characteristics derived from literature review. Potential screenees 
could also comment on the list of characteristics and rank them in order of importance. Based 
on these data we selected the two most important characteristics as identified by both groups: 
risk reduction of CRC related mortality (RR) and screening interval. Noteworthy, characteristics 
that are directly related to the test (e.g. oral bowel cleansing solution is not required for FOBT 
and always for TC) were already captured by the specific screening test (FOBT, FS and TC). All 
subjects were informed about the incorporated test characteristics of the three screening tests 
(Appendix 2). The specific values (levels; e.g. amount of risk reduction, or length of screening 
Chapter 6 
Fig 1 Screening-naive Screened  
1498 were invited 
400 (82%) analysable
1009 did not respond 
489 (33%) responded
769 were invited 
496 (91%) analysable
545 (71%) responded
89 failed the 
rationality test  
224 did not respond
49 failed the 
rationality test 
257 FS 
participants
256 gFOBT 
participants 
256 FIT 
participants
ï
fig 1: Study profile.
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interval) for each test characteristic incorporated the range of possible test outcomes of a spe-
cific screening test (FOBT, FS and TC) based on the current literature (Table 1). The levels were 
test specific to create realistic scenarios (Table 1). Levels of risk reduction were presented in the 
questionnaire as absolute values to reduce framing effects, in accordance to the literature.25 In 
the presentation of the results in this paper we used the relative risk on CRC related death, since 
this is most commonly used in the screening literature (e.g. FOBT 13-18% risk reduction). The 
absolute risk on CRC related death without screening was set at 3.0%. People aged 50 in the 
Netherlands have a 3.0% risk of dying from CRC, based on data of the Dutch comprehensive 
cancer centre. (IKC, www.ikc.nl).
Study design and questionnaire  
The design contained three tests (FOBT, FS and TC) and two characteristics (risk reduction of 
CRC related mortality and screening interval) with three levels each (Table 1). The test specific 
levels (e.g. screening interval of FOBT between four months and triennial) were required to 
select realistic combinations. Furthermore, unrealistic combinations of the characteristics’ 
levels were blocked (i.e. a combination of the lowest RR with the shortest screening interval 
as well as the highest RR combined with the longest screening interval). The combination of 
the characteristics and levels resulted in 21 (i.e. 7*3) possible test scenarios, and thus 343 (i.e. 
73) possible combinations of the scenarios (i.e. full factorial design). It is not feasible to present 
a single individual with all these combinations. We therefore reduced the design in such away 
that two-way interactions could be estimated (i.e. we created a fractional factorial design). We 
therefore used SAS software (Version 9.1, SAS Institute Inc., Cary, NC, USA), which is capable of 
generating designs that are highly efficient (i.e. maximizing D-efficiency or minimizing D-error) 
in such circumstances.26 We chose a design with 84 choice sets divided over 7 versions of the 
questionnaire (D-error 0.573). Each choice set included two CRC screening tests and an option 
not to be screened (opt-out) (Appendix 1). A design in which all three screening tests and the 
option not to be screened were presented was not feasible, since the pilot study (n=20) showed 
a significant decrease in subjects’ understanding and acceptance of the questionnaire.
A rationality test was included in the questionnaire to determine the understanding of the 
questionnaire by each subject. The rationality test was a choice set of which one screening 
table 1: Alternatives, attributes and the alternative specific levels based on the literature.
Alternatives Alternative specific levels Literature References
Screening interval (yr)
FOBT
Sigmoidoscopy
Colonoscopy
1/3 - 1 - 3
1 - 5 - 10
2 - 5 – 10
1 - 2
5 - 10
5 - 10
(2; 3)
(2; 3)
(2; 3)
Risk reduction (%)
FOBT
Sigmoidoscopy
Colonoscopy
10 - 25 - 40
40 - 50 - 70
75 - 85 - 95
13 - 33
49 - 62
80 - 84
(4-7)
(8-12)
(9; 13)
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option was logically preferred to the other option given the levels of each test characteristic 
(biennial FS screening resulting in 40% RR against biennial FS screening resulting in 70% RR). 
It is common practice to exclude irrational responses 27-29, and we therefore adopted this 
approach. However, some recent discussions in the literature suggest that these responses 
could be included.30, 31 Further sensitivity analyses were conducted and inclusion of irrational 
responses led to similar results. 
Subjects’ social economic status (SES), previous lower endoscopy experience (sigmoidoscopy 
or colonoscopy) and experience with CRC in family and close friends were determined. Fur-
thermore, the generic health status (EQ-5D summary score) was assessed. This is a validated 
classification of subject’s own health.32 
We conducted a pilot study (n=20) to ascertain that subjects could manage the length of 
the questionnaire and to evaluate subjects’ understanding, acceptance and face-validity of the 
questionnaire and the background information on the three screening tests (Appendix 2). The 
questionnaire was mailed to all subjects. Background information on the three screening tests 
was printed on the first page of the questionnaire (Appendix 2). A reminder was sent to non-
responders four weeks later.
Data Analysis
Each choice between two tests and the opt-out was considered as a specific observation. The 
DCE was analysed using multinomial logit regression models with test specific parameters. The 
model was implemented in SAS software (Version 9.1, SAS Institute Inc., Cary, NC, USA). A priori 
we expected the test as well as the two characteristics to be important for subjects’ choices and 
that a higher risk reduction and lengthening of ‘screening interval’ would have a positive effect 
on preferences. 
We assumed that there was no linear relationship between the different levels of the charac-
teristics. Therefore, we estimated the following models for the DCE: 
UFOBT  = VFOBT + ε FOBT = β0 + β1 Interval1yr + β2 Interval3y r+ β3 RR25 + β4 RR40 + ε FOBT
UFS  = VFS + ε FS = β5 + β6 Interval5yr + β7 Interval10yr + β8 RR50 + β9 RR70 + ε FS
UTC  = VTC + ε TC = β10 + β11 Interval5yr + β12 Interval10yr + β13 RR85 + β14 RR95 + ε TC
Uno test = 0
Utility (U) represents the preference for a (hypothetical) CRC screening programme. U consists 
of the deterministic and observable component (V) and the random component (ε) to the anal-
ysis, accounting for unobserved or unobservable components of choice. The observed utility 
(V) in this study is referred to as preference (V). The absolute value of V has a relative interpreta-
tion: the higher the score of V, the stronger a respondent’s preference for a particular screen-
ing strategy. The constant terms (screening test; β0, β5, β10) are alternative specific constants 
that indicate the general attitude of subjects towards screening with a specific screening test 
compared to no screening. β1,2, β6,7, β11,12  are coefficients of the levels of the test characteristic 
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‘screening interval’ and β3,4, β8,9, β13,14  are coefficients of the levels of the test characteristic ‘risk 
reduction of CRC related mortality’; each coefficient indicates the relative weight individuals 
place on that test specific level compared with the reference level for that test specific test 
characteristic (for the reference levels see Table 3). A two-sided p-value smaller than 0.05 was 
considered statistically significant. 
Generic health status was dichotomized to an EQ-5D summary score of ‘1’, representing full 
health, versus an EQ-5D summary score ‘<1’, indicating sub-optimal health. Aggregate data on 
social economic status (SES) were available at the level of the area postal code (www.cbs.nl) of the 
subject, weighted by population size and classified into three groups (high, intermediate, low). 
Chi-square and Student t-tests were used to assess the differences in the value of charac-
teristics between screening naïve and screened subjects as well as between subgroups (age, 
gender, SES, EQ-5D, prior endoscopy experience, or knowing someone affected by CRC) within 
the screening-naïve population.
To examine the predicted uptake of CRC screening based on our results, we applied previ-
ously proposed models to our data.33, 34 We also investigated the effect of changing the char-
acteristics, as identified by the results of our multinomial logit model, on the expected uptake 
of CRC screening. 
Ethical approval
The study was approved by the Institutional Review Board of the Erasmus Medical Centre (MEC-
2007-224).
resuLts
A total of 489/1498 (33%) screening-naïve and 545/769 (71%) screened subjects returned the 
questionnaire. Screening-naïve subjects were of higher SES than screened subjects (p<0.001, 
Table 2). A higher proportion of screened subjects previously underwent a lower endoscopy 
compared to screening-naïve subjects (49% vs. 23%; p<0.001). Among the subjects that 
participated in the CRC screening trial 22% (70/324) of the screenees that performed a FOBT 
previously underwent a lower endoscopy and obviously all (172/172) FS screenees.  
DCE 
A significantly higher proportion of the screened subjects (91%) passed the rationality test 
compared to the screening-naïve subjects (82%; p<0.001). 
Screening-naïve subjects did not prefer FOBT to no screening. They expressed a positive 
attitude towards FS and TC (positive and statistically significant sign, Table 3, Fig2). A high RR 
was preferred to intermediate and low RR for all screening tests (p-values <0.01). Screening-
naïve subjects expressed a more positive attitude towards an intermediate (FOBT: annually; 
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FS: five-yearly; TC: five-yearly) compared to a short screening interval (FOBT: four monthly; FS: 
annual; TC: biennial). Further lengthening of the screening interval (FOBT: triennial; FS: ten-
yearly; TC: ten-yearly) had only a small positive effect on subjects’ preferences for FOBT (p=0.02) 
and FS (p=0.02), and no effect on subjects’ preferences for TC screening.
Screened subjects had a positive attitude towards all screening tests (p<0.001). A high RR 
was preferred to intermediate and low RR for all screening tests, and an intermediate screening 
interval was preferred to a short screening interval (Table 3, Fig 2). Screened subjects did not 
prefer an intermediate to a long interval for all screening tests (FOBT p=0.67; FS p=0.99; TC 
p=0.10). 
Screening-naïve versus screened subjects
Screened subjects had a more positive attitude towards all screening tests than screening-
naïve subjects (Table 3, p<0.001). The differences in preferences regarding RR and screening 
interval between screening-naïve and screened subjects were statistically not significant, 
except for preferences regarding five- and ten-yearly FS screening. The more positive attitude 
of screening-naïve subjects towards longer screening intervals (Five-yearly p<0.001; ten-yearly 
p<0.001) indicated that screening naïve-subjects valued infrequent screening more positively 
than screened subjects. 
Differences in preferences between subgroups 
No differences in preferences were found between men and women, apart from a more positive 
attitude towards TC among men (TC p=0.02). Men, in contrast to women, did prefer FS and TC 
to no screening (men: FS p<0.001; TC p<0.001; women FS p=0.07; TC p=0.84). Respondents’ age, 
SES and EQ-5D summary score did not influence the attitude towards a screening test, interval 
table 2: Subjects’ characteristics.
Screening-naïve
subjects
Previously screened 
subjects
p-value
Analysable subjects
Sex (male; n-%)
Age (mean-SD)
EQ5D score (mean-SD)
Social economic status (n-%)
High
Intermediate
Low
400
209 (52)
60.7 (6.6)
0.94 (0.11)
195 (49)
77 (19)
128 (32)
496
260 (52)
61.1 (6.4)
0.93 (0.10)
196 (40)
96 (19)
204 (41)
0.96
0.36
0.76
<0.01
Lower endoscopy experience (n-%)
Yes
No
Unknown
Knowing someone affected by CRC (n, %)
Yes
No
Unknown
92 (23)
307 (76)
1 (1)
53 (13)
285 (71)
62 (16)
242 (49)
251 (50)
3 (1)
67 (13)
381 (77)
48 (10)
<0.01
0.78
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or RR. Subjects who reported to have a close friend or family member with CRC expressed a 
more positive attitude towards TC screening than subjects without (p=0.01). Experience with 
FS or TC was positively associated with the willingness to undergo a TC (p<0.001). Subjects 
that underwent FS screening had a more positive attitude towards FS and TC screening than 
subjects who performed a FOBT (p<0.001)
Trade-offs
Screening-naïve subjects were, when assuming the same interval (annual) and RR (40%), more 
willing to undergo FOBT than FS screening (Preference/Observed utility (V) FOBT: V=1.32; FS: 
V=0.30; p<0.001). Preferences were similar for a five-yearly FS and an annual FOBT if both tests 
table 3: Regression coefficients from the discrete choice experiments for the different tests and 
attributes.
Attribute levels
Screening-naïve 
subjects
 Coefficient          (95%CI)
Previously screened 
subjects
Coefficient          (95%CI) p-value‡ 
Screening test (base level ‘no screening’)
No screening (reference level)
FOBT -0.18 (-0.44;0.08) 0.38 (0.15;0.62)* <0.001
Sigmoidoscopy 0.30 (0.06;0.54)* 0.94 (0.72;1.16)* <0.001
Colonoscopy 0.33 (0.08;0.57)* 1.05 (0.84;1.27)* <0.001
Risk reduction of CRC related mortality
FOBT
3% to 2.7% (RR 10%) (reference  level)
3% to 2.4% (RR 25%) 0.19 (-0.01;0.38) 0.17 (-0.01;0.34) 0.88
3% to 1.8% (RR 40%) 0.78 (0.54;1.02)* 0.65 (0.44;0.87)* 0.45
Sigmoidoscopy
3.0 to 1.8% (RR 40%) (reference  level)
3.0 to 1.5% (RR 50%) 0.10 (-0.09;0.29) 0.33 (0.16;0.50)* 0.08
3.0 to 0.9% (RR 70%) 0.65 (0.42;0.89)* 0.65 (0.44;0.86)* 0.97
Colonoscopy 
3.0 to 0.8% (RR 75%) (reference  level)
3.0 to 0.5% (RR 85%) 0.16 (-0.03;0.35) 0.19 (0.02;0.36)* 0.79
3.0 to 0.1% (RR 95%) 0.40 (0.17;0.62)* 0.41 (0.20;0.61)* 0.95
Screening interval
FOBT
Four-monthly (reference  level)
Annual 0.73 (0.52;0.93)* 0.64 (0.44;0.83)* 0.50
Triennial 0.96 (0.72;1.20)* 0.67 (0.46;0.89)* 0.07
Sigmoidoscopy
Annual (reference  level)
Five-yearly 0.92 (0.74;1.11)* 0.55 (0.39;0.72)* <0.001
Ten-yearly 1.14 (0.91;1.37)* 0.56 (0.36;0.75)* <0.001
Colonoscopy
Biennial (reference  level)
Five-yearly 0.71 (0.52;0.90)* 0.56 (0.39;0.73)* 0.22
Ten-yearly 0.72 (0.48;0.95)* 0.42 (0.21;0.63)* 0.06
‡ p-value describes the difference between screening-naïve and screened subjects
* p-value < 0.05 compared to the reference level; Abbreviations: RR: risk reduction; FOBT: faecal occult 
blood test.
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would generate a RR of 40% (FOBT: V=1.32; FS: V=1.23; p=0.40). A five-yearly FS was preferred 
to annual FOBT if FOBT was associated with a less favourable RR than FS screening (FOBT 25% 
RR: V=0.73; FS 40% RR: V=1.23; p<0.001). 
A five-yearly FS was preferred to a ten-yearly TC if the difference in RR was 25% in favour of 
TC (e.g. FS: RR 50%; TC RR 75%; p<0.001). The preferences for a five-yearly FS and a ten-yearly TC 
were similar if TC would achieve an additional 35% RR (p=0.24), while more than 45% difference 
in RR was associated with a preference for 10-yearly TC (e.g. FS: RR 50%; TC RR 95%; p<0.001). 
Screening-naïve subjects equally preferred FS and TC screening, but did prefer both endo-
scopic screening options to FOBT screening if, based on the literature, the most realistic screen-
ing intervals and mortality reduction were applied (annual FOBT RR 25%: V=0.73; five-yearly 
FS RR 50%: V=1.33; ten-yearly colonoscopy RR 85%: V=1.22 ; FS vs. FOBT p<0.001, TC vs. FOBT 
p<0.001; TC vs. FS p=0.24).
Screened subjects made similar trade-offs between the screening test, interval and RR as 
screening-naïve subjects.
Screening-naive subjects               
                     FOBT                 Sigmoidoscopy               Colonoscopy 
 Previously screened subjects                
                     FOBT                 Sigmoidoscopy               Colonoscopy 
Fig 2 
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fig 2: Preferences for the different screening strategies at a long (--), intermediate (…) and short (__) 
Screening interval and different levels of mortality risk reduction for screening-naïve and previously 
screened subjects. 
Preferences for colorectal cancer screening strategies 103
Predicted uptake
Predicted uptake of screening naïve subjects for FOBT, FS and TC screening was 45%, 58% and 
58% respectively, assuming screening with the reference level for RR and screening interval. 
Based on realistic screening intervals and mortality reduction from the literature, these num-
bers were 68% for FOBT, 79% for FS, and 77% for TC. The screening programme characteristics 
had substantial impact on the expected uptake among screening naïve subjects (Figure 3). 
discussion
Principle findings
In this population-based study we found that the type of screening test, screening interval, 
and risk reduction of CRC related mortality significantly influenced individual preferences 
among screening naïve and screening experienced subjects in the target population (aged 
50-74 years old). These data provide insight in the relative importance of the effect of screening 
interval and risk reduction of CRC related mortality on preferences for the three most com-
monly used screening tests. Both screened and screening-naïve subjects preferred FS and 
TC to FOBT screening if, based on the literature the most realistic screening interval and risk 
reduction on CRC related mortality were applied (annual FOBT with 25% RR; five-yearly FS with 
50% RR, ten-yearly colonoscopy with 85% RR).2, 4-7, 10, 35, 36 This underlines the importance of 
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fig 3: Effects of changing the screening programme characteristics on the average probability of uptake 
for respectively FOBT (45%), FS (58%) and TC (58%) in screening-naïve subjects.
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adequate information on those aspects of CRC screening to achieve informed decision-making 
by potential screenees.
Five studies investigated preferences in CRC screening using a DCE 19, 20, 37-39, with two stud-
ies investigating preferences among available screening tests.20, 37 This is the first DCE including 
both a screening naïve and screening experienced population. In agreement with previous DCE 
studies, we found that RR dominated preferences for a screening test. Both FS and TC screening 
were therefore preferred to FOBT screening when associated with sufficient RR.20, 37 
The literature on preferences for the optimal screening interval per test is limited. One study 
reported a preference for five or ten-yearly to annual screening irrespective of the screening 
test.37 However, deciding on screening interval without information on the screening test 
leads to unrealistic choices, since an annual FOBT is less burdensome than an annual TC. We 
therefore used test specific screening intervals, which add to the validity of our results. In our 
study, screened subjects equally preferred intermediate and long screening interval for all tests. 
Reassurance may be a reason for preferring frequent screening.40 However, both intermediate 
and long interval of all three screening tests were preferred to a short interval, suggesting that 
subjects trade-off between reassurance and frequency of undergoing a screening test.
Men had a more positive attitude towards FS and colonoscopy screening than women. 
This finding is in accordance with FS screening programmes which described a lower uptake 
among women than among men.12-14 Known barriers for women to participate in endoscopy 
screening are male endoscopists 41, and anxiety prior to screening.42 A different approach to 
inform both sexes on screening or sex-specific screening strategies might be considered in a 
nation-wide screening programme to improve acceptance.
The results of this study may be relevant to predict population preferences for newer screen-
ing tests with a similar profile or an improved version of a screening test. For example, recently 
randomised trials demonstrated more favourable detection rates for FIT than gFOBT suggest-
ing a larger reduction of CRC related mortality.12, 15, 43 According to our data, informing people 
in the target population about a more favourable effect on CRC related mortality of FIT would 
lead to a higher acceptance of FIT screening and most likely a higher uptake. 
Predicted uptake of FS or TC screening based on our model was significantly higher than 
uptake of FOBT screening, given realistic levels. This finding is in contrast to the observed 
higher uptake of FOBT than FS screening in the randomised screening trial performed in the 
same population as this DCE. Screenees in this trial were however not specifically informed on 
test efficacy. This suggests that increasing awareness on the efficacy of a screening test may 
enhance uptake. It is therefore of paramount importance to improve the level of awareness on 
achievable risk reduction of CRC related mortality to obtain a higher uptake, especially for the 
more effective endoscopic screening tests. This is further underlined by two European studies. A 
Swiss study, in which the majority (75%) of all screenees chose to undergo a TC, and only a small 
proportion (25%) preferred FOBT or FS screening after they were informed about the efficacy of 
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the three screening tests.44 A large population-based Italian study found similar participation 
rates for FS and FOBT when subjects were offered a choice between both strategies.45
Strengths and weaknesses of this study
In contrast to previous DCE studies we used a labelled instead of an unlabelled DCE design. 
In a labelled design the specific screening test is mentioned in each choice option (FOBT, FS, 
TC; appendix 1), while in an unlabelled design the screening test is presented as ‘screening 
test ‘A’, ‘B’ or ‘C’ and is further described by certain characteristics that are presented in the 
choice set. CRC screening tests may evoke individual feelings, which can not be described in 
a questionnaire (e.g. anxiety for an endoscopy). It is therefore difficult to adequately convey 
the essential differences from a subject’s perspective between FOBT and endoscopic tests in 
terms of, for example, ‘more burdensome’ or ‘less burdensome’. Using a labelled design, the 
scenarios are more realistic, which adds to the validity of the results. Furthermore, we assessed 
preferences among screening-naïve and screened subjects within the target population (aged 
50-74 yrs old) including all social economic classes, which add to the generalisability of the 
results. Experienced subjects stated a more positive attitude towards all screening tests than 
screening-naïve subjects. A selection bias may explain this difference in attitude, as experi-
enced subjects have already demonstrated interest in screening and therefore express a more 
positive attitude towards screening. There is however also an experience effect, i.e. anticipated 
discomfort and pain might be higher than actually experienced. This experience might reduce 
anticipated pain and discomfort for successive screening round. Additionally, there may also 
be an expose effect, i.e. people tend to develop a preference merely because they are familiar 
with it. Our results suggest that subjects who underwent screening are willing to return for a 
successive screening round, which is of vital importance for efficacy of a screening program. 
Costs of screening were not included as a test characteristic in this study. All CRC screening pro-
grams in Europe including the Netherlands do not require out-of-pocket costs. Including cost 
would therefore influence the results in an unrealistic manner. A limitation of this study is the 
significantly lower response rate in screening-naïve than in screened subjects. This may have 
led to selection bias. Non-respondents may have a more negative attitude towards screening 
than respondents. Our results may therefore reflect a more positive attitude than exists in the 
general population as a whole. The method of framing the levels of risk reduction may have 
influenced our results. However, we minimised the framing effect in accordance to the literature 
by presenting absolute values in the questionnaire.25 It is common practice to exclude irrational 
responses from the analysis 27-29, and that was why this approach was adopted here. Ryan et 
al recently postulated that researchers should be cautious when excluding respondents, who 
failed the rationality test.30 Additional information on respondents’ considerations for failing 
the rationality test is required. The usage of a “think aloud technique” in the group of subjects 
who failed the rationality test to determine truly irrational responses has been suggested.30, 31 
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Further research on the effects of excluding subjects based on additional information on failing 
the rationality test is needed to adopt this approach as common practice. 
Conclusions
This data provide insight to which extend interval and risk reduction of CRC related mortality 
affect preferences for CRC screening tests in the experienced and screening naïve subjects. Both 
screening-naïve and screened subjects stated a more positive attitude towards both endo-
scopic screening strategies than FOBT if, based on the literature, the most realistic screening 
interval and risk reduction on CRC related mortality were applied. Risk reduction of CRC related 
mortality determined preferences for endoscopic screening. This underlines the importance of 
awareness on achievable risk reduction of CRC related mortality of the different screening test 
to enhance uptake particularly for endoscopic screening tests and to optimise informed choice.
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Appendix 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suppose screening for colon cancer is introduced. 
Which situation do you prefer? (fill in: A, B or C) 
 
Choice 
options: 
The test you will be 
examined with: 
In the following 10 years you 
will undergo the test: 
The chance of dying from colon 
cancer decreases from: 
A Sigmoidoscopy 1x            3%          to            1,8% 
                     
B Colonoscopy 1x           3%          to             0,8% 
                 
C None 0x 
 
 
         3% 
     
appendix 1: Choice set.
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appendix 2: background information on all screening test as applied to all subjects.
Faecal occult blood test Sigmoidoscopy Colonoscopy
Preparation None. - One or two enemas (bowel
  preparation).
- No fasting.
- You have to drink 4 litres of 
special
  cleansing solution the day 
before 
  the procedure.  
- You have to fast for 12 hours 
prior
  to the procedure.  
- You cannot work the afternoon
  prior to and the day of the 
  procedure.
The procedure How do I carry out the 
test?
At home, you collect a 
small amount of faeces 
of 1-3 bowel movements 
using a test set (see 
picture). You can return 
the test by mail to the 
laboratory. 
What does the test 
measure?
The test measures if there 
are (in)visible traces of 
blood present in the 
stools. 
What happens if the test 
results are abnormal? 
You will be advised to 
undergo a colonoscopy.
    
The procedure
The last 60 cm of the large 
bowel is examined by using 
a flexible tube with a small 
camera on the tip. This tube is 
inserted through the anus. 
During the procedure the large 
bowel will be filled with air in 
order to carefully examine the 
bowel.
What do I feel of the 
investigation?
Because of the air put into your 
bowel you may feel abdominal 
cramps.
What happens if abnormalities 
are found?
Precursors of colon carcinoma 
(polyps) are removed during 
the procedure (this is painless). 
You will be advised to undergo 
a colonoscopy to see if there 
are other abnormalities in the 
remainder large bowel. 
The procedure
You will be given conscious 
sedation (‘short narcosis’). 
Therefore, you may fall into a 
light sleep. The entire large bowel 
(100-120 cm) is examined by 
using a flexible tube with a small 
camera on the tip. This tube is 
inserted through the anus. 
During the procedure the large 
bowel will be filled with air in 
order to carefully examine the 
bowel. 
What do I feel of the 
investigation?
Due to the air and tube in your 
bowel you may feel abdominal 
pressure and cramps.
What happens if abnormalities 
are found?
Precursors of colon carcinoma 
(polyps) are removed during the 
procedure (this is painless).
After the 
procedure
- You can return to your 
daily 
  activities immediately. 
- You may eat and drink again
  immediately and go home. 
- You may eat and drink again 
and
  go home after one hour.
- You cannot drive a car, ride a
  motorcycle or bicycle.
Perceived burden Low. High. High.
Results - You will receive the 
result by
  mail within two weeks.
- Directly after the procedure.
- When tissue has been 
removed,
  you will receive the pathology
  results by mail within two 
weeks.
- Directly after the procedure.
- When tissue has been 
removed,
  you will receive the pathology
  results by mail within two 
weeks.
Test at home or 
in the hospital
At home. Hospital. Hospital.
Total duration of 
the procedure
30 minutes. 15 minutes. 1 hour and 45 minutes.
Complications Never. In 1 in 10.000 individuals: severe 
blood loss or a perforation or a 
tear through the bowel wall.  
In 1 in 1.000 individuals: severe 
blood loss or a perforation or a 
tear through the bowel wall.  
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abstract
In many countries uptake of colorectal cancer (CRC) screening remains low. We aimed to 
assess how procedural characteristics of CRC screening programmes determine preferences 
for participation and how individuals weigh these against the perceived benefits from par-
ticipation in CRC screening. A discrete choice experiment was conducted among subjects in 
the age-group of 50–75 years, including both screening-naïve subjects as well as participants 
of a CRC screening programme. Subjects were asked on their preferences for aspects of CRC 
screening programmes using scenarios based on: pain, risk of complications, screening loca-
tion, preparation, duration of procedure, screening interval and risk reduction of CRC related 
death. The response was 31% (156/500) for screening-naïve and 57% (124/210) for CRC screen-
ing participants. All aspects proved to significantly influence the respondents’ preferences. 
For both groups combined, respondents required an additional relative risk reduction of CRC 
related death by a screening programme of 1% for every additional 10 minutes of duration, 5% 
in order to expose themselves to a small risk of complications, 10% to accept mild pain, 10% to 
undergo preparation with an enema, 12% to use 0.75 litres of oral preparation combined with 
12 hours fasting and 32% to use an extensive bowel preparation. Screening intervals shorter 
than 10 years were significantly preferred to a 10-year screening interval. This study shows that 
especially type of bowel preparation, risk reduction and length of screening interval influence 
CRC screening preferences. Furthermore, improving awareness on CRC mortality reduction by 
CRC screening may increase uptake.  
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introduction
Colorectal carcinoma (CRC) is the second most frequently occurring malignancy in the Euro-
pean Union, and the second leading cause of cancer related death in the Western world.1 A 
recent study demonstrates that for many European countries CRC mortality rates are decreasing 
while incidence is rising, suggesting an increasing CRC prevalence.2 CRC screening is effective 
in reducing CRC mortality.3-11 Screening can reduce CRC mortality by early detection of CRC 
and endoscopic removal of premalignant precursors of CRC (adenomas).5, 6, 12 There are several 
methods available for CRC screening. The various types of faecal occult blood tests (FOBTs) 
primarily aim at the early detection of CRC, whereas endoscopic and radiologic screening tests 
(flexible sigmoidoscopy (FS), colonoscopy) are effective at both early detection and removal of 
premalignant lesions.12  Different screening methods are expected to have a different impact 
on CRC mortality reduction due to these differences in preventive potential. CRC screening 
methods also differ with respect to procedural characteristics, which determine the subject’s 
burden of a screening method. CRC screening methods perceived as the most burdensome 
(FS, colonoscopy) also have the largest potential for prevention of CRC.12  Currently, insufficient 
evidence is available to recommend one screening method over another. 
Attendance is an important determinant of the effectiveness of CRC screening programmes. 
Uptake of CRC screening in a pilot screening programme in the Netherlands has remained 
lower than uptake of breast and cervical cancer screening.13-15 In many other countries, uptake 
of CRC screening, as well as continuing adherence to CRC screening, has also remained sub-
optimal.3, 4, 13, 16-18 It has been established that increasing colorectal cancer screening uptake, 
in comparison with other targets, has a large potential for reducing CRC related mortality.19 
Attendance rates depend on the willingness of individuals to undergo a certain screening test. 
This willingness may be influenced by perceived advantages and drawbacks of CRC screening 
tests and furthermore, by knowledge and awareness of CRC, CRC risk and CRC screening.16, 20, 
21 Individuals may be willing to undergo a screening test despite several drawbacks in order to 
maximize health benefit or vice versa (to accept a lower health benefit in order to avoid several 
burdensome test characteristics). To optimise a CRC screening programme it is of paramount 
importance to gain insight in factors that influence population preferences for CRC screening 
programmes, and the trade-offs individuals are willing to make between benefits and draw-
backs of a CRC screening programme. Research has shown that patient preferences can have 
a major impact on their willingness to use services and furthermore, there is an increasing 
emphasis on involvement of patients in health care decisions.22  
This study therefore investigated preferences for CRC screening using a discrete choice 
experiment (DCE). DCE is a survey methodology with its origin in market research. DCEs are 
widely used for the assessment of preferences in transport and environmental economics and 
marketing research.23 They are increasingly used for health care purposes.24, 25 
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It has been demonstrated that awareness of CRC and CRC screening in the Netherlands has 
remained low.26 There is currently no organised CRC screening programme in the Netherlands, 
except for hereditary or familial CRC. A similar situation is encountered in many countries in the 
EU, in fact, only approximately 50% of the target population is offered any type of screening for 
CRC. It is of particular importance to study preferences in a screening naïve population, since 
they may guide the introduction and adjustment of new CRC screening programmes in these 
countries. 
The aim of our study was to determine how procedural characteristics of various CRC screen-
ing methods determine preferences for participation, and how individuals weigh these against 
the expected health benefits from CRC screening. We compared the relative importance of 
aspects of the three most commonly used CRC screening tests: FOBT, FS and colonoscopy.
materiaLs and metHods 
Study population
We conducted the study in two groups. The first group included a total of 500 screening-naïve 
individuals aged 50-74 years old who were randomly selected from the population registry of 
the region Rijnmond in the Southwest of the Netherlands. The region includes Rotterdam and 
surrounding suburbs and harbours 338000 inhabitants in the target age groups. The second 
group included 210 participants of a randomised screening trial for CRC in the Netherlands 
from the same target population as mentioned above. This screening trial invited average risk 
individuals to participate in a CRC screening programme with guiac-based FOBT (gFOBT), fae-
cal immunochemical test (FIT) or FS.13
Invitation of subjects
Subjects were contacted by mail. They received a questionnaire and an information brochure 
with general and background information about CRC and CRC screening. Individuals could 
return the questionnaire in a postage-paid self-addressed envelope that was included in the 
mailing package. A reminder was sent four weeks later in case of non-response. 
DCE
DCE is a formal technique to assess preferences, assuming that a healthcare intervention (e.g. a 
screening programme) can be described by its characteristics (attributes; e.g. test duration).27 
Those attributes are further specified by variants of that attribute (levels; e.g. for test duration: 
10, 20, 30 minutes). The DCE assumes that the individual preference for a test is determined by 
the levels of those attributes.27 Individuals are presented with a number of choice sets contain-
ing several scenarios (screening programmes). Those programmes are described by several 
attributes with varying levels (Figure 1). The results of a DCE provide information on the relative 
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importance of the attributes and the trade-offs individuals are willing to make between these 
attributes. The DCE design will be explained in more detail further on. 
Attributes and attribute levels 
The attributes and attribute levels of the DCE were derived from literature review, expert 
opinions, interviews with screening naïve (n=10) and screened (n=10) individuals of the target 
population. In the interviews we asked individuals to point out which of these attributes they 
expected to be important or had been important in their decision to participate in a CRC screen-
ing programme. The attributes identified as most relevant were: pain, risk of complications, 
location of the screening test, preparation for the procedure, duration of the procedure, screen-
ing interval and risk reduction of CRC related death (Table 1). Attribute levels were derived from 
the literature. The levels for each attribute incorporated the range of characteristics or possible 
test outcomes of all different screening methods (FOBT, FS and colonoscopy). The attribute 
‘interval’ was related to a CRC screening programme, the other attributes were test-related.
Study design and questionnaire
The design contained three attributes with two levels and four attributes with four levels. The 
combination of those attributes and levels resulted in 2048 (i.e. 23*44) possible test scenarios. 
Since it is not feasible to present a single individual with all these scenarios, we reduced the 
model to 16 scenarios (a fractional factorial design) by means of a website, containing a library 
of orthogonal arrays.28 These 16 scenarios were used to create 16 choice sets. Each choice set 
contained two screening programmes and an opt-out (the option to choose ‘no screening’, see 
figure 1). A special technique (fold-over; 29) was used to create the second programme of each 
choice set. As a result, our design was an efficient orthogonal design; there was no correlation 
between any pairs of attributes (orthogonality), all levels of each attribute were represented in 
the same frequency (level balance), and similar levels of an attribute did not occur within the 
same choice set (minimal overlap). A rationality test was included in the DCE to investigate the 
4 subjects not be included 
in the analysis (3%) 
156 subjects responded 
(31%)  
124 subjects completed the 
questionnaire (59%)
120 questionnaires were 
analysable (97%)
4 subjects not be included 
in the analysis (3%) 
Chapter 7: Figure 1: Overview of subjects accessing the study 
 
 
 
Screening naïve group                 Colorectal cancer (CRC) screening participants group 
 
           
 
 
152 questionnaires were 
analysable (97%) 
500 subjects were invited  210 subjects were invited 
(70 per screening arm)
gFOBT 
screenees 
(n=36) 
FIT 
screenees 
(n=36) 
FS 
screenees  
(n=48) 
fig 1: Choice set example
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understanding of the questionnaire. This was a choice set of which one screening programme 
was logically preferable over the other given the attribute levels.
The questionnaire further contained questions on background variables (e.g. generic 
health status (EQ-5D; 30) and a question assessing experienced difficulty of the questionnaire 
(5-point scale). A written description of the attributes and levels was given at the beginning. 
We conducted a pilot study (n=20) to ascertain respondents could manage the length of the 
questionnaire and to examine the intelligibility, acceptability and validity of the questionnaire. 
The study was approved by the Medical Ethical Committee of the Erasmus Medical Centre 
(MEC-2007-224).
Analyses 
Each choice between three options (two screening programmes and the opt-out) was con-
sidered as a specific observation. A multinomial logit model was used to analyse the data. We 
excluded individuals who answered less than 13 questions of the DCE.
table 1: Attributes and levels for colorectal cancer (CRC) screening
Attributes and levels Beta coefficients in regression analysis
Pain
No pain (reference level)
Mild pain β1
Risk of complications
None (reference level)
Small β2
Location
At home (reference level)
Hospital β3
Preparation
None (reference level)
Enema. no fasting
Drinking of 0.75 litre of fluid. 12 hours fasting
Drinking of 4 litres of fluid. 18 hours fasting   
β4
β5
β6
Duration
10 minutes 
30 minutes
60 minutes
90 minutes
β7
Interval
1x in 10 years (reference level)
2x in 10 years
5x in 10 years
10x in 10 years
β8
β9
β10
Risk reduction of death from CRC
3% → 2.7% (10% relative risk reduction) 
3% → 1.8% (40% relative risk reduction)
3% → 1.2% (60% relative risk reduction)
3% → 0.3% (90% relative risk reduction)
β11
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We assumed that there was no linear relationship between the different levels of the attri-
butes ‘preparation’ and ‘screening interval’ and that all attributes had independent effects on 
preferences. On this basis, we estimated the following model for the DCE: 
U=  V + ε = β0 + β1 pain + β2 complications + β3 location + β4 enema + β5 0,75lfluid + β6 4lfluid + β7 duration + β8 
interval2+ β9 interval5 + β10 interval10 + β11 mortalityreduction + ε
U represents latent utility of a CRC screening alternative in a choice set. It is assumed that an 
individual will choose the CRC screening alternative which maximises his/her utility amongst 
all alternatives in a choice set. V is a systematic, explainable, component specified as a function 
of the attributes of the CRC screening alternatives. ε is the random (unexplainable) component 
representing unmeasured variation in preferences. The constant term (screening programme; 
β0) is an ‘alternative specific constant’ and indicates the relative weight individuals place on 
screening programmes compared to no screening. β1-β11 are coefficients of the attributes 
indicating the relative weight individuals place on a certain attribute(level). The value of each 
coefficient represents the importance respondents assign to a certain level. However, different 
attributes utilise different units of measurement. For example, the coefficient for ‘risk reduction 
of death from CRC’ represents the importance per relative 10% risk reduction. When looking at 
a screening programme that generates a 50% risk reduction, the coefficient should be multi-
plied five times in order to enable comparison to the coefficients of other levels. An attribute 
with a two sided p-value smaller than 0.05 was considered to be important in the decision to 
participate in a certain screening programme.
Given the current DCE literature 31, 32, further sensitivity analyses were conducted to explore 
the impact of excluding respondents who failed the rationality test by removing such individu-
als from the sample and rerunning the analysis. 
The trade-offs respondents were willing to make between the attributes were calculated by 
the ratios of the coefficients of the different attributes with risk reduction as the denominator. 
For example, β1/β11 indicates how much additional relative risk reduction respondents think 
a test should generate in order to undergo a test that causes mild pain instead of a test that 
causes no pain. 
To examine the expected uptake of CRC screening based on our results, we applied the 
model as presented by Gerard and colleagues and Hall and colleagues to our data. 33, 34 
                           1             
                    (1+e^-V)
The model assumes that a preference score of 0 indicates that individuals have an equal 
preference for either participation or non-participation, hence the expected participation 
rate equals 50%. Additionally, we investigated the effect of changing the most important 
CRC screening programme characteristics, as identified by the results of our multinomial logit 
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model, on the expected uptake of CRC screening. The average probability of participation was 
calculated by entering the constant term (β0) into the model as described above. 
The expected uptake of the different screening tests was calculated by adding up the dif-
ferent levels corresponding with the screening test concerned, and entering this value into 
the model. The levels we applied for assessing the uptake of FOBT were ‘no pain’, no risk of 
complications, location ‘at home’, no preparation and a duration of 15 minutes. For FS we 
applied ‘mild pain’, a small risk of complications, location ‘hospital’, preparation by an enema 
and a duration of 30 minutes. For colonoscopy we used ‘mild pain’, a small risk of complications, 
location ‘hospital’, preparation by ‘drinking of 4 litres of fluid and a duration of 90 minutes.  
The influence of the different levels on expected uptake was calculated by entering the 
coefficients of the levels, added to the constant term, into the model. 
Aggregate data on socio-economic status (SES) were available at the level of the respon-
dents’ area zip code, weighted by the number of inhabitants per postal code and classified into 
three groups (high, average, low). 
Characteristics of the different groups were compared using parametric and non-parametric 
tests. For categorical data, we used Chi-square and Fisher Exact Test to test for differences 
between screening naïve individuals and CRC screening participants. For continuous variables, 
we used the Independent Samples T-Test. To assess whether there were differences in pref-
erences among participants of the FOBT (either gFOBT or FIT) and FS screening programme 
and those with and without endoscopy experience, we performed subgroup analyses. For 
comparing subgroups, we included all respondents in the same model and used the subgroup 
as interaction term.
resuLts
Respondents
The response rate was higher among CRC screening participants (59%; 124/210) compared to 
screening naïve individuals (31%; 156/500) (Table 2). The characteristics of the respondents are 
shown in Table 2. Among the screening naïve group, 22% had undergone an endoscopy in the 
past. Within the group of CRC screening participants, 53% had previous endoscopy experience 
including 22% (16/72) of FOBT screenees and logically all FS screening subjects (48/48). 
dce resuLts
Forty-three percent of the screening-naïve individuals and 50% of the CRC screening partici-
pants rated the questionnaire as ‘easy’ (p=0.24). 
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The signs of all coefficients of the attributes were consistent with our initial hypotheses (see 
Table 3). The positive sign given to the coefficient ‘risk reduction of death from CRC’ indicated 
that respondents preferred a test generating a higher risk reduction over a test that generates 
a lower risk reduction. The positive sign of the coefficients for shorter screening intervals indi-
cated that individuals preferred those screening intervals over screening once every 10 years. 
The negative signs for all other attributes indicate that individuals preferred a screening test of 
shorter duration, with no preparation, no pain and no risk of complications. 
The non-significant coefficient of the constant term in the screening-naïve group indicated 
that these subjects had, if assuming a screening programme with the reference level for all the 
attributes, no preference for either screening or no screening whereas the group of CRC screen-
ing participants expressed a positive attitude towards screening compared to no screening 
(positive significant coefficient). All screening attributes proved to be important determinants 
of the preferences in each of the respondent groups, except for location of the screening test, 
which only significantly influenced preferences of CRC screening participants and not those of 
the screening naïve individuals and a preparation with ‘0.75 litres of fluid and 12 hours fasting’, 
that did not influence preferences of CRC screening participants. 
The results of the sensitivity analyses indicated that removing respondents who failed the 
rationality test did not entail drastic changes in the outcomes of those analyses. We therefore 
included them in our further analyses.  
The differences in preferences between screening naïve-individuals and participants of a 
CRC screening programme were statistically not significant, except for preferences regarding 
risk reduction of CRC related death. Screening naïve individuals demanded more effectiveness 
from a CRC screening programme compared to participants (p<0.01). We performed subgroup 
analyses, analysing FOBT and FS screenees separately, which showed that participants of FOBT 
table 2: Respondent characteristics 
Characteristics Screening naïve Participants Difference
Response (n respondents/n invited - %) 156/500 (31.0) 124/210 (59.0) p<0.01
Analyzable questionnaires (n - %) 152 (97.4) 120 (96.8) p=0.74
Age (mean – standard deviation (SD)) 59.9 (5.7) 62.2 (6.4) p<0.01
Gender (male; n - %) 74 (48.7) 59 (49.2) p=0.94
Socio economic status (n - %)
High
Intermediate 
Low
78 (51.3)
21 (13.8)
53 (34.9)
53 (44.2)
20 (16.7)
47 (39.2)
p=0.49
Endoscopy experience (n - %)
Yes
No
Unknown
33 (21.7)
117 (77.0)
2 (1.3)
64 (53.3)
54 (45.0)
2 (1.6)
p<0.01
Knowing someone affected by colorectal cancer (CRC) 
(n - %)
Yes
No
Unknown
19 (12.5)
115 (75.7)
18 (11.8)
18 (15.0)
88 (73.3)
14 (11.6)
p=0.84
Generic health status (EQ-5D) summary score (mean - SD) 0.92 (0.11) 0.93 (0.12) p=0.48
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and FS screening did differ in preferences: FS screenees expressed a positive attitude, while 
FOBT screenees expressed a negative attitude towards a test in the hospital (p<0.001). Further-
more, FS screenees attached more importance to a 5-yearly screening interval (p=0.01) and to 
the effectiveness of a screening test (p<0.001) than FOBT screenees. 
When comparing those with previous endoscopy experience to those without endoscopy 
experience, it could be seen that pain had a significant greater influence on preferences for 
those without previous endoscopy experience (p=0.02). The location hospital was negatively 
associated with preferences for those without endoscopy experience, but it had a positive 
affect on preferences for those who had undergone a previous endoscopy (difference: p<0.01). 
Individuals without endoscopy experience also demanded more effectiveness from a screen-
ing test (p<0.01).  
Screening-naïve individuals and CRC screening participants significantly preferred no 
preparation to all other preparations (p-values <0.03). Both groups significantly preferred 
preparation with an ‘enema’ or ‘0.75 litres of fluid’ instead of a preparation with ‘4 litres of fluid’ 
table 3: Preferences of the screening naïve individuals and participants of a colorectal cancer (CRC) 
screening programme
Levels Screening naïve Participants
β-coefficient 95% confidence 
interval
β -coefficient 95% confidence 
interval
Constant (screening)  0.25 (-0.00 to 0.50)  0.62 (0.35 to 0.90)*
Pain
No pain (ref)
Mild pain -0.31 (-0.42 to -0.20)* -0.23 (-0.34 to -0.11)*
Risk of complications
None (ref)
Small -0.16 (-0.28 to -0.05)* -0.13 (-0.25 to -0.01)*
Location
At home (ref)
Hospital -0.09 (-0.20 to 0.02) -0.01 (-0.13 to 0.10)*
Preparation
None (ref)
Enema. no fasting
Drinking of 0.75 liter of fluid. 12 hours fasting
Drinking of 4 liters of fluid. 18 hours fasting
-0.37
-0.51
-0.98
(-0.57 to -0.16)*
(-0.72 to -0.29)*
(-1.18 to -0.77)*
-0.23
-0.22
-0.88
(-0.45 to -0.02)*
(-0.45 to 0.01)
(-1.10 to -0.67)*
Duration
None 
Per 10 minutes spent in the screening process -0.03 (-0.05 to -0.01)* -0.03 (-0.06 to -0.01)*
Interval
1x in 10 years (ref)
2x in 10 years
5x in 10 years
10x in 10 years
0.28
0.40
0.33
(0.11 to 0.45)*
(0.21 to 0.59)*
(0.18 to 0.49)*
0.24
0.33
0.27
(0.06 to 0.42)*
(0.13 to 0.53)*
(0.10 to 0.44)*
Risk reduction of death from CRC
None 
Per relative 10% risk reduction 0.32 (0.29 to 0.35)* 0.26 (0.24 to 0.29)*
* significant at the 5% level
(ref ) = reference level
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(p-values <0.001). Preparation with an ‘enema’ and ‘0.75 litres of fluid’ were valued equally by 
both groups (p-values>0.09).
Trade-offs
It can be seen in Table 4 that, based on the expressed preferences, screening-naïve individuals 
required an additional relative risk reduction of 30% (95% confidence interval (CI) 24-37%) for 
participation in a screening programme with a test requiring a preparation with ‘4 litres of fluid 
and 18 hours fasting’ instead of a test that required ‘no preparation’. Respondents preferred 
shorter screening intervals and they were willing to give up a 12% (CI 7-18%) relative risk reduc-
tion if the screening interval was shortened from once every 10 years to a 2-yearly screening 
interval. Participants of a CRC screening programme made trade-offs that were comparable to 
those of the screening naïve individuals. 
table 4: Individuals’ tradeoffs between risk reduction and different aspects of a colorectal cancer (CRC) 
screening programme
Levels Screening 
naïve
Participants Interpretation note
% of additional relative risk 
reduction respondents think a 
test should generate....
Pain
None (ref )
Mild pain 10% (6-13%) 9% (4-13%)
.. in order to undergo a test that causes 
mild pain instead of a test that causes 
no pain 
Risk of complications
None (ref )
Small 5% (1-9%) 5% (0-10%)
.. in order to undergo a test that carries 
a small risk of complications instead of 
a test with no risk of complications
Preparation
No preparation (ref )
Enema. no fasting
Drinking of 0.75 liter of fluid and
12 hours fasting
Drinking of 4 liters of fluid and 
18 hours fasting
11% (2-5%)
16% (9-23%)
30% (24-37%)
9% (1-17%)
8% (0-17%)
33% (25-41%)
.. in order to accept a test that requires 
a preparation with one of these three 
methods instead of a test requiring no 
preparation at all
Duration
None
For each additional 10 minutes 
spent in the screening process
1% (0-2%) 1% (0-2%)
.. in order to accept a test with an 
additional 10 minutes of duration 
compared to the standard duration
Interval
1x in 10 years (ref )
2x in 10 years
5x in 10 years
10x in 10 years
9% (3-14%)
12% (7-18%)
10% (5-15%)
9% (2-16%)
13% (5-20%)
10% (5-16%)
.. if the screening interval is lengthened 
from one of the shorter, more 
preferred, screening intervals (5-yearly, 
biennial, annual) to the longest 
screening interval (once every 10 
years)
(ref ) = reference level
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Expected uptake of CRC screening
The average expected uptake of CRC screening was 56% (CI 50 - 62%) for screening naïve indi-
viduals. Assuming that all screening tests would generate a 10% risk reduction of CRC related 
death, uptake would be 72% for biennial FOBT screening, 46% for 5-yearly FS screening and 
22% for 10-yearly colonoscopy screening. We would expect that, if individuals are aware of the 
achievable risk reduction as currently known from the literature, the uptake would increase to 
75% for biennial FOBT screening, 80% for five-yearly FS screening and 71% for 10-yearly colo-
noscopy screening (risk reduction of CRC related death respectively 16% 35, 59% 6 and 74.5% 
36). The effects of changing the CRC screening programme characteristics on average expected 
uptake of CRC screening are shown in Figure 3. 
discussion
Our study demonstrates the importance of several procedural characteristics of CRC screening 
programmes for the preferences of potential and actual screenees: risk reduction of CRC-
related death, preparation for the procedure, procedure related pain and complications and 
screening interval. To optimise a screening programme, the attendance rate should be high. A 
high attendance rate is only possible when the utilised screening strategy and the information 
given connect with the preferences of the target population. The results of this DCE in the first 
place indicate targets for improvement of CRC screening programmes. Secondly they stress the 
importance of several aspects of screening programmes regarding the information provided 
to screening invitees. To our knowledge, this is the first study assessing preferences for CRC 
screening among both screening-naïve subjects and CRC screening participants. 
Chapter 7: Fig 2 
 
 
 
 
               Choice options: A B C 
Preparation: Enema, 
No fasting 
Drinking of 0.75 liters of fluid, 
12 hours fasting 
None 
Location: At home Hospital None 
Pain: None Mild pain None 
Risk of complications: None Small None 
 
The chance of dying from 
colon cancer decreases 
from: 
 
 
 
 
           3%          to        1.8% 
 
           3%         to          1.2% 
 
 3% 
 
 
 
In the following 10 years 
you will undergo the test: 
5x 2x 0x 
Duration: 30 minutes 60 minutes None 
Suppose screening for colon cancer is introduced. 
Which test do you prefer? (Fill in: A. B or C) 
fig 2: Overview of subjects accessing the study
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In our study, especially mortality reduction had an important positive influence on prefer-
ences for CRC screening methods. A few other studies have investigated preferences for CRC 
screening using a DCE.37-42 Our finding that individuals attach much importance to CRC mortal-
ity reduction by a screening method is consistent with the results of previous studies.38, 42, 43 
The finding that individuals are prepared to undergo more burdensome screening tests if this 
results in sufficient additional risk reduction of CRC related mortality demonstrates that they 
trade benefits and harms of a screening test. 
The burden of the required preparation was considered the main drawback of undergoing 
CRC screening. A preparation commonly used for colonoscopy (i.e. drinking 4 litres of fluid 
and 18 hours fasting) would only be chosen when an additional relative risk reduction of, on 
average, 33% would be achieved. In line with our results, Canadian investigators found that 
preparation was ranked as the most important process related attribute. In contrast, American 
investigators found that preparation was rated as the least important attribute.37 The levels 
that were chosen for the attributes may explain those differences. The results of our DCE are 
of utmost importance when for example starting a colonoscopy screening programme with a 
burdensome preparation. Emphasis should be laid on adequate information that should be pro-
vided to the target population about the burden and benefits including expected CRC mortality 
reduction by colonoscopy screening, since this may compensate for a burdensome preparation.
Interestingly, we found that respondents significantly preferred shorter screening intervals 
to a 10-year screening interval irrespective of health benefit. This finding is consistent with a 
previous study suggesting that women preferred shorter (annual and biennial) over longer (3-, 
4- or 5-year) screening intervals for cervical cancer screening.44 One study among Danish indi-
viduals and another among both American and Canadian individuals could not confirm prefer-
ences for shorter CRC screening intervals.38, 39 A second American study could not determine if 
individuals preferred shorter or longer screening intervals.37 Several studies have showed that 
reassurance may be a motivation for and/or a result of undergoing cancer screening.45, 46 The 
preference for shorter screening intervals found in our study may be associated with expected 
reassurance. This again stresses the importance of adequate information provided to potential 
screenees. It emphasises the need to adequately inform individuals that longer screening 
intervals for CRC screening do not imply lower reductions in mortality, but that specific CRC 
screening tests with longer screening intervals have more potential for CRC prevention and 
therefore require less frequent testing.
There were some differences in preferences between FOBT and FS screenees. Assessment 
of preference variations across subgroups is advisory because of status quo bias; in other 
words the tendency of people to value services higher once they have experienced them.47 
We conducted the study among both screening-naïve individuals and individuals who had 
prior experience with CRC screening tests, so that we were able to investigate if status quo bias 
was present. The preferences of screening-naïve subjects and CRC screening participants were 
not significantly different. The fact that FOBT screenees expressed a negative attitude towards 
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a test in the hospital, while FS screenees expressed a positive attitude towards a test in the 
hospital may be explained by the phenomenon of status quo bias. However, it may also be 
a result of selection bias; that those subjects with a preference for the location ‘home’ do not 
participate in FS screening and vice versa. Interestingly, the same significant difference regard-
ing the influence of screening location on preferences was observed when comparing those 
with endoscopy experience to those without. A possible explanation might be that individuals 
on beforehand have a negative association with the location hospital, but develop a positive 
attitude towards a hospital-based examination once they have experienced it.  
Research has consistently shown that expected pain is one of the most important reasons 
for declining the endoscopic screening offer.16, 48, 49 The results from our study confirm that 
finding and furthermore they demonstrate that pain has significant less influence on prefer-
ences of those with endoscopy experience, suggesting that pain actually experienced during 
endoscopic screening is not as severe as expected on beforehand. 
This study revealed uptake levels of the FOBT, FS and colonoscopy based on the characteristics 
in our model. The uptake levels for FOBT and FS as predicted by our model are somewhat higher 
than observed in the Dutch screening trial conducted in the same target population 13, however 
participants in this trial were not informed on achievable risk reduction of CRC related death and 
the required frequency of testing for FOBT and FS which have both shown to positively influ-
ence CRC screening preferences. We found that mainly risk reduction of CRC related death highly 
influenced the participation that could be expected for the different screening tests, suggesting 
that increasing awareness on efficacy of the screening tests might enhance uptake. 
Given the low levels of awareness of CRC screening in the Netherlands, it may be of vital 
importance to raise knowledge on achievable risk reduction of CRC related death in order to 
increase screening uptake especially for the more effective endoscopic screening tests. The 
importance of awareness on efficacy of the available screening tests is further underlined by 
data of a Swiss study, in which 75% of all screenees chose to undergo a colonoscopy and only 
25% preferred FOBT or FS screening after they were informed about the efficacy of all screening 
methods.50 This study involved testimonies from patients with CRC in their campaign in order to 
raise CRC awareness. This strategy has also been used in various other campaigns throughout 
the European Union, among others in the United Kingdom, Germany and the Netherlands. CRC 
patients and their relatives may be important advocates for raising awareness, and possibly 
also for increasing public familiarity with endoscopic screening which has been demonstrated 
to influence CRC screening preferences in our study.
There are some limitations to our study. There was a significant difference in response rate 
between screening-naïve individuals and CRC screening participants. This may have given a 
selection bias and thereby be a limitation regarding the interpretation of our results. 
Furthermore, the way we framed the information on risk reduction may have influenced 
our results. In order to minimise framing effects we attempted to frame our information, where 
possible, according to the current literature.51
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In conclusion, individuals are willing to trade-off benefits and harms of CRC screening 
programmes. Especially type of bowel preparation, length of screening interval and mortality 
reduction influenced individuals’ trade-offs. The results provide insight in the decision-making 
process regarding the decision to participate in a CRC screening programme. This information 
can be used to improve information provided to CRC screening invitees, and identify targets for 
increasing participation rates. 
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abstract 
We aimed to determine the interobserver variation in the histological diagnosis of colorectal 
polyps. 440 polyps were randomly selected from a colorectal cancer (CRC) screening program. 
Polyps were first evaluated by a general (324 polyps) or expert (116 polyps) pathologist, and 
subsequently re-evaluated by an expert pathologist. Conditional agreement was reported 
and interobserver agreement was determined by using Kappa statistics. In 421/440 polyps 
(96%) agreement for the non-adenomatous or adenomatous nature was obtained, cor-
responding with a very good kappa of 0.88. Differentiating adenomas in non-advanced and 
advanced obtained consensus in 266/322 adenomas (83%), with a moderate kappa of 0.58. 
For the non-adenomatous or adenomatous nature, both general and expert pathologists, and 
expert pathologists among each other, showed very good agreement (kappa-values (95%CI); 
0.89 (0.83-0.95) and 0.86 (0.73-0.98), respectively). Categorizing adenomas in non-advanced 
and advanced showed moderate agreement between general and expert pathologists, and 
between expert pathologists (kappa-values (95%CI); 0.56 (0.44-0.67) and 0.64 (0.43-0.85), 
respectively). General and expert pathologists demonstrate very good interobserver agree-
ment for differentiating non-adenomas and adenomas, but only moderate agreement for 
non-advanced and advanced adenomas. The considerable variation in the interpretation of 
advanced histology suggests that less subjective criteria are needed for risk stratification in 
screening and surveillance guidelines.
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introduction
Colorectal cancer (CRC) is the third most commonly diagnosed cancer and the second leading 
cause of cancer-related death in the Western world.1, 2 The detection and removal of adeno-
matous colorectal lesions reduces CRC incidence and mortality.3, 4 Advanced adenomas have a 
greater likelihood of malignant transformation and development of metachronous adenomas 
than non-advanced adenomas.5 Conversely, hyperplastic lesions carry minimal risk of adenoma 
occurrence.6, 7
Histopathological diagnosis of colorectal lesions plays a crucial role in patient management 
and surveillance after polypectomy. Postpolypectomy surveillance guidelines stratify patients 
in high and low risk according to their risk of an advanced neoplasia at subsequent colonoscopy. 
Current guidelines recommend surveillance colonoscopy 3 years after removal of an advanced 
adenoma or 3 or more adenomas, and 5 to 10 years after removal of 1 or 2 non-advanced 
adenomas.8 Histopathologic assessment is also vital in screening for CRC. Advanced adenomas 
are considered the surrogate biological marker for CRC risk and are the primary target of screen-
ing.9 As many countries have implemented or are considering nation-wide CRC screening10, 11, 
accurate pathologic assessment of colorectal lesions is of paramount importance with influ-
ence on intensity, burden, cost-efficacy, and potentially outcome of CRC screening.
Concern has been expressed about the reproducibility of the histological interpretation, 
between general and between expert gastrointestinal pathologists.12, 13  The aim of the present 
study was to evaluate inter-observer variation in histological diagnosis of colorectal polyps 
detected in a CRC screening program. Furthermore, inter-observer variation was assessed 
between general and expert gastrointestinal pathologists, and between expert gastrointestinal 
pathologists.
metHods
Study setting
As part of a Dutch population-based randomized screening trial (CORERO I trial) we randomly 
selected 440 polyps. The CORERO I study has been described in detail elsewhere 14. In brief, 
this randomized population-based trial compared uptake and diagnostic yield of guaiac based 
faecal occult blood test (g-FOBT), faecal immunochemical test (FIT) and sigmoidoscopy (FS) 
screening for CRC. Recruitment took place between November 2006 and November 2007. In 
total 15011 individuals aged 50-74 years old aged 50-74 were 1:1:1 randomized to be invited 
for gFOBT, FIT or FS screening. Participants with a positive gFOBT (Hemoccult II) or FIT (OC-
Hemodia Latex; ≥50 nanogram haemoglobin/ml) were referred for colonoscopy. Participants 
to FS screening were referred for colonoscopy when one of the following criteria was met: 
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presence of a polyp with a diameter ≥10 mm; an adenoma with villous histology (≥25% villous) 
or high-grade dysplasia; three or more adenomas; ≥20 hyperplastic polyps; or invasive CRC.
Sampling procedure and organization  
All polyps detected at sigmoidoscopy or colonoscopy, were removed. The interobserver evalu-
ation was conducted on 440 randomly selected polyps. For initial pathological evaluation, 324 
polyps were evaluated by a general pathologist (n=23), and 116 polyps were evaluated by 
an expert gastrointestinal pathologist (n=1). Subsequently, the 440 samples were blindly re-
evaluated by an expert gastrointestinal pathologists (n=2). 
criteria for PatHoLogic cLassification
The WHO classification was adopted to classify the selected polyps as non-adenomatous or 
adenomatous.15 Adenomatous lesions were further categorized according to histologic type, 
degree of dysplasia, and presence of infiltrating carcinoma. Tubular adenomas were defined as 
adenomas containing less than 25% of a villous component. Adenomas containing 25% - 75% 
and more than 75% of a villous structure were defined as tubulo-villous and villous adenoma, 
respectively. The degree of dysplasia was classified as low or high grade dysplasia. According to 
the revised Vienna criteria, patients with intramucosal carcinoma or carcinoma in situ were clas-
sified as having high-grade dysplasia.16 Advanced adenomas were defined as adenomas of at 
least 10mm, or as adenomas with villous histology (≥25%villous) or with high-grade dysplasia. 
CRC was defined as the invasion of malignant cells beyond the muscularis mucosa and was 
classified according to the TNM classification.17-19
Statistical analysis
Descriptive statistics were used to analyze and report the data. Conditional agreement was 
reported using percentages. Inter-observer agreement was determined by using Cohen κ 
statistics, which are widely used mathematical coefficients adjusting for agreement by chance 
alone. A value of 0 indicates no agreement better than what would be expected by chance 
alone. Values of < 0.21, 0.21–0.40, 0.41–0.60, 0.61–0.80 and >0.80 correspond to poor, fair, 
moderate, substantial and very good inter-observer agreement, respectively.20 The histologi-
cal diagnoses were categorized as non-adenomatous or adenomatous. Adenomatous lesions 
were further categorized as non-advanced or advanced based on histology only. For further 
categorization, the degree of dysplasia was classified as low or high grade dysplasia. Adenomas 
were categorized as tubular adenoma or adenoma with >25% villous component. In addition, 
inter-observer agreement between a general and expert pathologist, and between expert 
pathologists was assessed. Statistical analysis was performed using the SPSS 15.0 program 
(SPSS Inc. Chicago, IL). A two-sided p-value of ≤ 0.05 was considered statistically significant.
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resuLts
The interobserver agreement between pathologists in the histological diagnosis of colorectal 
polyps is summarized in Table 1. In 421 out of 440 polyps (96%) agreement for the non-adeno-
matous or adenomatous nature of polyps was obtained, corresponding with a very good kappa 
of 0.88 (95% CI; 0.83 - 0.94). More specifically, there was consensus for 99 non-adenomatous 
and 322 adenomatous polyps. Categorizing the 322 adenomatous lesions in non-advanced and 
advanced adenomas obtained consensus in 266 adenomas (83%), including 198 non-advanced 
adenomas and 68 advanced adenomas. Inter-observer agreement for classifying adenomas as 
non-advanced or advanced was moderate with a kappa of 0.58 (95% CI; 0.48 – 0.68).
Among the 322 adenomatous polyps, agreement for low or high grade dysplasia was obtained 
in 304 polyps (94%), corresponding with a kappa of 0.62 (95% CI; 0.46 – 0.79). There was con-
sensus for 287 low grade and 17 high grade dysplastic neoplastic lesions. Pathologists agreed 
that five high grade neoplastic lesions had intramucosal carcinoma or carcinoma in situ, but for 
two high grade dysplastic neoplasms there was no agreement in the classification; high grade 
adenoma vs. intramucosal carcinoma or high grade adenoma vs. carcinoma in situ. Pathologists 
did not find carcinoma invading the submocusa or beyond in any of the samples. Categorising 
the 315 adenomas (without intramucosal carcinoma or carcinoma in situ) as tubular adenoma 
or as adenoma with >25% villous component, obtained consensus in 259 polyps (85%). 
Pathologists agreed on 203 tubular adenomas and 56 adenomas with >25% villous histolology 
giving a kappa-value of 0.55 (95% CI; 0.44 – 0.66). Overall consensus for categorising polyps in 
non-adenoma or adenoma, histological type and grade of dysplasia was obtained in 336/440 
polyps (76%).
Agreement: general vs. expert pathologists, and between expert pathologists
Table 2 summarizes the inter-observer agreement between a general and an expert patholo-
gist on the one hand, and between two expert pathologists on the other hand. Both groups 
showed very good interobserver agreement in categorizing polyps as non-adenomatous or 
adenomatous. The general and expert pathologist agreed on 310/324 polyps (96%), including 
80 non-adenomatous and 230 adenomatous polyps. This corresponded with a kappa of 0.89 
(95% CI; 0.83 - 0.95). The two expert pathologists agreed on 111/116 polyps (96%). There was 
table 1: Inter-observer agreement between pathologists.
n Agreement, n (%) K-values (95% CI)
Non-adenomatous / Adenomatous polyps 440 421 (96%) 0.88 (0.83 - 0.94)
Non-advanced / Advanced adenoma 322 266 (83%) 0.58 (0.48 – 0.68)
Low grade / High grade dysplasia* 322 304 (94%) 0.62 (0.46 – 0.79)
Tubular / Tubulo-villous and villous adenoma 315 259 (82%) 0.55 (0.44 – 0.66)
* including carcinoma in situ and intramucosal carcinoma.
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consensus for 19 non-adenomatous and 92 adenomatous polyps, corresponding with a kappa-
value of 0.86 (95% CI; 0.73 – 0.98).
Categorizing adenomas in non-advanced and advanced adenomas showed moderate 
agreement between general and expert pathologists, and between expert pathologists. The 
general and expert pathologist agreed on 184/230 adenomas (80%), including 128 non-
advanced adenomas and 56 advanced adenomas. The kappa for differentiating non-advanced 
and advanced adenomas was 0.56 (95% CI; 0.44 - 0.67). The expert pathologists agreed on 
82/92 adenomas (89%). There was consensus for 70 non-advanced adenomas and 12 advanced 
adenomas, corresponding with kappa 0.64 (95% CI; 0.43 – 0.85).
discussion
This study reported the inter-observer variation in the histological diagnosis of colorectal pol-
yps detected in a CRC screening program. Our data demonstrated that pathologists had very 
good inter-observer agreement in categorizing polyps as non-adenomatous or adenomatous 
(kappa-value 0.88). This level of concordance was better than observed by Yoon et al 13, but 
consistent with other studies.12, 21-24 In addition our results showed that inter-observer agree-
ment was only moderate for differentiating between non-advanced and advanced adenomas 
(kappa-value 0.58). More specific, pathologists had moderate agreement for the interpretation 
of grade of dysplasia and villous histology. In line with our results, several studies also found a 
poor to moderate agreement for the classification of grade of dysplasia and villous histology. 
These studies however did not specifically investigate agreement after stratifying adenomas as 
non-advanced and advanced.12, 13, 21-26 
Furthermore, our results showed that the inter-observer variability in the classification of 
colorectal polyps was comparable between general and expert pathologists one the one hand, 
and between expert pathologists on the other hand. This is in agreement with previous stud-
ies.12, 13, 21-26 In addition, in other fields of pathology it was also found that expert pathologists 
are just as likely to disagree as general pathologists.27-29
Our data confirm that the assessment of advanced histology is subjective.12, 13, 21-26 This has 
clinical impact in adenoma less than 10 mm, as adenoma of at least 10 mm are already clas-
sified as advanced adenoma. A recent systematic review in a screening population detected 
advanced adenomas in 5.6% of subjects, adenomas less than 10 mm represented 12.5% of 
advanced adenomas.30
table 2: Inter-observer agreement between general (GP) and expert pathologists (EP), and between 
expert pathologists (EP`s). 
GP and EP
K-values (95% CI)
EP and EP
K-values (95% CI)
Combined
K-values (95% CI)
Non-adenomatous / Adenomatous 0.89 (0.83 - 0.95) 0.86 (0.73 - 0.98) 0.88 (0.83 - 0.94)
Non-advanced / Advanced adenoma 0.56 (0.44 - 0.67) 0.64 (0.43 - 0.85) 0.58 (0.48 - 0.68)
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The subjective advanced histologic criteria, more specific villous histology and grade of dyspla-
sia, are of influence on patient management and postpolypectomy colonoscopy surveillance 8. 
Misclassification of patients as low risk may postpone colonoscopy surveillance with the risk of 
missing preventable cancer. Misclassification of patients as high risk may impose further burden 
on the limited endoscopic resources.31-36 Postpolypectomy surveillance is the most common 
reason for performing colonoscopy. Approximately 22% of all colonoscopies are performed for 
surveillance.37 It has been suggested that the current postpolypectomy surveillance guidelines 
have limited predictability for advanced adenoma recurrence.38 A risk profile based on cumula-
tive findings from multiple previous colonoscopies might better stratify patients in high and 
low risk than the adenoma findings from the most recent examination.39 In addition, recent 
evidence indicates that other factors besides the histological diagnosis, are stronger associated 
with the development of metachronous advanced adenomas. A pooled multivariate analysis of 
postpolypectomy patients showed that after four years of follow-up, the risk of metachronous 
advanced colorectal neoplasia was strongly associated with the number, size, and location 
of prior adenomas, as well as patient age. In the multivariate analysis, the presence of villous 
histology was only modestly associated, and the grade of dysplasia was not associated with 
metachronous advanced neoplasia.40 In addition, the level of inter-observer variability needs to 
be considered in the context of the outcome of current studies and colorectal cancer screening 
programs. Colorectal cancer screening programs rely on advanced adenoma as intermediate 
endpoint.  
In conclusion, this study demonstrated that pathologists have a very good inter-observer 
agreement for differentiating between non-adenomatous and adenomatous polyps, while 
the agreement is only moderate for non-advanced and advanced adenomas. Agreement is 
comparable between general and expert pathologists on the one hand, and between expert 
pathologists on the other hand. These results show that it is important to modify the criteria for 
advanced neoplasia or to use other objective and quantitative criteria for the risk prediction, 
surveillance recommendations, outcome of studies and colorectal cancer screening programs.
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abstract
Screening with a guaiac faecal occult blood test (gFOBT) has been shown to reduce the mortal-
ity from colorectal cancer by 15-33% while being cost-effective. Immunochemical FOBT has 
been introduced more recently. Two recent Dutch randomised trials (n=30,000) compared 
gFOBT with quantitative faecal immunochemical testing (FIT) and found a higher attendance 
and detection rate for FIT (OC-Sensor micro, Eiken, Japan). We aimed to compare the cost-
effectiveness of both tests and to identify the most cost-effective FIT cut-off level for referral 
to colonoscopy. We used the validated MISCAN-Colon micro-simulation model to estimate 
costs and effects of different screening strategies comparing gFOBT with FIT at cut-off levels of 
50, 75, 100, 150 and 200 ng haemoglobin/ml. Screening strategies varied with respect to age 
range and screening interval. FIT resulted in lower costs and more (quality adjusted) life-years 
gained than gFOBT. FIT screening was most cost-effective if the 50 ng/ml cut-off level was used. 
Biennial screening between ages 55 and 75 using FIT at 50 ng/ml resulted in an incremental 
cost-effectiveness ratio of 3900 euro per life-year gained. Widening the age range to ages 50 
and 80 was more cost-effective than shortening the screening interval to one year (5800 versus 
14900 euro per life-year gained). In the sensitivity analyses, 50 ng/ml remained the most cost-
effective FIT cut-off level. FIT screening is more cost-effective than gFOBT screening. For FIT, 
a low cut-off level of 50 ng/ml is preferred to higher cut-off levels, including the 100 ng/ml 
recommended by the manufacturer.
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introduction
Randomised controlled trials have shown that screening for colorectal cancer (CRC) with fae-
cal occult blood tests (FOBT) reduces CRC mortality with 15-33% in the general population.1-3 
These trials have been performed with the Hemoccult II test, a guaiac-based FOBT (gFOBT). 
Faecal immunochemical tests (FIT) have become available more recently. Most of the (Euro-
pean) countries with a national screening programme use gFOBT.4 Several countries consider 
changing to FIT, now that evidence accumulates that FIT is superior to gFOBT both with respect 
to attendance rate and diagnostic yield.5-7
Screening with gFOBT has been shown to be cost-effective.8 The additional costs of substi-
tuting gFOBT with FIT in a biennial screening program in France have been estimated at 3000 
euro per life-year gained.9 A cost-effectiveness analysis based on data directly comparing both 
tests is lacking. Such data have recently become available in the Netherlands, where imple-
mentation trials have been performed to compare the attendance, positivity and detection 
rates and costs of gFOBT and FIT. In these trials individuals aged 50-74 were randomised to 
a gFOBT (Hemoccult II, Biopharma, Weesp, the Netherlands) or a quantitative FIT (OC-Sensor 
micro, Eiken, Tokyo, Japan).6, 7 Because the FIT is a quantitative test, it is possible to choose the 
cut-off level for referral to colonoscopy. The recommended cut-off level (by the manufacturer) 
is 100 ng heamoglobin/ml. In both trials the FIT cut-off level used for colonoscopy referral was 
set at 50 ng/ml, so that analyses of test characteristics could be performed for levels of 50 ng/
ml and above. We used the trial results in a cost-effectiveness analysis to compare gFOBT and 
FIT at different cut-off levels, varying the screen interval and the age range.
metHods 
MISCAN-Colon
The MISCAN-Colon micro-simulation model and the data sources that inform the quantifica-
tion of the model are described in detail in the Appendix, in previous publications 10, 11 and 
in a standardized model profile.12 In brief, the model simulates the relevant biographies of a 
large population of individuals from birth to death, first without screening and subsequently 
with the changes that would occur under the implementation of a screening program. In 
every individual one or more adenomas may arise and some of them may develop into cancer. 
Adenomas can progress from small (1-5 mm) to medium (6-9 mm) to large (10+ mm). The 
majority of adenomas is assumed to be non-progressive and will never develop into cancer. 
The progressive adenomas have the ability to become cancer but not all of them will make 
it to cancer due to competing death of other causes than CRC. The adenomas that become 
malignant transform into stage I cancers and may successively progress to stage II, III and IV 
until they are diagnosed in one of these stages. After diagnosis, the individual will die or not 
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from CRC, depending on the stage specific survival, and again, the competing death from other 
causes (first death counts). This completes the life history without screening. The same life his-
tory is simulated in the situation with screening. An individual with an adenoma or cancer has a 
chance of having it detected during a screening round depending on the sensitivity of that test 
for that lesion. After a person is detected with adenomas or CRC, he is referred for colonoscopy 
for removal of adenomas and diagnosis of cancers. In this way, CRC incidence or CRC death 
can be prevented. The life-years gained by screening are calculated by comparing the model 
predicted life-years lived in all the individuals with and without screening. 
The model simulated the Dutch population in 2005 (Statistics Netherlands, www.cbs.nl), with 
cancer incidence based on Dutch data from 1999-2003 (Comprehensive Cancer Centre (CCC), 
www.ikcnet.nl). Survival after clinical diagnosis of a cancer was based on relative survival data 
from 1985-2004 from the South of the Netherlands (CCC), since national data were not avail-
able. The survival for individuals aged 75 or older was adjusted to fit the observed increasing 
mortality/incidence ratio (CCC).
The validity of the model has been tested on the results of large screening and surveillance 
studies, such as the randomised FOBT trials in Minnesota, Funen and Nottingham 13, the CoCap 
sigmoidoscopy study 10, and the National Polyp Study.14 Finally, the model was able to explain 
observed incidence and mortality trends in the US when accounting for risk factor trends, 
screening practice and chemotherapy treatment.15
Test characteristics
We assumed that the sensitivity of gFOBT for CRC was dependent on the time until a cancer 
becomes clinically diagnosed based on an earlier analysis using the MISCAN-Colon model 
calibrating on three FOBT-trials.13  Other test characteristics were chosen to meet the positivity 
and detection rates as observed in the Dutch trials 5-7, 16 (Tables 1 and 2), while assuming that 
the sensitivity of FIT for CRC is also dependent on the time until diagnosis. 
Screening Strategies
We simulated screening in the Dutch population over a period of 30 years starting in 2005 for 
in total 48 combinations varying by:
Age to start screening:  45, 50, 55, 60
Age to stop screening:  70, 75, 80
Screen interval:   1, 1.5, 2 and 3 years
After a positive FOBT a diagnostic colonoscopy was offered. If no adenomas were found at 
colonoscopy, an individual was offered a next FOBT after 10 years. If one or more adenomas 
were found at colonoscopy, the adenomas were removed and the individual entered surveil-
lance according to the Dutch guidelines 17: A next colonoscopy was offered after 6 years in case 
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of 1 or 2 adenomas and after 3 years in case 3 or more adenomas were found. We assumed that 
surveillance stopped at the age of 80, the oldest stop age for screening. 
Attendance
We simulated the strategies assuming both 100% attendance (for gFOBT, FIT, diagnostic 
and surveillance colonoscopies) and observed attendance (gFOBT 50%, FIT 60%, diagnostic 
colonoscopies 85%).6, 7 Attendance to surveillance colonoscopies was assumed 80% in the 
observed attendance scenario.18 Based on gFOBT trial observations, we assumed that 10% 
of the individuals never attended FOBT screening 19 and had a higher risk for CRC than the 
general population (RR=1.15).1 The remainder attended at least one round. Of the individuals 
that attended in a certain screening round, 80% attended again in the subsequent screening 
round.20 
Costs 
We included screening and treatment costs (Table 3). Organisational costs for FOBT screening 
were based on current expenses in the Dutch cervical screen program, adjusted for differences 
table 1: Model assumptions: test characteristics of gFOBT and FIT at cut-off levels 50, 75, 100, 150 and 200 
ng/ml.
Test Specificity
(per person, %)
Sensitivity* (per lesion, %)
Adenoma ≤ 
5 mm
Adenoma 
6-9 mm
Adenoma ≥ 
10 mm
CRC long 
before 
clinical
CRC short 
before 
clinical
gFOBT 98.9 0 1.3 6.5 18.2 50.8
FIT 200 98.7 0 2.0 10.6 46.0 80.0
FIT 150 98.3 0 2.3 12.2 47.0 81.0
FIT 100 97.8 0 4.0 13.0 51.0 83.0
FIT 75 97.0 0 4.1 15.2 56.0 85.5
FIT 50 95.8 0 8.4 16.7 61.0 88.0
*Excluding the probability that an adenoma or cancer is found due to the lack of specificity.
table 2: Modelled (observed) positivity rates and detection rates per 100 screened individuals (highest 
grade finding per individual) for gFOBT an FIT at cut-off levels 50, 75, 100, 150 and 200 ng/ml.
Test  Positivity rate No Findings Non advanced 
adenomas
Advanced 
adenomas*
CRC
gFOBT 2.5 (2.5) 98.5 (98.5) 0.35 (0.33) 0.98 (0.97) 0.20 (0.24)
FIT 200 3.7 (3.7) 97.6 (97.6) 0.48 (0.48) 1.54 (1.54) 0.39 (0.39)
FIT 150 4.4 (4.4) 97.2 (97.2) 0.59 (0.58) 1.78 (1.82) 0.40 (0.40)
FIT 100 5.3 (5.3) 96.8 (96.8) 0.83 (0.80) 1.98 (2.01) 0.42 (0.42)
FIT 75 6.4 (6.4) 96.3 (96.3) 0.99 (1.02) 2.30 (2.27) 0.45 (0.45)
FIT 50 8.4 (8.4) 95.2 (95.3) 1.57 (1.54) 2.73 (2.71) 0.48 (0.48)
*Advanced adenoma was defined as adenoma ≥ 10 mm or with a histology showing either a ≥ 25% 
villous component or high-grade dysplasia in the trials. In the model, adenomas are classified by size only 
and advanced adenomas were all assumed ≥ 10 mm.
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table 3: Model assumptions of the baseline and sensitivity analyses.
Variable Baseline analysis Sensitivity analyses
Quality of life loss
Colonoscopy - 1 day per 
colonoscopy
CRC treatment* 
(1-utility per year in 
treatment)
- Initial treatment 31: 
Stage I:   0.26 
Stage II:  0.3
Stage III: 0.4
Stage IV: 0.75
Continuous care 32: 0.15
Terminal care death by CRC: 0.75
Terminal care death by other cause: 
0.35
Correlation FOBT results - 74% of the large adenomas (>9 
mm) that are not detected, will not 
be detected in a next screening 
round 24
Low value High value
Fatal complications 
after colonoscopy
1 per 10,000 colonoscopies No fatal 
complications
1 per 1,000 
colonoscopies 
with polypectomy, 
1 per 10,000 
colonosocpies 
without 
FOBT costs
gFOBT FIT
Costs per invitation 
(organisational 
costs and test kit)
€14.05 €14.85 50% 200%
Costs per attendee 
(personnel and 
material costs for 
analysis)
€1.90 €4.37
Low value High value
Colonoscopy costs
Without 
polypectomy
€303 50% 200%
With polypectomy €393
Costs complications 
after colonoscopy **
€1250 50% 200%
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with FOBT screening. Costs for the test kits were based on prices of the manufacturer. Costs for 
analysis of the tests consisted of costs for material and personnel needed during the process of 
registration, analysis and authorisation of returned tests. Colonoscopy costs were based on an 
internal study at the Erasmus MC after a six months continuous monitoring (data not shown). 
Additional costs for polypectomy were based on additional time and polypectomy materials 
needed for the procedure and costs for pathology. Costs for complications after colonoscopy 
were based on DBC-rates (Diagnose Treatment Combination), derived from the Dutch Health 
Care Authority (http://ctg.bit-ic.nl/Nzatarieven/top.do). 
Costs of CRC treatment were divided into three clinically relevant phases of care: initial 
treatment, continuous care and terminal treatment. Initial treatment costs were based on 
DBC-rates, except for Oxaliplatin. The costs for Oxaliplatin were derived from the Dutch Health 
Care Insurance Board (www.medicijnkosten.nl). We assumed that during the continuous care 
phase, individuals followed the Dutch guidelines (www.oncoline.nl) and costs for periodic 
control were based on DBC-rates. Terminal treatment costs for patients that ultimately died of 
CRC were based on a last year of life analysis and were estimated at  €19700.21 We assumed that 
these costs increase with stage, as observed for US patients.22, 23 Dutch terminal care costs for 
individuals that die of CRC were approximately 40% of the US costs. We assumed that terminal 
care costs of CRC patients that did not die from the disease were also 40% of the US costs. 
Variable Baseline analysis Sensitivity analyses
Treatment costs *
Initial 
treatment
Continuous 
care
Terminal 
care 
death 
CRC
Terminal 
care 
death 
other 
cause
Stage I €12500 €340 €17500 €4400 50% 200%
Stage II €17000 €340 €17500 €4000
Stage III €21000 €340 €18500 €5200
Stage IV €25000 €340 €25000 €14000
** Assumed complication rate is 2.4 per 1000 colonoscopies, 0.1 per 1000 colonoscopies is assumed fatal
*CRC treatment was divided into three clinically relevant phases – initial, continuous and terminal care. 
The initial phase was defined as the first 12 months following diagnosis, the terminal phase was defined 
as the final 12 months of life, and the continuous phase was defined as all months between the initial and 
last year of life phases.  For patients surviving less than 24 months after diagnosis, the final 12 months of 
observation and costs of care were then allocated first to the last year of life phase, because the content of 
care for patients with short survival is more similar to the last year of life phase than the initial phase. The 
remainder of months of observation and costs were allocated to the initial phase, with no contribution to 
the continuing phase
table 3 continued
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Cost-effectiveness analysis
We used MISCAN-Colon to estimate costs and number of life-years gained for all strategies 
with both FOBTs compared to the situation without screening. Costs and life-years gained 
were discounted by 3%. Strategies that were more costly and less effective than one or more 
other strategies were ruled out by simple dominance. Strategies that were more costly and less 
effective than a mix of other strategies were ruled out by extended dominance. The remaining 
strategies are known as efficient. The incremental cost-effectiveness ratio (ICER) of an efficient 
strategy was determined compared to the next less expensive option. On a plot of costs vs. 
life-years gained, the line that connects the efficient strategies is called the efficient frontier, 
and all dominated strategies lie below this line.
Sensitivity analysis
We performed 12 sensitivity analyses on 7 parameters (Table 3). We adjusted for reduced qual-
ity of life due to screening as well as CRC treatment. Correlated FOBT results were assumed 
because lesions that did not bleed in the first round may have a higher than average prob-
ability of not bleeding in a next screening round too. We used the results of a population based 
screening program in Italy to estimate the correlation between false negative FIT results for 
cancers and advanced adenomas in subsequent screening rounds.24 Low and high values were 
evaluated for fatal complications as well as costs.
resuLts
Cost-effectiveness analysis
At all cost levels, FIT with the recommended cut-off level of 100 ng/ml (FIT 100) resulted in more 
life-years gained than gFOBT (Figure 1). When comparing different FIT cut-off levels (Figure 2), 
FIT 50 resulted in even more life-years gained at the same or lower costs. Consequently, the 
efficient frontier consisted of FIT 50 strategies only. The higher the cut-off level used, the further 
the strategies lied below the efficient frontier.
The costs and life-years gained of the efficient strategies are given in Table 4 under the assump-
tion of 100% attendance. Widening the age range or shortening the screening interval resulted 
in more life-years gained, but increased the costs as well. Biennial screening between ages 55 
and 75 resulted in 95 life-years gained per 1000 individuals compared to no screening, at a 
cost of 201,000 euro. The incremental costs per life-year gained compared to the next least 
expensive efficient strategy (screening every 3 years between ages 55 and 73) of this strategy 
was 3,900 euro. Increasing the screening frequency to annual screening (between ages 55 and 
75) was as expensive as widening the age range to 50 and 80 (with biennial screening), but 
resulted in less health benefits (110 compared to 114 life-years gained per 1000 individuals). 
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In other words, it was more cost-effective to intensify the screening program by widening the 
age range than by shortening the screening interval to one year. Only when a wide age range 
is already used, it becomes cost-effective to switch to annual screening.
Chapter 9: 
Fig 1 
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fig 1: Costs and life-years gained (3% discount) per 1000 individuals aged 45-80 years in 2005 of 
strategies varying by age to begin screening, age to end screening and screen interval for gFOBT and FIT 
100, with 100% attendance.
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fig 2: Costs and life-years gained (3% discount) per 1000 individuals aged 45-80 years in 2005 of 
strategies varying by age to begin screening, age to end screening and screen interval for FIT 50-100, with 
100% attendance. The efficient strategies are connected by the efficient frontier, and are given in Table 4.
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Effect of attendance rate
When accounting for observed attendance rates (50% for gFOBT, 60% for FIT and 80% for diag-
nostic colonoscopy), FIT 50 remained more cost-effective than gFOBT or FIT at higher cut-off 
levels. Costs and life-years gained decreased due to the non-attendees, while the incremental 
cost-effectiveness remained similar (Table 5). Based on the attendance rates observed in the tri-
als, the expected costs and effects of biennial screening between ages 55 and 75 were 180000 
euro and 68 life-years gained per 1000 individuals compared to no screening. Compared to 
the situation with full attendance, shorter intervals between the screening rounds became 
efficient when we accounted for observed attendance rates. The shorter screening intervals 
compensated the screening intervals of individuals that attended some but not every screen-
ing round. For example, annual screening between ages 50 and 80 was efficient now with an 
table 4: Efficient screening strategies in case of 100% attendance. All strategies use FIT with cut-off 
level 50 ng/ml. Costs and life-years gained per 1000 individuals aged 45-80 years in 2005 and the ICER 
compared to the next least expensive efficient strategy (3% discount). 
begin - end age / interval / # screens Costs Life-years gained ICER
60-69    / 3    /   4* 91000 57 1600
55-70    / 3    /   6 131000 75 2200
55-73    / 3    /   7* 149000 82 2800
55-75    / 2    / 11* 201000 95 3900
55-74.5 / 1.5 / 14* 237000 103 4300
55-79    / 1.5 / 17* 273000 110 5300
50-80    / 2    / 16 293000 114 5800
50-80    / 1.5 / 21 344000 119 8900
45-79.5 / 1.5 / 24 397000 125 9400
45-80    / 1    / 36* 515000 133 14900
*This strategy is both efficient for 100% and for realistic attendance
table 5: Efficient screening strategies in case of observed attendance**. All strategies use FIT with cut-
off level 50 ng/ml. Costs and life-years gained per 1000 individuals aged 45-80 years in 2005 and ICER 
compared to the next least expensive efficient strategy (3% discount).
begin - end age / interval / # screens Costs Life-years gained ICER
60-69    / 3    /   4* 76000 35 2100
60-70    / 2    /   6 106000 47 2600
55-73    / 3    /   7* 127000 53 3400
55-69    / 2    /   8 138000 56 3400
55-75    / 2    / 11* 180000 68 3600
55-74.5 / 1.5 / 14* 215000 77 4100
55-79    / 1.5 / 17* 252000 84 4900
55-80    / 1    / 26 337000 95 7700
50-80    / 1    / 31 415000 104 8400
45-80    / 1    /36* 493000 109 16100
*This strategy is both efficient for 100% and for realistic attendance 
**Realistic attendance rates: 60% for FIT, 85% for diagnostic colonoscopy and 80% for surveillance 
colonoscopy
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ICER of 8400 euro per life-year gained, while biennial screening between ages 50 and 80 was 
not efficient anymore. 
Sensitivity analyses
The optimal cut-off level of 50 ng/ml for FIT was very robust for alternative model assumptions. 
Only if colonoscopy costs doubled, higher cut-off levels became efficient next to the 50 ng/ml 
cut-off. Biennial screening starting at age 50 or 55 and stopping at age 75 or 80 was an efficient 
strategy in 9 of the 12 analyses. Considering all sensitivity analyses for which biennial screening 
from 50/55 to 75/80 was efficient, the ICER was 10800 euro per life-year saved at most (in case 
of doubled cost for colonoscopy). The highest ICER value for annual screening between ages 45 
and 80 was 26600 euro per life-year gained, again when costs for colonoscopy were doubled. 
discussion
Our study shows that FIT screening with OC-Sensor micro is more cost-effective than gFOBT 
screening with Hemoccult II. Within the range analysed (50-200 ng/ml), the optimal cut-off 
level was 50 ng/ml. This outcome appeared very robust in the sensitivity analyses. A 50 ng/ml 
cut-off value is lower than the 100 ng/ml that is recommended by the manufacturer.  
The number of strategies included in this analysis was limited in two ways. First of all, we did 
not analyse the cost-effectiveness of cut-off levels below 50 ng/ml. Observations from a cut-off 
below 50 ng/ml were not available because individuals with a FIT result below 50 ng/ml were 
not referred to colonoscopy in the trials we used. This was based on the fact that 50 ng/ml is the 
lower limit of test reliability. Lowering the cut-off level by definition increases the proportion 
of individuals referred to colonoscopy. In the hypothetical situation of screening with a cut-off 
of 0 ng/ml, all individuals would be invited for a colonoscopy, getting a repeat colonoscopy 
after 10 years if nothing was found. Therefore, the favourable result for low cut-off levels could 
be a result of the favourable cost-effectiveness of 10-yearly screening in our model. However, 
a 10-yearly colonoscopy strategy was not a cost-effective alternative compared to FIT 50 in our 
simulations. We also limited the number of screenings in our analysis. Even though the ICERs of 
the screening strategies included were well below 20000 euro per life-year gained, we did not 
include more intensive screening strategies (wider age ranges or shorter screening intervals), 
as they strongly increase the need for colonoscopy and colonoscopy capacity is limited in the 
Netherlands.25 In those situations where colonoscopy capacity is unlimited, more intensive 
screening strategies than included in this analysis could be considered. 
Other investigators came to similar results and conclusions with regard to the optimal cut-
off level of FIT. In Italy, the recommendation was not to increase the cut-off level above 100 
ng/ml, while lower cut-off levels were not analysed.26 In a study in Taiwan, individuals with a 
test result below 100 ng/ml were followed up for two years, and sensitivity was estimated for 
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various cut-off levels based on interval cancers.27 The authors concluded that 110 ng/ml was 
the optimal cut-off level. However, the estimated costs were lowest at a cut-off value of 40 
ng/ml, while the estimated number of life-years gained decreased from 40 ng/ml to higher 
cut-off levels (see Figure 4a in the study by Chen 27). The 40 ng/ml cut-off was therefore to be 
preferred to higher cut-off values, which is close to our finding. Some studies came to different 
conclusions due to the use of different optimisation criteria. In a Japanese study, workers were 
offered colonoscopy above a cut-off level of 50 ng/ml.28 The authors recommend a cut-off level 
of 200 ng/ml based on levelling off of the ROC-curve and minimal costs per CRC case detected 
in one screening round. In that analysis, only screening costs and no savings of treatment costs 
were taken into account. Including potential savings resulting from prevented cancers would 
lead to a lower optimal cut-off level. Other studies based on the same data we used recom-
mended a cut-off level of 75 ng/ml.6, 16 In these studies, burden from and a limited capacity 
of colonoscopy were reasons to use the criteria that no more than two individuals need to 
undergo colonoscopy to detect one individual with advanced neoplasia. 
The optimal cut-off level for FIT remained 50 ng/ml when taking observed attendance rates 
into account (50 % for gFOBT, 60% for FIT, 85% for colonoscopy after a positive FOBT). In this 
scenario, some of the individuals do not attend all screening rounds. As a consequence, shorter 
intervals between screening rounds become somewhat more cost-effective to compensate for 
the fact that some individuals skip a round every now and then. The shorter intervals are not 
necessarily optimal for individuals that do attend to every screening round.  For that reason we 
considered 100% attendance, identifying the strategies that are optimal for individuals that 
follow the recommendations. This is justified because the cost-effectiveness level appeared to 
be very similar in both scenarios. 
gFOBT is currently used in several European screening programs because of its potential 
to substantially reduce mortality from CRC 1-3 and its acceptable cost-effectiveness.8 However, 
the sensitivity of FIT is higher than the sensitivity of gFOBT, in some studies even with a better 
or equal specificity.29, 30 This was confirmed by the combined results from the Dutch trials 6, 7, 
16, in which FIT 250 produced the same false positivity rate (no advanced neoplasia detected 
during follow-up colonoscopy) as gFOBT, while FIT 250 detected almost twice as many cases 
with advanced neoplasia. Regarding the unit costs, although the actual test material is more 
expensive for FIT than for gFOBT, personnel costs of FIT are reduced by the ease of automated 
handling of large volumes of FIT tests, whereas gFOBT cards have to be handled and read 
separately by hand. When these effects were measured in the Dutch trials, total costs for both 
tests appeared not to differ as much as often assumed in cost-effectiveness analyses. Given the 
better test performance and the limited difference in costs, it is not surprising that the effec-
tiveness and cost-effectiveness of FIT screening are even better than the (cost)-effectiveness 
of gFOBT screening. The higher attendance to FIT screening further increases the additional 
effectiveness of FIT compared to gFOBT. Based on our results, changing from gFOBT to FIT 50 
in a biennial screening program for individuals aged between 55 and 75 would increase the 
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number of life-years gained by screening with 130%, at an incremental cost of 1000 euro per 
life-year gained. Even when changing to the suboptimal FIT 100 would double the number of 
life-years gained compared to gFOBT screening, at an incremental cost of only 1300 euro per 
life-year gained.
In conclusion, this analysis strongly supports the use of FIT for future population-based CRC 
screening programs based on faecal occult blood testing, and to do so with a relatively low 
cut-off value for colonoscopy referral.
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faecaL occuLt bLood testing
Main findings
The guaiac-based faecal occult blood test (gFOBT) is the most commonly used stool blood test 
for CRC screening and the only CRC screening test for which there is evidence of CRC-related 
mortality reduction from prospective randomised controlled trials (RCT).1-4 Guaiac-based FOBT 
is lacking specificity as it cannot differentiate between human blood and animal blood derived 
from the diet. The introduction of the faecal immunochemical test (FIT) has considerably 
improved the detection of human occult blood in faeces by using an antibody (immunoglobu-
lin) specific to human (haemo)globin. FIT can detect blood at lower concentrations than gFOBT, 
and is significantly more specific as FIT is not subject to interference from dietary blood and 
upper gastrointestinal blood loss.5 Furthermore, FIT samples can be analysed automatically 
which has important advantages for reproducibility, quality control, capacity, and costs.6, 7
We demonstrated a 12% higher participation rate to FIT (62%) than gFOBT (50%) screen-
ing. A previous study suggested that dietary restrictions required for gFOBT screening were 
responsible for a lower uptake.8 In this thesis we show that gFOBT screening performed with-
out dietary restrictions still resulted in a lower uptake than FIT screening (chapter 2). The less 
demanding sampling method for FIT (swab vs. the conventional card used for gFOBT) and the 
sampling from a single instead of multiple consecutive bowel movements seem likely explana-
tions for this difference in participation rate.9 
Limited data on experienced test burden of gFOBT and FIT screening are available.10-12 To 
determine the actual experienced burden of both FOBTs, we administered a questionnaire to 
a random sample of participants to gFOBT and FIT screening (chapter 5). Significantly less FIT 
than gFOBT screenees experienced discomfort during faecal collection and test performance. 
Again, the sampling method and the number of faecal samples required may explain this dif-
ference in discomfort.9  
Several studies demonstrated more favourable test characteristics of FIT compared to gFOBT 
screening.13-17 In a randomised trial we demonstrated that the FIT (OC-Sensor micro) with a 
cut-off value of 100ng/ml detected significantly more advanced neoplasia than the gFOBT 
(Hemoccult II), whereas the number of false negatives was similar for both tests (chapter 2). 
We used a quantitative FIT, which allows determination of an optimal cut-off level for a nation-
wide screening programme based on colonoscopy capacity and the intended detection rate in 
the screened population. We therefore determined the optimal cut-off value in a second study 
described in chapter 3. A cut-off value of 75ng haemoglobin/ml provided an adequate posi-
tivity rate and an acceptable trade-off between detection rate and number needed to scope 
(NNscope) to find one screenee with an advanced neoplasia. One could argue to use a higher 
cut-off value for women as the detection rate and NNscope was less favourable in women than 
in men given the lower prevalence of advanced neoplasia in women. 
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In Europe, screening programmes are mostly covered by local or national governments. 
Therefore, the actual decision about the implementation of a CRC screening programme should 
preferably also be based on its cost-effectiveness. Biennial gFOBT screening has demonstrated 
to be cost-effective.18, 19 Previously, a French study estimated the additional costs of using 
biennial FIT in stead of a biennial gFOBT  at 3000 euro per life-year gained.20 We performed the 
first cost-effectiveness analysis comparing gFOBT and FIT based on randomised data (chapter 
9). For this study we used the MISCAN-Colon micro-simulation model to estimate costs and 
effects of different screening strategies comparing gFOBT (hemoccult II) with one sample FIT 
(OC-Sensor micro) at cut-off levels of 50, 75, 100, 150 and 200ng Hb/ml. Screening strategies 
in the model varied with respect to age range and screening interval. The costs per invitation 
were similar for both tests, as the FIT we used can be analysed automatically which reduces 
personnel need and thus lowers the costs per test. FIT screening was estimated to be more 
cost-effective than gFOBT screening based on the better performance and similar costs. The 
optimal cut-off level was 50ng/ml. Biennial FIT (cut-off 50ng/ml) screening between ages 55 
and 75 resulted in an incremental cost-effectiveness ratio of 3900 euro per life-year gained. 
Extending the programme by a wider age range (50-80 years) was more cost-effective than 
shortening the screening interval (annual). However, randomised trials on the optimal screen-
ing interval are not available, and for the model we therefore made assumptions based on 
gFOBT trial observations.
Conclusions and further research 
Several countries have a nation-wide screening programme mainly based on gFOBT, since this 
is the only available test with a proven mortality reduction.1-4 Although prospective RCTs on FIT 
screening are lacking, we conclude based on this thesis that FIT should be preferred over gFOBT 
screening. FIT has superior participation and detection rates, lower test burden, and higher 
cost-efficacy. The results are based on Dutch data, but will also be applicable to other countries 
in the Western World. A biennial screening programme was estimated to be most cost-effective. 
However, evidence from randomised studies investigating the optimal time interval for detect-
ing advanced colorectal neoplasia in a screening programme by FIT are eagerly awaited.
Our results are based on the one sample FIT. Further investigation on the optimal number 
of samples per round is required. Recently, a French study reported a similar performance on 
the relative ROC curves (in reference to G-FOBT) of a one sample FIT and a two-sample FIT with 
a referral for TC if at least one sample was positive. The most gain in sensitivity and specificity 
was obtained with a two-sample FIT when the mean of measured Hb levels was used for TC 
referral.21 This finding needs to be further explored in cost-effectiveness analyses.
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fLexibLe sigmoidoscoPy
Main findings
Sigmoidoscopy has shown to be a feasible screening tool.22-25 The main drawback for introduc-
ing a nation-wide FS screening programme is the low participation rate. In agreement with data 
from other countries 22, 25-28, we demonstrated that 32% of eligible average risk subjects was 
willing to undergo a FS (chapter 2). However, a Norwegian study reported significantly higher 
uptake levels (65%). Research has consistently shown that expected pain or discomfort is one of 
the most important reasons for declining the endoscopic screening offer.29, 30 An Italian study 
demonstrated that 23% of non-participants of a FS screening programme reported anticipated 
pain, discomfort, or injury as the main reason for refusing FS screening.31 Those barriers may be 
overcome by offering non-participants an alternative screening test, for example FIT. We there-
fore invited non-participants of our FS screening programme for FIT screening. In total 25% of 
non-participants to FS screening was willing to undergo a non-invasive and less burdensome 
FIT test. Our results validate the finding of Senore et al. in a true experimental setting (chapter 
4).31 Thus, the FS itself seems to be a strong barrier for participation. 
To determine which specific aspects of screening tests mainly determine the preference for 
a screening test, we performed an unlabelled discrete choice experiment (DCE). Our results 
confirmed that expected pain is an important determinant of preference for a screening 
strategy in screening naïve individuals and significantly influences the expected participation 
rate based on our model (chapter 7). Furthermore, we demonstrated that pain significantly 
less influenced preferences among those with endoscopy experience. This suggests that pain 
actually experienced during endoscopic screening is not as severe as expected beforehand 
(chapter 7). 
We determined level of embarrassment, discomfort, and pain among participants to FS 
screening (chapter 6). As suggested before, we and others found only a small proportion of 
screenees reporting severe embarrassment, discomfort or pain during the procedure.22, 27, 32-34 
Even more important, only 8% of subjects was not willing to return for a successive FS screening 
round and only 2% would not recommend others to undergo FS screening. FS screening is thus 
an acceptable screening method among participants, which has very important implications 
for the implementation of a nation-wide screening programme, since FS screening must be 
repeated five or ten-yearly to be effective.35-37 Furthermore, participants will share their (posi-
tive) experience with FS screening with other potential screenees. This may improve uptake in 
successive cohorts. 
The low participation rate to more invasive screening tests, like FS, might also be explained 
by the lack of information on a more substantial risk reduction on CRC-related mortality than 
seen with the non-invasive FOBTs. Screenees in our and other large population-based trials 
were however not specifically informed on test efficacy (chapter 2).22, 24-28 We performed a 
labelled DCE, in which respondents had to choose between FOBT, FS and total colonoscopy 
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(TC) with test-specific risk reduction on CRC-related mortality (chapter 6). The predicted 
uptake of FS and TC screening based on our model was significantly higher than uptake of 
FOBT screening, given realistic levels of CRC-related mortality reduction. Our findings are 
further underlined by a Swiss study, in which the majority (75%) of all screenees chose to 
undergo a TC, and only a small proportion (25%) preferred FOBT or FS screening after they 
were informed about the efficacy of the three screening tests.38 We therefore believe that 
increasing awareness on the efficacy of FS screening will enhance uptake, prevent unrealistic 
expectations, and optimise informed choice. Uptake of FS screening in the Netherlands may 
thus be higher in future programmes if invitees will be informed on efficacy of FS screening. 
The effectiveness of FS screening has been evaluated in case-control studies 39-41, and recently 
results of a RCT have been published.42 The mortality reduction in this trial was 59% among 
attendees.42 The results of three large RCT are still being awaited.22, 23, 25 In this thesis we 
describe the detection rate (DR) of advanced neoplasia as surrogate end-point for the effective-
ness of FS screening (chapter 2). The DR of advanced neoplasia (8.0%) in the FS arm was high 
compared to other studies (3.6-5.2%).22, 24, 26-28 The inclusion of an older age group (50-74 years) 
with a higher prevalence of advanced neoplasia partly explained this difference. In addition, we 
aimed to examined the colon until the splenic flexure, which will ultimately lead to a higher DR, 
while other studies reached for the transition from sigmoid to descending colon as anatomic 
extent of FS.22, 25, 27 
Recently, a Canadian case-control study demonstrated that colonoscopy is associated with 
a reduction in CRC-related mortality rates, but primarily for left-sided cancer.43 This study is lim-
ited by the retrospective design, the lack of information on the indication for the colonoscopy, 
and the use of billing codes instead of actual endoscopy reports. Nevertheless, the results are 
supported by two population-based cohort studies which reported similar trends as the occur-
rence of CRC 44 and advanced neoplasia 45 was decreased in the left and not the right sided 
colon ten year after a screening colonoscopy. Assumptions for the lack of protective effect in 
the right colon are: (i) reduced quality of colonoscopy (e.g. caecal intubation, adenoma detec-
tion rate, withdrawal time) as in those population-based studies colonoscopies have been 
performed by others than a gastroenterologist (surgeons, general practitioners); (ii) increased 
prevalence of flat or sessile lesions in the right colon, which are more likely to be missed; and (iii) 
adenoma in the right colon may develop through a different, possibly fast-growing pathway 
(e.g. microsatellite instability). Although prospective population-based trails are required to 
confirm these findings, we postulate that a high quality FS until the splenic flexure and referral 
of high risk subjects for TC might be a reasonable alternative for TC screening in the era of 
limited colonoscopy capacity.46 The efficacy of a FS programme can be further improved by 
adding biennial FOBT screening, as FOBT screening has been proven to reduce CRC related 
mortality mainly in the right colon.47, 48 A recent cost-effectiveness analyses based on US data 
demonstrated that the combination of FS and FOBT (Hemoccult II) was the most effective, 
cost-saving screening method. Lansdrop-Vogelaar et al. did not describe the combination of FS 
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and FIT. Based on our randomised trial FIT outperformed gFOBT in uptake, detection rate and 
cost-effectiveness (chapter 2 and 9). Combining FS with FIT in stead of gFOBT will probably 
be more cost-effective. Until now only one small population-based study has been performed 
showing a 10% increase in detection rate when a FIT was added to FS screening.49  
Conclusions and further research 
FS is a feasible screening test for use in a nation-wide screening programme. For improving 
effectiveness of FS screening, the focus should be on higher participation rates. Invitees of a 
FS screening programme should be informed on the expected reduction of CRC related mor-
tality with FS screening, as this may improve uptake and enhance informed choice. Further 
population-based trials using FS screening, in which subjects in the target population are 
informed on the effectiveness, are required. Furthermore, RCT results on FS screening to reveal 
the CRC-related incidence and mortality reduction are eagerly awaited. 
The combination of gFOBT and FS is more cost-effective than FS alone. Guidelines recom-
mend the combination of FS with a sensitive FOBT .37 Based on our data a combination with FIT 
seems the most (cost-) effective, and should be preferred over gFOBT. However, large popula-
tion based studies determining uptake and diagnostic yield of a combined FS/FIT programme 
are required.
gender differences in endoscoPic crc screening
Main findings
International guidelines recommend similar screening strategies (test, interval, age to initiate 
screening) for men and women 35, 37, 50, despite disparity in epidemiology of CRC.51 The ques-
tion is raised whether gender-specific screening policies should be introduced.52 
Age-specific CRC incidence and mortality rates in men are similar to women who are 
approximately 4–8 years older.53 Colonoscopy studies found a considerable lower detection 
rate of advanced neoplasia in women than men in their sixth decade, whereas the detection 
rate was similar for both sexes above the age of 60.54-56 These findings may provide a rationale 
for delaying initiation of CRC sceening in women. 
The incidence of CRC per colon segment also varies between both sexes, as women are more 
likely to have a right-sided CRC.57 A FS has been shown to predict the presence of advanced 
neoplasia in the proximal colon only in a minority of cases (35%).55 In agreement with all large 
population-based FS studies, we found a significant larger number of advanced neoplasia in 
men than in women (chapter 2) 22, 24, 25, 27, and thus a higher number needed to screen among 
women. FS screening therefore seems less effective in women. However, we have to take into 
account that women have a longer life expectancy which may partly compensate for the fewer 
neoplasia found. 
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In chapter 2 we demonstrated a significantly lower uptake of FS screening among women 
compared to men. A subsequent invitation for FIT screening resulted in a higher response 
among female than male FS non-participants, indicating that the test rather than the CRC 
screening itself was a barrier to participation (chapter 4). These results are in agreement with 
our labelled DCE demonstrating a more negative attitude towards both FS and TC screening 
among women than among men (chapter 6). Compared to men, women reported more fear 
and embarrassment to undergo a FS 58, which were the main reasons for refusing FS.31 We 
conducted a questionnaire study among participants of FS screening to reveal the actual dif-
ference in experienced burden between both sexes. Our observations reflect those of other 
studies reporting that women were more likely to experience burden during FS, 59, 60 and were 
therefore less willing to return for successive screening rounds. Interestingly, experienced 
embarrassment was less pronounced in women who underwent a FS performed by a same-sex 
endoscopist.61, 62 Nickelson et al. previously reported expected embarrassment as the most 
important reason for preferring a same-sex endoscopist.58 Our results demonstrate that, in this 
case, the expectation reflects the actual experience (chapter 5).
Conclusions and further research 
Indirect evidence suggest less effectiveness of FS screening in women, based on a higher 
prevalence of right-sided CRC, worse prediction of advanced neoplasia in the proximal colon 
based on distal findings and a less favourable attendance rate. Sex-specific data of RCTs and 
cost-effectiveness analyses CEAs for FS screening are being awaited to decide on FS as a screen-
ing tool in women.
If the results are favourable, attempts should be made to improve attendance among 
women. Endoscopists should be aware of potential embarrassment, discomfort and pain in 
women, and should consider steps to reduce burden during FS (e.g. using sedation or a more 
flexible, smaller-calibre endoscope). Furthermore, a nation-wide screening programme should 
offer potential screenees a choice between a male or female endoscopist or directly allocate 
all female participants to a female endoscopist. Further research should focus on sex-specific 
information to reduce anticipated embarrassment and fear. 
end-Points of crc screening
Main findings
The detection rate of advanced adenomas is used as a surrogate end-point for the effective-
ness of a screening strategy. Additionally, surveillance and screening guidelines for subjects 
with colorectal polyps rely on the histological characteristics of polyps removed. Concerns 
have been raised on the reproducibility of pathology results. In this thesis we demonstrated 
that pathologists show a very good inter-observer agreement for differentiating between 
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non-adenomatous and adenomatous polyps (kappa-value 0.88), and a moderate agreement 
for non-advanced and advanced adenomas (kappa-value 0.58). Our findings are in line with 
previous studies.63-70 Surprisingly, pathologists with expertise in gastroenterology demon-
strated similar inter-observer variability in the classification of advanced and non-advanced 
adenoma as other pathologists (chapter 8).63-70
Conclusions and further research 
The moderate inter-observer agreement between general and expert pathologists in the 
field of gastroenterology for advanced and non-advanced adenoma has serious implications 
for evaluation of the effectiveness of screening strategies and for risk stratification of patients 
with neoplasia removed. An adenoma with advanced characteristics remains an important 
determinant of cancer risk. We therefore recommend focusing on education and continuous 
quality improvement efforts with regard to interpretation of colon neoplasia. A consensus 
meeting on interpretation of colon neoplasia prior to implementation of a nation-wide screen-
ing programme seems warranted. Further research on more reliable markers for predictability 
of recurrence of advanced neoplasia is required. 
roLe of tHe generaL Practitioner in crc screening
Main findings
The role of the general practitioner (GP) is of paramount importance for a nation-wide screen-
ing programme, especially in the Netherlands where the GP is the central stakeholder of health 
care. GP’s recommendation on CRC screening is a major predictor for attending CRC screen-
ing.30, 31, 71, 72 Before implementing a nation-wide screening programme, it is of vital importance 
that the majority of GP’s have a positive attitude towards screening. Furthermore, GP’s should 
achieve adequate information on all aspects of CRC screening. 
On the other hand, involvement of the GP in the invitation process is questionable, as two 
randomised population-based trial did not demonstrate any benefit of personalised invita-
tion by the GP.9, 28, 73 This should therefore not be recommended for a nation-wide screening 
programme. In addition, a central invitation system is more opportune and will not overlook 
subjects in the target population without a GP.74 
Involving GPs in the process of informing screenees on a positive test result and the 
subsequent referral considerably increases uptake of a follow-up TC. In this thesis, nearly all 
positive screenees underwent a colonoscopy (97%) (chapter 2). This is considerably higher 
than observed in the study of Van Rossum et al (83%), which had a similar design and was 
also conducted in the Netherlands.16 We, other than van Rossum et al., put the GP in charge 
of informing the screenee on the positive test result and further handling the referral of the 
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screenee. Furthermore, in our study GPs could refer positive screenees to all hospitals in the 
region, while in the study by Van Rossum et al. all TC were performed in the university hospital. 
Conclusions and further research
The GP has an important role in a nation-wide screening programme to inform subjects in 
the target population on CRC screening and in the referral process of subjects with a positive 
screen.
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chapter 1 provides an overview of the current knowledge on epidemiology of and screening 
strategies for colorectal cancer (CRC). Furthermore, the general aims and outline of the thesis 
are described in this chapter.
In chapter 2 a randomised trial comparing uptake and detection rate of guaiac-based faecal 
occult blood test (gFOBT), faecal immunochemical test (FIT), and flexible sigmoidoscopy (FS) 
screening in a Dutch average-risk screening naïve population (n=15 011) is described. Faecal 
immunochemical test at a cut-off value of 100ng Hb/ml provided a higher uptake (62% vs. 
50%, p<0.001) and detection rate of advanced neoplasia (2.4% vs. 1.1%, p<0.001) than gFOBT 
screening. Based on these findings FIT is preferred over gFOBT for population-based screening. 
Uptake of FS screening (32%) was significantly lower than for both FOBTs. Despite this lower 
uptake, FS screening demonstrated a higher diagnostic yield per 100 invitees than both FOBTs 
(gFOBT 0.6; FIT 1.5; FS 2.4 advanced neoplasia/invitee p<0.001). 
The FIT (OC-Sensor micro) provides quantitative test results allowing for determination 
of an optimal cut-off value for a nation-wide screening programme based on colonoscopy 
capacity and the intended detection rate in the screened population. chapter 3 describes 
the characteristics of FIT at different cut-offs in the range of 50-200ng Hb/ml and provides a 
random comparison with gFOBT screening. FIT was a more effective screening test than gFOBT 
within the range of tested cut-off values. A cut-off value of 75ng Hb/ml provided an adequate 
positivity rate (5.8%) and an acceptable trade-off between positive predictive value (PPV) (49% 
CI 42-57%) and detection rate of advanced neoplasia (2.7%; CI 2.2-3.3%). PPV (65% vs. 42%; 
p<0.001) and detection rate (4.1% vs. 1.7%; p<0.001) of advanced neoplasia in FIT screening 
were significantly higher in men than in women. A different cut-off level for men and women to 
achieve a similar PPV may therefore be considered. 
Uptake of FS screening generally remains low, as described in chapter 2. In chapter 4 we 
therefore determined uptake of FIT screening among non-participants of FS screening. In total 
25% (CI 24-26%) of the non-participants of FS screening did attended FIT screening. The overall 
participation rate of the two-stage recruitment for FS and FIT screening was 45% (CI 44-46%). 
However, the attendance remains lower than for primary FIT screening (62%). Women in the 
target population were more likely to attend FIT than FS screening (p<0.001). 
Perceived burden of a screening test is an important determinant of acceptance of a pop-
ulation-based screening programme. In chapter 5 experienced burden of gFOBT, FIT and FS 
screening was determined among participants. A significant larger proportion of gFOBT than 
FIT screenees reported test-related burden (gFOBT: 2.5%; FIT: 1.4%; p=0.05). Both FOBTs were 
reported to be less burdensome than FS screening (12.9%, p<0.001). Furthermore, FS-related 
burden was more frequently reported by women than by men (18.2% vs. 7.7%; p<0.001). Our 
data demonstrate that a same-sex endoscopist may reduce the level of perceived embar-
rassment in women, whereas no differences in pain or discomfort were found. A nation-wide 
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FS screening programme should therefore offer women in the target population a choice 
between a female and male endoscopist. All three screening tests seem to be acceptable for 
population-based screening as the majority was willing to attend successive screening rounds 
(gFOBT: 94.1%; FIT: 94.0%; FS: 83.8%). This positive experience with CRC screening may affect 
uptake of subsequent screening rounds. 
International guidelines recommend screening with any test, as insufficient evidence is 
available to prefer one screening test over the other. Individual preferences therefore play 
an important role in the choice for a screening strategy. In chapter 6 and 7 we describe two 
studies to determine individuals’ preferences for and to predict uptake of CRC screening 
programmes with various screening tests. A discrete choice experiment (DCE) questionnaire 
was conducted among screening naïve and previously screened subjects aged 50-74. DCEs 
can measure individuals’ preferences for health care interventions. The DCE assumes that the 
individual preference for a test is determined by the characteristics of a test. In chapter 6 we 
performed a labeled DCE. In a labelled design the specific screening test is mentioned in each 
choice option (FOBT, FS, TC), while in an unlabelled design (chapter 7) the screening test is 
presented as ‘screening test ‘A’, ‘B’ or ‘C’, and is further described by certain characteristics that 
are presented in the choice set. Type of screening test, screening interval, and risk reduction of 
CRC related mortality influenced subjects’ preferences (all p<0.05). Screening-naïve and previ-
ously screened subjects equally preferred five-yearly FS and ten-yearly total colonoscopy (TC) 
(p=0.24; p=0.11), but favoured both strategies to annual FOBT screening (all p-values <0.001) if, 
based on the literature, realistic risk reduction of CRC related mortality was applied. 
chapter 7 describes how procedural characteristics of various CRC screening methods 
determine preferences for participation, and how individuals weigh these against the expected 
health benefits from CRC screening. In this study an unlabelled DCE was used. The type of bowel 
preparation, risk reduction of CRC-related mortality and screening interval mainly determined 
the preferences for a screening strategy. Both DCEs demonstrate that the expected risk reduc-
tion of CRC mortality dominated preferences for a screening strategy. Subjects in the target 
population should therefore be informed on risk reduction by different screening strategies to 
prevent unrealistic expectations and to optimise informed choice.
The histopathological diagnosis is crucial for management of patients in a screening 
or surveillance programme for CRC. Furthermore, the definition of advanced adenoma is 
increasingly used as a primary end-point in screening trials. In chapter 8 we determined the 
inter-observer variation in histopathological diagnosis of colorectal polyps derived from a CRC 
screening programme. Furthermore, inter-observer variation was assessed between general 
and expert gastrointestinal pathologists, and between expert gastrointestinal pathologists. 
The inter-observer agreement was very good for differentiating between non-adenomas and 
adenomas (kappa: 0.88; CI: 0.83-0.94), but only moderate for distinguishing non-advanced from 
advanced adenomas (kappa: 0.58; CI: 0.48–0.68). The inter-observer variation in the interpreta-
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tion of colorectal polyps was similar between a general and an expert pathologist as between 
two expert pathologists. 
A cost-effectiveness analysis mainly determines the governmental decision on a nation-
wide screening programme. chapter 9 describes the cost-effectiveness of both gFOBT and FIT 
screening at different cut-off levels based on a random comparison of both tests in an average-
risk population. In this chapter the validated MISCAN-Colon micro-simulation model was used 
to estimate costs and effects of different screening strategies. FIT screening at a cut-off level of 
50 ng Hb/ml was most cost-effective. Biennial FIT screening between ages 55-74 resulted in an 
incremental cost-effectiveness ratio of 3900 euro per life-year gained. Adjusting the age range 
to ages 50-80 was more cost-effective than adjusting the screening interval to annual screening 
(5800 versus 14900 euro per life-year gained).
The main findings of this thesis and directions for future research are discussed in chapter 10.
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In hoofdstuk 1 wordt een overzicht gegeven van de huidige kennis over de epidemiologie van 
darmkanker en screening naar darmkanker. Tevens worden de algemene doelstellingen van dit 
proefschrift beschreven. 
In hoofdstuk 2 wordt een gerandomiseerde studie beschreven waarin de guaiac feces 
occult bloed test (gFOBT), immunochemische feces occult bloed test (FIT) en de sigmoidos-
copie (FS) met elkaar worden vergeleken op basis van opkomst en diagnostische opbrengst 
in mensen met een gemiddeld risico op darmkanker (n=15011). In deze studie werd voor de 
FIT een verwijsdrempel van 100ng hemoglobine (Hb)/ml gebruikt. In vergelijking met gFOBT 
resulteerde FIT screening niet alleen in een hogere opkomst (62% vs. 50%, p<0.001), maar 
detecteerde tevens een groter aantal hoogrisico neoplasieën (advanced neoplasia) (2.4% vs. 
1.1%, p<0.001). Deze studie toont aan, dat FIT de voorkeur verdient boven gFOBT screening. De 
opkomst voor FS screening was significant lager dan voor beide FOBTs (32%). Desondanks was 
de diagnostische opbrengst per uitgenodigde persoon hoger voor FS dan voor beide FOBTs, 
doordat FS screening significant meer hoogrisico neoplasieën detecteerde (gFOBT 0.6; FIT 1.5; 
FS 2.4 hoogrisico neoplasieën / uitgenodigde persoon p<0.001). 
De FIT (OC-Sensor micro) is een kwantitatieve test. Hierdoor is het mogelijk de verwijs-
drempel te verschuiven en de afkapwaarde te bepalen, waarbij de testprestaties het meest 
optimaal zijn. De colonoscopie capaciteit en de gewenste diagnostische opbrengst spelen bij 
de keuze voor een afkapwaarde een belangrijke rol. Hoofdstuk 3 beschrijft de testkenmerken 
van de verschillende afkapwaarden variërend van 50-200 ng Hb/ml in een gerandomiseerde 
vergelijking met de gFOBT. FIT was een effectievere screeningsmethode dan de gFOBT binnen 
het bereik van de geteste afkapwaarden. Een afkapwaarde van 75ng Hb/ml (FIT75) resulteerde 
in een aanvaardbaar aantal mensen met een positieve test (5.8%). Met de FIT75 werden twee 
en een half maal zoveel hoogrisico neoplasieën (2.7% vs. 1.1%) gevonden dan met de gFOBT, 
terwijl de positief voorspellende waarde (PVW) voor hoogrisico neoplasieën vergelijkbaar was 
voor beide testen (49% vs. 45%). Op basis van deze resultaten wordt een afkapwaarde van 75ng 
Hb/ml geadviseerd. De PVW (65% vs. 42%; p<0.001) en het aantal gedetecteerde hoogrisico 
neoplasieen (4.1% vs. 1.7%; p<0.001) was significant hoger in mannen dan in vrouwen. Verschil-
lende afkapwaarden voor FIT screening in mannen en vrouwen op basis van een vergelijkbare 
PVW kan derhalve worden overwogen. 
Uit hoofdstuk 2 blijkt, dat de opkomst bij FS screening beduidend lager is dan bij FOBT 
screening. In hoofdstuk 4 wordt de opkomst bij FIT screening bestudeerd in een groep 
niet-deelnemers aan FS screening. De uitnodiging werd door 25% (CI 24-26%) van de niet-
deelnemers geaccepteerd. De totale opkomst bij de gecombineerde uitnodiging voor FS en FIT 
screening was 45% (CI 44-46%). Dit opkomstpercentage was echter lager dan beschreven voor 
primair FIT screening (hoofdstuk 2, 62%). Vrouwen in de doelgroep waren meer bereid om FIT 
dan FS screening te ondergaan (p<0.001). 
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De mate waarin een screeningtest als belastend wordt ervaren, is bepalend voor de accep-
tatie van en deelname aan vervolgronden van een screeningstest. In hoofdstuk 5 wordt de 
test belasting van gFOBT, FIT en FS screening onderzocht onder deelnemers. Deelnemers aan 
gFOBT rapporteerden vaker enige mate van testbelasting dan deelnemers aan FIT screening 
(gFOBT 2.5%; FIT 1.4%; p=0.05). Beide ontlastingstesten werden als minder belastend ervaren 
dan de FS (12.9%, p<0.001). De meerderheid van de deelnemers was bereid om deel te nemen 
aan een vervolgronde met dezelfde test (gFOBT: 94.1%; FIT: 94.0%; FS: 83.8%). Deze positieve 
ervaring met screening voor darmkanker heeft zeer waarschijnlijk een positieve invloed op de 
opkomst voor vervolgronden. Verder wordt in hoofdstuk 5 beschreven, dat een groter aantal 
vrouwen dan mannen de FS als belastend ervoeren (18.2% vs. 7.7%; p<0.001). Uit onze analyses 
blijkt dat vooral de mate van schaamte, die bijdraagt aan de ervaren belasting tijdens een onder-
zoek, gereduceerd kan worden wanneer een vrouw gescopieerd wordt door een vrouwelijke 
endoscopist. Deze data benadrukken het belang van het aanbieden van een keuze voor een 
vrouwelijke endoscopist aan vrouwen in de doelgroep voor darmkanker screening middels FS.
Internationale richtlijnen bevelen al langere tijd screening voor darmkanker aan. Daar er 
onvoldoende bewijs is om een test boven een andere test te verkiezen, wordt screening met 
één van de bestaande testen aanbevolen. Individuele preferenties spelen dus een belangrijke 
rol in de keuze voor een screeningstest. In hoofdstuk 6 en 7 hebben we de individuele prefe-
renties voor de verschillende screeningstesten onderzocht door middel van een discrete keuze 
experiment (DCE) uitgevoerd onder mensen tussen de 50-74 jaar met en zonder ervaring met 
darmkanker screening. Bij een DCE wordt aangenomen dat individuele preferenties voor een 
test bepaald worden door de verschillende testeigenschappen. In hoofdstuk 6 wordt een 
gelabeld DCE beschreven. Een gelabeld DCE neemt ook de test zelf mee in de keuze, die wordt 
voorgelegd (FOBT, FS, TC). Terwijl bij een niet-gelabeld DCE de test wordt beschreven aan 
de hand van de testeigenschappen, die worden weergegeven in de geschetste scenario’s. In 
het gelabelde DCE waren de test zelf, het screeningsinterval en de verwachte risico reductie 
van darmkanker gerelateerde mortaliteit belangrijk voor de individuele preferenties voor 
een bepaalde screeningsstrategie (p<0.05). De groep met en de groep zonder ervaring met 
darmkanker screening hadden geen voorkeur voor vijfjaarlijks FS of tienjaarlijks screenen 
middels colonoscopie (p=0.24; p=0.11). Echter beide endoscopische screeningsmethoden 
werden verkozen boven jaarlijks screenen middels FOBT (p-waarden <0.001) indien, op basis 
van de literatuur, realistische getallen voor het verwachte effect op darmkanker gerelateerde 
mortaliteit werden toegepast. De meer gunstige risico reductie en langere screeningsinterval 
zijn de reden, dat mensen endoscopie screening prefereren boven een FOBT.
Hoofdstuk 7 beschrijft hoe de testeigenschappen van de verschillende screeningstesten 
individuele preferenties beïnvloeden en hoe individuen negatieve testeigenschappen afwe-
gen tegen het verwachte effect op darmkanker gerelateerde mortaliteit. Voor deze studie is 
gebruik gemaakt van een niet-gelabeld DCE. Het type darm voorbereiding, het screeningsin-
terval en het verwachte effect op darmkanker gerelateerde mortaliteit bepalen hoofdzakelijk 
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de preferenties voor een bepaalde screeningsmethode. Beide DCEs laten zien, dat de risico-
reductie op darmkanker gerelateerde mortaliteit preferenties voor een screeningsmethode 
domineert. Mensen in de doelgroep voor darmkanker screening moeten daarom worden 
geïnformeerd over het effect op de darmkanker gerelateerde mortaliteit van de verschillende 
screeningsmethoden om onrealistische verwachtingen te voorkomen en mensen een goed 
geïnformeerde keuze te laten maken.
De histologische diagnose van colorectale poliepen is van doorslaggevend belang voor 
darmkanker screening en surveillance programma’s. Tevens wordt de aanwezigheid van een 
hoogrisico neoplasie in toenemende mate gebruikt als primair eindpunt in studies over darm-
kanker screening. In hoofdstuk 8 beschrijven wij de interobserver variatie tussen pathologen 
in de beoordeling van colorectale poliepen, die zijn verwijderd tijdens darmkanker screening. 
De interobserver variatie werd bepaald tussen een algemeen patholoog en een patholoog met 
maag-, darm- en lever ziekten als aandachtsgebied (expert) en tussen twee expert pathologen. 
De interobserver overeenstemming was erg goed voor de differentiatie tussen niet-adenomen 
en adenomen (kappa 0.88; CI: 0.83-0.94), maar slechts matig voor het onderscheid tussen laag 
en hoogrisico adenomen (kappa 0.58; CI: 0.48–0.68). De interoberserver variatie was vergelijk-
baar tussen een algemeen en een expert patholoog en twee expert pathologen. 
De overheidsbeslissing over de invoering van een bevolkingsonderzoek naar darmkanker 
zal hoofdzakelijk worden bepaald door de kosteneffectiviteit van een screeningsmethode. In 
hoofdstuk 9 wordt de kosteneffectiviteit van gFOBT en FIT screening op de verschillende afkap-
punten berekend door middel van het gevalideerde MISCAN-Colon micro simulatie model. FIT 
screening was meer kosteneffectief dan gFOBT screening. FIT was het meest kosteneffectief bij 
een afkapwaarde van 50 ng/ml. De incrementele kosteneffectiviteit per gewonnen levensjaar 
voor tweejaarlijks screenen middels FIT in de leeftijdsgoep van 55-75 jaar was 3900 euro. Het 
vergroten van de doelgroep (50-80 jaar) was meer kosteneffectief dan het aanpassen van het 
screeningsinterval (jaarlijks) (5800 versus 14900 euro per gewonnen levensjaar).
De belangrijkste bevindingen van dit proefschrift en aanwijzingen voor toekomstig onder-
zoek worden besproken in hoofdstuk 10. 
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commissie.
Dr. de Man, uw voorstel om de kwaliteit in plaats van de kwantiteit van tijd te vergroten is 
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ding en jullie onuitputtelijke inzet om dit project te laten slagen. Op het lab wil ik Jan Francke, 
Martine Ouwendijk, Angela Heijens en Nicole Nagtzaam bedanken voor het verwerken van alle 
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Zonder de bijdrage van de endoscopie verpleegkundigen, secretaresses, poli-assistenten, 
arts-assistenten en MDL-artsen van het Erasmus MC was dit onderzoek niet tot een goed eind 
D
an
kw
oo
rd
188
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Lieve Melanie, bedankt voor je hulp de afgelopen maanden, maar ook zeker ook voor alle leuke 
klets-momenten! 
Paul heel erg bedankt voor je equal contribution aan het pathologie manuscript, maar ook 
voor alle gezellige fietstochten! Lieve Dakkers bedankt voor de leuke tijd! De borrels, congres-
sen, fietstochten, skireizen en het kletsen op de gang zorgen ervoor dat ik met een beetje 
heimwee terugkijk. Leonieke, Marianne, Joyce A, Jilling, Geert, Martijn, Erik, Jurriën, Daphne, 
Jildou, Judith, Joyce K, Sarwa, Sanna, Jolanda, Femme, Margot, Nicoline, Desirée, Robert, Vin-
cent, kleine Vincent, bedankt! 
Natuurlijk wil ik mijn colon-maatjes bedanken. Aaf en Leonie het colaatje om drie uur is een 
belangrijk moment op de dag! Aaf je onaflatende steun binnen maar ook zeker buiten het werk 
is erg belangrijk geweest! Leonie, als student zag ik in jou vaak mijzelf terug. Nu ben je in korte 
tijd uitgegroeid tot een volwaardig onderzoeker. Jij komt er wel!
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vandaag. Lieve Edith twee jaar samen op 6m2 was erg leuk, jouw aanstekelijke lach en positieve 
instelling hebben er voor gezorgd dat ik elke dag met veel plezier naar het “Dak” kwam. Lieve 
Suus, jij bent degene die de afgelopen maanden vaak de juiste dingen heeft weten te zeggen! 
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en is onbeschrijfelijk belangrijk geweest tijdens het doorlopen van dit promotie traject! 
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